

# THE PATHOLOGICAL SOCIETY OF GREAT BRITAIN AND IRELAND

England & Wales · Charity number 1154851

## Details

---

Other names	PATHSOC
Status	Registered
Legal form	Charitable company
Company number	<a href="#">08759028</a>
Registered	2013-12-03
Register	<a href="#">View on the Charity Commission register</a>

## Contact

---

Address	The Pathological Society 6 Alie Steet London E1 8QT
Phone	02074848046
Email	<a href="mailto:operationsmgr@pathsoc.org">operationsmgr@pathsoc.org</a>
Website	<a href="http://www.pathsoc.org/">http://www.pathsoc.org/</a>

## Activities

---

**Objects:** TO ADVANCE PATHOLOGY AND FACILITATE COMMUNICATION BETWEEN PATHOLOGISTS.

**Activities:** The charity's mission is to promote any activity that furthers the understanding of disease. Such an understanding is both a direct and indirect benefit for patients. The Society encompasses a broad church ranging from those engaged in diagnostic pathology through to basic scientists, and its remit encompasses educational as well as research activities.

## Classification

---

- **How:** Makes Grants To Individuals, Sponsors Or Undertakes Research, Acts As An Umbrella Or Resource Body
- **What:** Education/training
- **Who:** The General Public/mankind

## Geography

---

- Ireland
- Northern Ireland
- Scotland

## Finances

---

Period end	Income	Expenditure	Assets	Employees
2024-12-31	£1,455,132	£1,742,773	£7,565,414	2
2023-12-31	£1,034,792	£1,832,265	£7,853,055	2
2022-12-31	£1,173,640	£960,820	£8,426,887	3
2021-12-31	£1,153,236	£1,536,737	£8,696,399	3
2020-12-31	£1,168,755	£1,077,115	£8,338,027	3

## Trustees

Name	Role	Appointed
<b>Prof Mark Johan Arends</b>	Chair	2015-06-25
DR Abhik Mukherjee		2017-06-22
Dr Alexander Kieron Haragan		2024-06-20
Dr Emma Louise Short		2024-06-20
Dr Helen Kalirai		2024-06-20
Dr Kieren Simon James Allinson		2025-06-26
Dr Marnix Jansen		2018-06-21
Dr Matthew Richard Pugh		2024-06-20
Dr Timothy James Kendall		2021-07-08
Honorary Prof Abeer Shaaban		2025-06-26
Prof Gareth Thomas		2025-06-26
Prof John Le Quesne		2025-06-26
Prof Mohammad Ilyas		2022-07-06
Prof Nicholas Paul West		2025-06-26
Professor Graeme Ian Murray		2016-06-30
Professor Sara Ellen Coupland		2020-09-02
Senior Lecturer Tomoko Iwata		2025-06-26

**THE PATHOLOGICAL SOCIETY OF GREAT BRITAIN AND IRELAND**

England & Wales - Charity number 1154851

---

# Accounts

---

**REGISTERED COMPANY NUMBER: 08759028 (England and Wales)**  
**REGISTERED CHARITY NUMBER: 1154851**

**REPORT OF THE TRUSTEES AND**  
**FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**  
**FOR**  
**THE PATHOLOGICAL SOCIETY OF GREAT**  
**BRITAIN AND IRELAND**

Xeinadin Audit Limited, Statutory Auditor  
8th Floor, Becket House  
36 Old Jewry  
London  
EC2R 8DD

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**CONTENTS OF THE FINANCIAL STATEMENTS  
for the year ended 31 December 2024**

	<b>Page</b>
<b>Report of the Trustees</b>	1 to 10
<b>Report of the Independent Auditors</b>	11 to 14
<b>Statement of Financial Activities</b>	15
<b>Balance Sheet</b>	16
<b>Cash Flow Statement</b>	17
<b>Notes to the Cash Flow Statement</b>	18
<b>Notes to the Financial Statements</b>	19 to 27

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND (REGISTERED NUMBER: 08759028)**

**REPORT OF THE TRUSTEES  
for the year ended 31 December 2024**

The trustees present their report and accounts for the year ended 31 December 2024.

The accounts have been prepared in accordance with the accounting policies set out in note 1 to the accounts and comply with the charitable company's governing document, the Companies Act 2006 and the Statement of Recommended Practice, "Accounting and Reporting by Charities", issued in March 2015.

**PUBLIC BENEFIT**

The trustees have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing the aim and objectives and in planning the charity's future activities. The aims of the charity for the public benefit are detailed in the 'Objectives and Activities' section of this report.

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND (REGISTERED NUMBER: 08759028)**

**REPORT OF THE TRUSTEES  
for the year ended 31 December 2024**

**OBJECTIVES AND ACTIVITIES**

The Pathological Society is dedicated to the "Understanding of Disease-Guiding Therapy" in the medical scientific and lay communities. It provides a forum for the presentation of new scientific and medical research findings with the aim of improving knowledge and understanding of human disease. As stated in the constitution; "The objectives of the Society shall be to advance pathology and facilitate communications between pathologists" but this has expanded to recognise its role in the wider community. The Society conforms to its stated objectives by the publication of its Journals, The Journal of Pathology and The Journal of Pathology: Clinical Research, by the organisation of meetings of the Society, by support of other scientific meetings and of a variety of educational and research schemes (see below).

The Society is also a Scottish registered charity and operates in Scotland.

In setting the objectives and activities for the year, the Society has referred to the guidance issued by the Charity Commission on public benefit. In particular, the Society considers how planned activities contribute to the objectives and activities they have set and how these provide public benefit. Some of the Society's normal activities such as meetings and grant activities continue to take place online after the pandemic however the Winter and Summer meetings have resumed with in person meetings.

The Pathological Society serves the public in a variety of ways. Through its scientific and educational meetings (the largest Pathology meeting in the UK and Ireland), the doctors and scientists who manage patients are kept up to date in the latest knowledge about the causes of diseases and its diagnosis. Our flagship journal, The Journal of Pathology, now in its 130th year of publication continues to enjoy very high international esteem and is widely recognised as the first choice journal in which to publish scientific papers on the mechanisms of disease. Our more recent journal, The Journal of Pathology: Clinical Research (JPCR) now in its 9th year of publication, publishes papers on the application of investigations, biomarkers and trials in clinical scenarios. Together they keep our members, pathologists worldwide and clinicians in other disciplines, apprised of developments in our understanding of the nature and causes of disease and in the resultant current expansion of new methods in diagnosis and treatment. This has immediate significance for patients, in helping to ensure that their management is supported by pathology based on the best diagnostic methods. The Society's provision of grants schemes for research training for its trainee (Concessionary) members will help to ensure that successive cohorts of young UK pathologists will have opportunities to contribute to these advances in medical care. We are hopeful that research will be able to recommence having been halted by the Pandemic.

The Pathological Society is also committed to enhancing the understanding of medical science by the general public and to this end runs Public Lectures; the most recent was given at the Sheffield Pathology Meeting in June 2024; Professor Jacqui Shaw gave an enlightening talk on "Hide and Seek: Searching for Cancer in the Blood". The next Public Lecture is planned for the Joint Pathology 2025 Meeting (June, 2025). The Public Lectures are filmed, with the permission of the lecturer, the videos are available on the Society's website. We also run the Public Engagement grant scheme which will fund a wide range of activities that help the public to understand disease, the pathology underlying the disease and the work of pathologists in the investigation, diagnosis and clinical management of disease. This has been expanded to accommodate applications for virtual events.

The Society continues to explore additional means of informing the public about research into human disease and the practice of pathology; it is envisaged that some of this will be conducted in association with other learned societies.

The Society normally runs two major scientific meetings per year. These meetings are open to the entire medical and scientific community and not restricted to Society members. Both Winter and Summer meetings include sessions dedicated to those in training. Summer meetings are usually run jointly with the BDIAP. As this has become established as the major pathology meeting in the UK and Ireland other specialist societies are increasingly collaborating in the development and delivery of these meetings.

The attendance at the most recent summer meetings averages approximately 500. The Society underwrites all these meetings on a 50/50 basis with the BDIAP in order to maintain registration fees at affordable levels. Winter Meetings are usually held in London, jointly with the Royal Society of Medicine. The Society holds a monthly online Pathology Grand Round Lecture series supported by The Jean Shanks Foundation which are open to members and non-members to attend free of charge.

Our current schemes include:

**RESEARCH GRANTS:**

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND (REGISTERED NUMBER: 08759028)**

**REPORT OF THE TRUSTEES  
for the year ended 31 December 2024**

Best Trainee Research Impact & Best Trainee Research Paper Awards

- **Research Impact Award** to encourage pathology trainees to highlight the most impactful research in the last 36 months and offer £500 and a Medal.

- Research Paper Award to encourage pathology trainees to highlight their best published single research paper relevant to pathology in the last 12 months and offers £500 and a certificate.

Our current annual allocation is £1,000 for each Award.

Cuthbert Dukes Medium Grant Scheme

This scheme was launched in 2019 to encourage early-mid career pathology researchers, in particular academic trainees, to undertake investigation tissue-based research and offers up to £20,000 with one deadline per annum.

Cancer Research UK/Pathological Society Pre-Doctoral Research Bursary

These jointly funded grants were introduced in 2018 and provide short term funding to allow clinicians to get involved in cancer research and provides funding for up to £45,000 for salary and/or research expenses for up to 12 months, with two deadlines per annum. The joint funding scheme ran for an initial period of three years up to 2020 and was then renewed for a further three years up to 2023. In August 2023 a decision was made to continue this scheme for a period of up to five years.

**Early Career Pathology Research Grant - Hodgkin & Leishman**

These were introduced in 2018 to trainees in their first few years of training to undertake investigative research, with two deadlines per annum. The Hodgkin offer up to £1,000 and Leishman up to £2,000. Our current annual allocation is £10,000

**Equipment Scheme**

This scheme is aimed at supporting pathologists engaged in research by providing funds for multi-user equipment. Our current annual allocation for this scheme is £20,000 with two deadlines per annum

**International Collaborative Scheme**

This is aimed at promoting collaboration in scholarly pathological activities between pathologists from any institution outside of the UK and UK pathologists. Our current annual allocation for this scheme is £20,000 with one deadline per annum.

**Jean Shanks Foundation/Pathological Society (JSPS) Joint Research Grants**

The five-year agreement with the Jean Shanks Foundation was launched in 2018 and renewed for a further five years in 2023. This provides a jointly funded range of research schemes to facilitate trainees in pathology to develop their academic and research schemes ranging from early career support through to support for new independent investigators. This initiative will result in a significant increase in the Society's research grant spend. The trustees of the Society agreed to commit money from the Society's investment funds to support this.

Applications have been considered by the Research Sub-committee during 2024 and a range of high-quality applications were recommended for support. These recommendations were endorsed by the Finance and General Purposes Sub-committee.

**All schemes have two application deadlines per annum:**

- JSPS Pre-Doctoral Research Bursary - to promote research in pathology to fund short projects for early career clinical academic research trainee pathologists for a period of 3, 6, 9 or 12 months. This covers salary and/or research expenses to a maximum of £50,000.

- **JSPS Clinical PhD Fellowship** - To provide 3 years of PhD funding for clinical trainee histopathologists to increase the research skills, abilities and interests of those medically qualified trainee histopathologists working on tissue-based projects in pathology. Funding covers salary, university fees and consumables of up to £20,000 pa for 3 years.

- **JSPS Clinical Lecturer Grant** - To offer histopathology trainees post MD/PhD who wish to continue research part-time whilst completing clinical training (part-time). Covers up to £220,000 over a maximum of 4 years and covers 50% salary (with 50% of salary provided by the NHS - similar to the NIHR Clinical Lectureships) and provides up to £20,000 consumables per annum.

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND (REGISTERED NUMBER: 08759028)**

**REPORT OF THE TRUSTEES  
for the year ended 31 December 2024**

- **JSPS Clinical Lecturer Support Grant** - To offer support for continuing research projects over a 2 year period by academic trainee histopathologists following the award of a PhD or MD, when progressing through the final stages of histopathological training leading up to the award of CCT. Covers £60,000 per annum funding over a 2 year period to be used flexibly to fund the costs of employing a research technician or assistant and associated consumables costs.

- **JSPS Intermediate Research Fellowship** - to support newly accredited pathologists during the period between completing their training (passing FRCPath part 2/completing the Certificate of Completion of Training) and obtaining full funding for a Clinician Scientist post through MRC, The Wellcome Trust, CRUK etc. Covers up to £120,000 over a maximum of 2 years and covers 50% of salary costs (with 50% of salary provided by the NHS) and up to £20,000 of consumables per annum.

- **JSPS Multidisciplinary Research Partnership (MRP) Grant** (formerly Clinical Academic Research Partnership (CARP) Grant) - to offer support for NHS consultants who wish to undertake research. The aim is to encourage consultants with an MD or PhD (or equivalent) who are currently not research active, to participate in high quality research collaborations with established leading biomedical researchers.

- **Joint Grant Scheme in Partnership with the UKRI MRC**- The Postdoctoral Clinical Research Fellowship is for trainee pathologists who have undertaken a PhD at some point before the start of their clinical pathology training. The aim of the Fellowship is to encourage trainees back into research to reacquire and update their research skills. The funding covers salary and consumables for up to 3 years.

**PhD Sponsorships** - supports a 3-year PhD and covers a stipend, research & training allowance, conference allowance and up to £20,000 per annum for consumables. Rates are set at MRC rates.

#### **Small Grant Schemes**

This is divided into four separate schemes, namely the Trainees' Small Grant, the Consultant's Pump Priming Small Grant, Postdoctoral Collaborative Small Grant and the Trainees Collaborative Small Grant. These awards are designed to support laboratory expenses for Trainees (speciality trainees or academic trainees) & consultants within their first five years of appointment to generate pilot data to support subsequent applications to major funding agencies. The maximum grant available is £10,000. The current annual allocation for these schemes is £10,000 for the Trainees Collaborative and £40,000 for all others.

#### **Trainee-Clinical Scientist Partnership Grant Scheme (formerly known as Trainee-Clinical Scientist Partnership in Morpho-Molecular Pathology)**

This scheme was introduced in 2019 to create long lasting scientific partnerships between trainee pathologists and clinical scientists in the pathology and genomics arenas, with funding up to £50,000 for a maximum of 3 years. This scheme has one deadline per annum.

#### **Visiting Fellowships**

The Fellowships are for members of the medical and allied scientific professions working in pathologically related bio-medical research to enable travel to other institutions to learn new techniques of value in their research. Applicants need not be Society members. Fellowships are available for a period of study of up to twelve months.

Preference is given to applicants wishing to learn new techniques in the fields of molecular and cell biology. A maximum sum of £5,000 is allocated to any one person. The current annual allocation to this scheme is £20,000.

#### **EDUCATION GRANTS:**

##### **Case Report Prize for Undergraduate & Concessionary (Trainees) Members**

Applicants are required to submit a case report and review of the literature of a standard suitable for publication that goes beyond basic morphological and immunohistochemical diagnostics. A prize of £100 is offered and the opportunity to present the case as an oral presentation at a Summer Meeting of the Society.

#### **Education Grant Scheme**

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND (REGISTERED NUMBER: 08759028)**

**REPORT OF THE TRUSTEES  
for the year ended 31 December 2024**

This scheme is designed to provide support to Academic staff for projects in relation to medical and scientific education (undergraduate and post-graduate) that foster the general area of understanding disease. Our current annual allocation for this scheme is £10,000 with two deadlines per annum

The following Education grants are available. Following the introduction of Associate Undergraduate Membership, these grants are restricted to Associate Undergraduate members:

**Intercalated Degree Awards**

These awards provide fees (up to £9,000) and stipend (£5,000) and £1,800 for consumables for able medical, dental or veterinary students to intercalate a year's Science training and study for a BSc or MSc degree. We support up to 10 awards per annum. There are two deadlines per annum.

**Vacation and Elective Bursaries for Undergraduate Students**

We will support any undergraduate medical, dental or veterinary student to a maximum of £220 per week for up to 8 weeks to undertake a project on any topic that bears on the issue of 'understanding disease' during elective or vacation periods. With two deadlines per annum, our current annual allocation for this scheme is £30,000.

**The Jean Shanks Foundation & Pathological Society Summer Joint Studentships (JSPS)**

This scheme was introduced in 2020 in order to support Year 1 & Year 2 medical and dental students to carry out a research project in pathology during vacation periods. Up to £220 per week, with a maximum of £1,100 per student.

The Society would like to thank the Trustees of the Jean Shanks Foundation for co-funding this important initiative. The current annual allocation for this scheme is £50,000.

**Undergraduate Essay Prize**

We make an award of £500 every year for the best essay written by an undergraduate on a pathologically orientated title. Winning entries can be seen on our website.

**Pathological Society Meeting Bursary for Undergraduates**

This covers travel costs of up to £350 to attend a Pathological Society meeting.

**Students Society Bursary Scheme**

This scheme is to provide support for the promotion of the understanding of pathology amongst medical, dental, biomedical students. The sum requested should not exceed £500, current annual allocation £4,400

All schemes are competitive and clear guidelines are published on our website. They are advertised on our website and in our journals where appropriate. They are awarded by the Society Committee and/or after consideration by the relevant Sub-committees.

**OTHER GRANTS:**

**Pathological Society Meetings Bursary**

Bursaries are made available to cover the cost of registration fees for Society members who are post graduate students (PhD, MD or MSc) or Pathology Trainees and wish to present their research at Society meetings. An applicant whose work is/has been selected for presentation in a plenary session will be favoured.

**Public Engagement Scheme**

This was established in order to foster and promote greater awareness by the lay public of advances in understanding disease which may include support of educational ventures with schools and further education colleges. Our current annual allocation for this scheme is £10,000.

**Open Scheme**

In addition to the above, the Open Scheme is designed to be a source of funds for other activities not covered by the above schemes but that will foster the Society's mission. Our current annual allocation for this scheme is £10,000.

**Travel & Conference Bursary**

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND (REGISTERED NUMBER: 08759028)**

**REPORT OF THE TRUSTEES  
for the year ended 31 December 2024**

These bursaries are to promote scientific communications at major international meetings. Applicants whose work has been selected for presentation are favoured.

**Society Lectures & Awards**

The Society makes several awards for Academic and other achievements. These include the Oakley Lecture for achievements by a young researcher: this has been held annually at Joint Meetings with the BDIAP (in the summer). The Sir Nicholas Wright Lecture was introduced in 2017 and the first lecture was given at the Maastricht Pathology 2018 meeting. This is held in alternative years with the Oakley Lecture from 2018. The most recent Oakley lecture was given at the Liverpool Pathology meeting in June 2023.

We promote the discipline among trainees (including PhD students and biomedical scientists) by offering a significantly discounted membership fee (£10 per annum) which includes all benefits as well as electronic access to the Journal of Pathology and other substantial subsidies (e.g. registration fees etc) including complimentary membership of the European Society of Pathology. On occasions, we can provide Society members with other benefits, such as reduced prices from the Society journals' publishers.

**STRATEGIC REPORT**

Achievement and performance

Charitable activities

The main source of income to the Society is from The Journal of Pathology and as scientific publication migrates to the Open Access model, there is a significant potential for loss of income from the Journal of Pathology. Professor Louise Jones, Editor-in-Chief and Wiley have been working hard to maintain the success of the Journal and its high impact factor, a major consideration for subscribers.

The budget of our regular meetings continues to fall well within the resources, representing less than 10% of annual turnover and 1% of current assets.

**Investment policy**

The Society has considerable investments held mostly in funds managed by our advisors, Cazenove Capital Management, the charities investment arm of Schroders. The investment policy is reviewed annually by the trustees bearing in mind the current income from the journals and membership subscriptions. A presentation is given by the portfolio director, Jeremy Barker, to all the trustees at the January Committee Meeting. The treasurer is in regular contact with the investment team and reviews/forwards relevant documentation to the trustees. The funds available to the Society are principally represented by the Investment portfolio held by the investment fund managers and consist of a variety of quoted investments and government stock. The trustees are aware of the level of income that is available from the investment portfolio and its ability to replace a loss of income from the journals.

The value of Listed investments has decreased from £7,374,145 to £6,712,837 at the end of the current year.

The Society is faced with a potential loss of income supporting its grants whilst facing increased expenditure and will increase the reliance on its investment portfolio. Until the long-term financial position is clearer, reserves will be maintained with judicious use of the investment portfolio to replace the loss of journal income.

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND (REGISTERED NUMBER: 08759028)**

**REPORT OF THE TRUSTEES  
for the year ended 31 December 2024**

**STRATEGIC REPORT**

**Financial position**

The financial results for the year to 31 December 2024 are shown in the attached financial statements.

Income has decreased for the year under review to £971,046 (2023: £1,034,792) due to decreases in investment income and income from the Journal of Pathology. Subscription income has slightly increased to £72,434 (2023: £70,983) and on its own would not enable the Society to function. The Meeting and Events income has increased to £44,809 (2023: £36,315). The main areas of expenditure continue to be charitable grants £1,157,151 (2023: £1,173,269), Society meetings £Nil (2023: £10,000) and support costs of the society £175,221 (2023: £178,124).

Overall expenditure has exceeded income by £287,641 (2023: £573,832) after realised and unrealised investment gains and losses. Fund balances total £7,565,414 (2023: £7,853,055).

It is the policy of the charitable company that unrestricted funds which have not been designated for a specific use should be maintained at a level equivalent to at least three and six month's expenditure. The trustees consider that reserves at this level will ensure that, in the event of a significant drop in funding, they will be able to continue the charitable company's current activities while consideration is given to ways in which additional funds may be raised. This level of reserves has been maintained throughout the year.

The trustees have assessed the major risks to which the charitable company is exposed and are satisfied that systems are in place to mitigate exposure to the major risks.

**Securing the future of pathology**

To ensure the future success of the Society, it has modified its subscription structures to encourage recruitment and greater involvement of more junior pathologists. In addition, as noted above, the Trainees' Sub-committee continues to develop. Changes have already been reflected in a significant up-turn in membership numbers and progression from concessionary to ordinary membership. Meetings to promote academic pathology amongst trainees have also been supported by The Society as well as the additional JSPS Summer Student bursary scheme for Year 1 & 2 medical students. The National Academic trainee network meetings continue, with 2 in-person meetings being held in 2024. The Society plans to continue these meetings, which are valued by the trainees.

To encourage applications for pathology amongst medical graduates, the Undergraduate Committee was established with funding to support attendance at conferences. We aim to promote interest in Pathology even before university, establishing careers days for sixth form students in association with the College and BDIAP.

The Society continues to support the Pathological Society Winter School, which continued to be run as a virtual event for 2024. The School trains participants in advance diagnostics and research skills and the programme now includes molecular pathology. The Society now fully underwrites this course and we need to ensure the course remains competitive with others around the UK.

The society also continues to run an online Education Workshop for Members and Non-Members. The workshop was introduced in 2021 and has been very popular amongst Consultants as well as Concessionary doctors.

**STRUCTURE, GOVERNANCE AND MANAGEMENT**

**Governing document**

The charitable company is a company limited by guarantee.

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND (REGISTERED NUMBER: 08759028)**

**REPORT OF THE TRUSTEES  
for the year ended 31 December 2024**

**STRUCTURE, GOVERNANCE AND MANAGEMENT**

**Risk management**

The Society performed a risk analysis, which has identified the main areas of risk as loss of membership, litigation, loss of accommodation, loss of key staff or services, financial losses on meetings and loss of income from the Journal of Pathology.

Litigation is covered jointly with the publishers of the Journal of Pathology, Wiley, by our own insurance and, by the change of legal status of the Society to become an incorporated charitable company.

All trustees are required to inform the Society of their financial interests and those of direct family members of significant others in an annual, signed declaration. At the start of all grant awarding sessions, committee members are required to declare any conflicts of interest and withdraw from those decisions.

The Committee meets twice annually, normally a day prior to the Winter and Summer Scientific Meetings. This is the formal meeting of all Trustees at which they agree on the broad strategy and areas of activity for the Society, including consideration of grant awarding, investment strategy and risk management.

The Society other sub-committees remain in place and continue to administer the activities of the Society; these are as follows:

- Research Sub-committee (chaired by Professor G Thomas) is responsible for assessing research grant applications and taking into account, where appropriate, external advice with a robust peer review process for grants which exceed £25,000.
- Education Sub-committee (chaired by Dr A Mukherjee) advises on the allocation of funds for intercalated degree students, undergraduate elective bursaries, educational grants and the Student Seminar Scheme and has recently taken on the Pathological Society Meeting Bursary and Travel & Conference Bursary awards.
- Programme Sub-committee (chaired by Professor M Ilyas), develops and approves programme content and the Society's scientific meetings strategy.
- Trainees' Sub-committee (chaired by Dr C McGenity), was established in order to encourage a greater involvement of pathologists in training and to represent their views to the Committee of the Society.
- An Undergraduate Committee has representatives on the main Committee and Trainees' Sub-committee meetings.

The Committee is aware of the Charity Commission's Governance Code and continues to apply the Code as appropriate.

**REFERENCE AND ADMINISTRATIVE DETAILS**

**Registered Company number**

08759028 (England and Wales)

**Registered Charity number**

1154851

**Registered office**

7th Floor,  
6 Alie Street  
London  
E1 8QT

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND (REGISTERED NUMBER: 08759028)**

**REPORT OF THE TRUSTEES  
for the year ended 31 December 2024**

**Trustees**

Prof M J Arends , Professor of Pathology  
Dr R J Byers Consultant Histopathologist  
Prof S E Coupland , Professor of Pathology  
Dr M Jansen Clinician Scientist-Honorary  
Dr A Mukherjee , Honorary Consultant Histopathologist  
Prof G I Murray , Professor of Pathology  
Dr G J Thomas , Professor of Experimental Pathology (resigned 20.6.24)  
Dr N P West Trustee (resigned 20.6.24)  
Dr C Coyne , Consultant Histopathologist  
Dr G S Petts , Clinical Lecturer in Pathology (resigned 20.6.24)  
Dr T J Kendall , Senior Clinical Research in Pathology  
Prof J P C Le Quesne , Professor Of Molecular Pathology (resigned 20.6.24)  
Dr N Pillay ,Group Leader/Hon Consultant Pathologist (resigned 20.6.24)  
Dr M F C Amary , Consultant Histopathologist (resigned 20.6.24)  
Dr D A Moore , Honorary Consultant Histopathologist  
Prof S C Burdak-Rothkamm , Consultant Histopathologist  
Professor E Soilleux , Honorary Consultant Pathologist  
Professor M Ilyas , Professor of Pathology  
Dr S D Richman Lecturer In Pathology  
Dr A K Haragan Consultant Thoracic Pathologist (appointed 20.6.24)  
Dr H Kalirai Senior Research Fellow (appointed 20.6.24)  
Dr M R Pugh Associate Clinical Professor/Hon Con His (appointed 20.6.24)  
Dr E L Short Consultant Histopathologist (appointed 20.6.24)

**Auditors**

Xeinadin Audit Limited, Statutory Auditor  
8th Floor, Becket House  
36 Old Jewry  
London  
EC2R 8DD

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND (REGISTERED NUMBER: 08759028)**

**REPORT OF THE TRUSTEES  
for the year ended 31 December 2024**

**TRUSTEES' RESPONSIBILITY STATEMENT**

The trustees, who are also the directors of The Pathological Society of Great Britain and Ireland for the purpose of company law, are responsible for preparing the Trustees' Report and the accounts in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charitable companies in England and Wales and in Scotland requires the trustees to prepare accounts for each financial year which give a true and fair view of the state of affairs of the charitable company and of the income and expenditure of the charitable company for that year. In preparing these accounts, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the accounts; and
- prepare the accounts on the going concern basis unless it is inappropriate to presume that the charitable company will continue in operation.

The trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the accounts comply with the Companies Act 2006 and the Charities and Trustee Investment (Scotland) Act 2005, the applicable Charities (Accounts and Reports) Regulations. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees' report was approved by the Board of Trustees

Report of the trustees, incorporating a strategic report, approved by order of the board of trustees, as the company directors, on 2 June 2025 and signed on the board's behalf by:

Prof G I Murray - Trustee

**REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF**  
**THE PATHOLOGICAL SOCIETY OF GREAT**  
**BRITAIN AND IRELAND**

**Opinion**

We have audited the financial statements of The Pathological Society of Great Britain and Ireland (the 'charitable company') for the year ended 31 December 2024 which comprise the Statement of Financial Activities, the Balance Sheet, the Cash Flow Statement and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 December 2021 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and Regulation 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended).

**Basis for opinion**

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

**Conclusions relating to going concern**

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

**Other information**

The trustees are responsible for the other information. The other information comprises the information included in the Annual Report, other than the financial statements and our Report of the Independent Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

**Opinions on other matters prescribed by the Companies Act 2006**

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the Report of the Trustees for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Report of the Trustees has been prepared in accordance with applicable legal requirements.

**REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF**  
**THE PATHOLOGICAL SOCIETY OF GREAT**  
**BRITAIN AND IRELAND**

**Matters on which we are required to report by exception**

In the light of the knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the Report of the Trustees.

We have nothing to report in respect of the following matters in relation to which the Charities (Accounts and Reports) Regulations 2008 and the Charities Accounts (Scotland) Regulations 2006 (as amended) require us to report to you if, in our opinion:

- the information given in the accounts is inconsistent in any material respect with the Trustees' Report; or
- sufficient and proper accounting records have not been kept; or
- the accounts are not in agreement with the accounting records; or
- we have not received all the information and explanations we require for our audit.

**Responsibilities of trustees**

As explained more fully in the Trustees' Responsibilities Statement, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

**REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF  
THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**Our responsibilities for the audit of the financial statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Independent Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Our approach to identifying and assessing the risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, was as follows:

- the engagement partner ensured that the engagement team collectively had the appropriate competence, capabilities and skills to identify or recognise non-compliance with applicable laws and regulations;
- we identified the laws and regulations applicable to the charitable company through discussions with management and from our commercial knowledge and experience of the sector The Pathological Society of Great Britain and Ireland belongs to;
- we focused on specific laws and regulations which we considered may have a direct material effect on the financial statements or the operations of the association, including the Charities Act 2011, Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable to the United Kingdom and Republic of Ireland (FRS 102) (effective 1 January 2019), Trustees Act, Bribery Act and data protection;
- we assessed the extent of compliance with the laws and regulations identified above through making enquiries of management and inspecting legal correspondence; and
- identified laws and regulations were communicated within the audit team regularly and the team remained alert to instances of non-compliance throughout the audit.

We assessed the susceptibility of the charity's financial statements to material misstatement, including obtaining an understanding of how fraud might occur, by:

- making enquiries of management as to where they considered there was susceptibility to fraud, their knowledge of actual, suspected and alleged fraud; and
- considering the internal controls in place to mitigate risks of fraud and non-compliance with laws and regulations, including the ones that ensure that the grants are used for intended purposes.

To address the risk of fraud through management bias and override of controls, we:

- performed analytical procedures to identify any unusual or unexpected relationships;
- tested journal entries to identify unusual transactions;
- assessed whether judgements and assumptions made in determining the accounting estimates were indicative of potential bias; and
- investigated the rationale behind significant or unusual transactions.

In response to the risk of irregularities and non-compliance with laws and regulations, we designed procedures which included, but were not limited to:

- agreeing financial statement disclosures to underlying supporting documentation;
- reading the minutes of meetings of those charged with governance;
- enquiring of management as to actual and potential litigation and claims.

There are inherent limitations in our audit procedures described above. The more removed that laws and regulations are from financial transactions, the less likely it is that we would become aware of non-compliance. Auditing standards also limit the audit procedures required to identify non-compliance with laws and regulations to enquiry of the trustees and other management and the inspection of regulatory and legal correspondence, if any.

Material misstatements that arise due to fraud can be harder to detect than those that arise from error as they may involve deliberate concealment or collusion.

**REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF**  
**THE PATHOLOGICAL SOCIETY OF GREAT**  
**BRITAIN AND IRELAND**

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at [www.frc.org.uk/auditorsresponsibilities](http://www.frc.org.uk/auditorsresponsibilities). This description forms part of our Report of the Independent Auditors.

**Use of our report**

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Mr Thurairatnam Sudarshan (Senior Statutory Auditor)  
for and on behalf of Xeinadin Audit Limited, Statutory Auditor  
8th Floor, Becket House  
36 Old Jewry  
London  
EC2R 8DD

11 August 2025

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**STATEMENT OF FINANCIAL ACTIVITIES  
for the year ended 31 December 2024**

	Notes	2024 Unrestricted fund £	2023 Total funds £
<b>INCOME AND ENDOWMENTS FROM</b>			
Donations and legacies	2	72,434	70,983
<b>Charitable activities</b>			
Journal of Pathology	4	656,332	711,388
Meetings and Events		44,809	36,315
Investment income	3	197,471	216,106
<b>Total</b>		971,046	1,034,792
<b>EXPENDITURE ON</b>			
<b>Raising funds</b>			
Investment management costs	5	29,842	30,409
		29,842	30,409
<b>Charitable activities</b>			
General	6	123,242	492
Journal of Pathology		83,200	228,181
Grants and Award payable		1,246,080	1,292,912
Meetings and Events		260,409	280,271
<b>Total</b>		1,742,773	1,832,265
Net gains on investments		484,086	223,641
<b>NET INCOME/(EXPENDITURE)</b>		(287,641)	(573,832)
<b>RECONCILIATION OF FUNDS</b>			
Total funds brought forward		7,853,055	8,426,887
<b>TOTAL FUNDS CARRIED FORWARD</b>		7,565,414	7,853,055

**CONTINUING OPERATIONS**

All income and expenditure has arisen from continuing activities.

The notes form part of these financial statements

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND (REGISTERED NUMBER: 08759028)**

**BALANCE SHEET**  
**31 December 2024**

	Notes	2024 Total funds £	2023 Total funds £
<b>FIXED ASSETS</b>			
Tangible assets	13	219	5,735
Investments	14	6,727,175	7,170,377
		6,727,394	7,176,112
<b>CURRENT ASSETS</b>			
Debtors	15	695,154	743,993
Cash at bank and in hand		310,037	246,916
		1,005,191	990,909
<b>CREDITORS</b>			
Amounts falling due within one year	16	(167,171)	(313,966)
		838,020	676,943
<b>NET CURRENT ASSETS</b>			
		7,565,414	7,853,055
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>			
		7,565,414	7,853,055
<b>NET ASSETS</b>			
		7,565,414	7,853,055
<b>FUNDS</b>			
Unrestricted funds:	17		
General fund		7,565,414	7,853,055
		7,565,414	7,853,055
<b>TOTAL FUNDS</b>			

The financial statements were approved by the Board of Trustees and authorised for issue on 2 June 2025 and were signed on its behalf by:

Prof G I Murray - Trustee

The notes form part of these financial statements

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**CASH FLOW STATEMENT  
for the year ended 31 December 2024**

	Notes	2024 £	2023 £
<b>Cash flows from operating activities</b>			
Cash generated from operations	1	(1,061,638)	(813,044)
Net cash used in operating activities		<u>(1,061,638)</u>	<u>(813,044)</u>
<b>Cash flows from investing activities</b>			
Purchase of fixed asset investments		(1,664,436)	(2,609,366)
Sale of fixed asset investments		2,569,873	3,001,522
Movement in capital accounts		21,851	35,253
Interest received		6,517	7,770
Dividends received		190,954	208,336
Net cash provided by investing activities		<u>1,124,759</u>	<u>643,515</u>
<b>Change in cash and cash equivalents in the reporting period</b>			
		63,121	(169,529)
<b>Cash and cash equivalents at the beginning of the reporting period</b>		<u>246,916</u>	<u>416,445</u>
<b>Cash and cash equivalents at the end of the reporting period</b>		<u><u>310,037</u></u>	<u><u>246,916</u></u>

The notes form part of these financial statements

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**NOTES TO THE CASH FLOW STATEMENT  
for the year ended 31 December 2024**

**1. RECONCILIATION OF NET EXPENDITURE TO NET CASH FLOW FROM OPERATING ACTIVITIES**

	2024	2023
	£	£
<b>Net expenditure for the reporting period (as per the Statement of Financial Activities)</b>	(287,641)	(573,832)
<b>Adjustments for:</b>		
Depreciation charges	5,516	12,120
Gain on investments	(484,086)	(223,641)
Interest received	(6,517)	(7,770)
Dividends received	(190,954)	(208,336)
Decrease in debtors	48,839	75,730
(Decrease)/increase in creditors	(146,795)	112,685
	<hr/>	<hr/>
<b>Net cash used in operations</b>	<b>(1,061,638)</b>	<b>(813,044)</b>
	<hr/> <hr/>	<hr/> <hr/>

**2. ANALYSIS OF CHANGES IN NET FUNDS**

	At 1.1.24	Cash flow	At 31.12.24
	£	£	£
<b>Net cash</b>			
Cash at bank and in hand	246,916	63,121	310,037
	<hr/>	<hr/>	<hr/>
	246,916	63,121	310,037
	<hr/>	<hr/>	<hr/>
<b>Total</b>	<b>246,916</b>	<b>63,121</b>	<b>310,037</b>
	<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>

The notes form part of these financial statements

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**NOTES TO THE FINANCIAL STATEMENTS  
for the year ended 31 December 2024**

**1. ACCOUNTING POLICIES**

**Basis of preparing the financial statements**

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (Charities SORP FRS 102), (effective 1 January 2015) the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

The financial statements have been prepared under the historical cost convention with the exception of investments which are included at market value, as modified by the revaluation of certain assets.

The charity constitutes a public benefit entity as defined by FRS 102.

The accounts are presented in sterling and are rounded to the nearest pound.

**Assessment of going concern**

The trustees have assessed whether the use of the going concern assumption is appropriate in preparing these accounts. The trustees have made this assessment in respect to a period of one year from the date of approval of these accounts.

The trustees of the charity have concluded that there are no material uncertainties related to events or conditions that may cast significant doubt on the ability of the charity to continue as going concern. The trustees are of the opinion that the charity will have sufficient resources to meet its liabilities as they fall due.

**Critical accounting judgements and key sources of estimation uncertainty**

Preparation of the financial statements requires the trustees and management to make significant judgements and estimates.

The items in the accounts where these judgements and estimates have been made include:

- the useful economic lives attributed to tangible fixed assets used to determine the annual depreciation charge; and
- the assumptions adopted by the trustees in determining the value of any designations required from the charity's general unrestricted funds.

**Income**

Income is recognised when the charitable company is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charitable company has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Deferred income is recognised for income received in advance for events and meetings taking place in future periods.

Membership subscriptions are recognised in the year to which they relate.

**Journal of Pathology**

The receipts in respect of journals supplied by the Society are credited to the financial statements in the year to which they relate. The income from journals is the proportion due to the Society under the relevant agreements and is net of direct costs met by the publishers.

**Meetings and events income**

Income and corresponding expenditure are recognised in the period the event has taken place. This results in deferred income and accruals recognised in balance sheet.

**Investment income**

Dividends and interest on securities are credited in the financial statements when the Society is entitled to receive the funds.

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**NOTES TO THE FINANCIAL STATEMENTS - continued**  
**for the year ended 31 December 2024**

**1. ACCOUNTING POLICIES - continued**

**Expenditure**

Expenditure is recognised once there is a legal or constructive obligation to make a payment to a third party, it is probable that settlement will be required and the amount of the obligation can be measured reliably.

The costs of raising funds consist of investment management fees.

**Journal of Pathology**

The cost of distributing copies of the journal to members is recognised as a charitable activity.

**Support costs for meetings**

Costs incurred for the Society's events and meetings are recognised in the period in which they take place.

All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the category.

**Grants payable**

Grants payable are payments made to third parties in the furtherance of the charitable objects of the Society. In the case of an unconditional grant offer this is accrued once the recipient has been notified of the grant award. The notification gives the recipient a reasonable expectation that they will receive the one- year or multi-year grant. Grants awards that are subject to the recipient fulfilling performance conditions are only accrued when the recipient has been notified of the grant and any remaining unfulfilled condition attaching to that grant is outside of the control of the Society.

**Tangible fixed assets**

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Fixtures and fittings	- 15% on reducing balance
Computer equipment	- 20% on cost

**Taxation**

The charity is exempt from corporation tax on its charitable activities.

**Fund accounting**

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Designated funds comprise funds which have been set aside at the discretion of the trustees for specific purposes. The purposes and uses of the designated funds are set out in the notes to the accounts.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

**Cash at bank and in hand**

Cash at bank and in hand represents such accounts and instruments that are available on demand or have a maturity of less than three months from the date of acquisition. Deposits for more than three months but less than one year have been disclosed as short term deposits.

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**NOTES TO THE FINANCIAL STATEMENTS - continued**  
**for the year ended 31 December 2024**

**1. ACCOUNTING POLICIES - continued**

**Creditors and provision**

Creditors and provision are recognised when there is an obligation at the balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably. Creditors and provision are recognised at the moment the charity anticipates it will pay to settle the debt. They have been discounted to the present value of the future cash payments where such discounting is material.

**Investments**

Listed investments are initially recognised at their transaction value and subsequently measured at their fair value as at the balance sheet date using the closing quoted market price.

Realised and unrealised investment gains (or losses) are combined in the statement of financial activities and are credited (or debited) in the year in which they arise.

**2. DONATIONS AND LEGACIES**

	Unrestricted funds £	Restricted funds £	2024 Total funds £	2023 Total funds £
Subscriptions	72,434	-	72,434	70,983
	<u>72,434</u>	<u>-</u>	<u>72,434</u>	<u>70,983</u>

**3. INVESTMENT INCOME**

	Unrestricted funds £	Restricted funds £	2024 Total funds £	2023 Total funds £
Income from listed investments	190,954	-	190,954	208,336
Deposit account interest	6,517	-	6,517	7,770
	<u>197,471</u>	<u>-</u>	<u>197,471</u>	<u>216,106</u>

**4. INCOME FROM CHARITABLE ACTIVITIES**

	2024 £	2023 £
Journal of Pathology	656,332	711,388
Meetings and events	44,809	36,315
	<u>701,141</u>	<u>747,703</u>

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**NOTES TO THE FINANCIAL STATEMENTS - continued  
for the year ended 31 December 2024**

**5. INVESTMENT MANAGEMENT COSTS**

	Unrestricted funds £	Restricted funds £	2024 Total funds £	2023 Total funds £
Investment management	29,842	-	29,842	30,409
	<u>29,842</u>	<u>-</u>	<u>29,842</u>	<u>30,409</u>

**6. CHARITABLE ACTIVITIES COSTS**

	Direct Costs £	Grant funding of activities (see note 7) £	Support costs (see note 8) £	Totals £
General	117,396	-	5,846	123,242
Journal of Pathology	83,200	-	-	83,200
Grants and Award payable	11,498	1,142,597	91,985	1,246,080
Meetings and Events	113,801	14,554	132,054	260,409
	<u>325,895</u>	<u>1,157,151</u>	<u>229,885</u>	<u>1,712,931</u>

**7. GRANTS PAYABLE**

	2024 £	2023 £
Grants and Award payable	1,142,597	1,163,269
Meetings and Events	14,554	10,000
	<u>1,157,151</u>	<u>1,173,269</u>

**8. SUPPORT COSTS**

	Management £	Finance £	Governance costs £	Totals £
General	5,846	-	-	5,846
Grants and Award payable	48,438	3,545	40,002	91,985
Meetings and Events	120,937	-	11,117	132,054
	<u>175,221</u>	<u>3,545</u>	<u>51,119</u>	<u>229,885</u>

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**NOTES TO THE FINANCIAL STATEMENTS - continued  
for the year ended 31 December 2024**

**8. SUPPORT COSTS - continued**

Support costs, included in the above, are as follows:

	2024	2023
	Total activities	Total activities
	£	£
General		
£		
Grants and Award payable		
£		
Meetings and Events		
£		
Wages	76,937	69,000
Social security	7,448	6,094
Pensions	8,793	6,774
Rent and insurance	27,714	35,155
Postage and stationery	45	122
Sundries	7,485	6,507
Website & computer	41,283	42,352
Depreciation of tangible and heritage assets	5,516	12,120
Bank charges	3,545	2,620
Wages	32,973	29,580
Auditors' remuneration	8,000	7,000
Committee meetings	11,117	20,753
Accountancy fees	(1,803)	26,296
Professional and legal fees	832	3,338
	<u>5,846</u>	<u>91,985</u>
	<u>132,054</u>	<u>229,885</u>
	<u>229,885</u>	<u>267,711</u>

**9. NET INCOME/(EXPENDITURE)**

Net income/(expenditure) is stated after charging/(crediting):

	2024	2023
	£	£
Auditors' remuneration	8,000	7,000
Depreciation - owned assets	5,516	12,120
	<u>8,000</u>	<u>12,120</u>

**10. TRUSTEES' REMUNERATION AND BENEFITS**

**Trustees' expenses**

None of the trustees (or any persons connected with them) received any remuneration during the year, there were also no travelling costs reimbursed this year.

No grants were received by trustees from the Society in the year.

No committee advisors (non-trustee) received grants from the Society in the year.

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**NOTES TO THE FINANCIAL STATEMENTS - continued  
for the year ended 31 December 2024**

**11. STAFF COSTS**

	2024	2023
	£	£
Wages and salaries	142,980	129,800
Social security costs	11,384	9,775
Other pension costs	15,508	13,330
	169,872	152,905
	169,872	152,905

The average monthly number of employees during the year was as follows:

	2024	2023
Administrative staff	2	2
	2	2
	2	2

No employees received emoluments in excess of £60,000.

**12. FINANCIAL COMMITMENTS, GUARANTEES AND CONTINGENT LIABILITIES**

The company is limited by guarantee - all members having a liability not exceeding £1 per member.

**13. TANGIBLE FIXED ASSETS**

	Fixtures and fittings £	Computer equipment £	Totals £
<b>COST</b>			
At 1 January 2024 and 31 December 2024	12,374	65,774	78,148
	12,374	65,774	78,148
<b>DEPRECIATION</b>			
At 1 January 2024	12,116	60,297	72,413
Charge for year	39	5,477	5,516
	12,155	65,774	77,929
At 31 December 2024	12,155	65,774	77,929
	12,155	65,774	77,929
<b>NET BOOK VALUE</b>			
At 31 December 2024	219	-	219
	219	-	219
At 31 December 2023	258	5,477	5,735
	258	5,477	5,735
	258	5,477	5,735

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**NOTES TO THE FINANCIAL STATEMENTS - continued  
for the year ended 31 December 2024**

**14. FIXED ASSET INVESTMENTS**

	2024	2023
	£	£
Shares	6,712,837	7,134,188
Other	14,338	36,189
	6,727,175	7,170,377

Additional information as follows:

	Listed investments £
<b>MARKET VALUE</b>	
At 1 January 2024	7,134,188
Additions	1,664,436
Disposals	(2,569,873)
Revaluations	484,086
	6,712,837
<b>NET BOOK VALUE</b>	
At 31 December 2024	6,712,837
At 31 December 2023	7,134,188

There were no investment assets outside the UK.

Investments (neither listed nor unlisted) were as follows:

	2024	2023
	£	£
Cash in portfolio	14,338	36,189
	14,338	36,189

**15. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	2024	2023
	£	£
Other debtors	685,946	733,371
Prepayments	9,208	10,622
	695,154	743,993

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**NOTES TO THE FINANCIAL STATEMENTS - continued  
for the year ended 31 December 2024**

**16. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	2024	2023
	£	£
Trade creditors	41,860	40,728
Other creditors	95	666
Accruals and deferred income	125,216	272,572
	167,171	313,966

**17. MOVEMENT IN FUNDS**

	At 1.1.24	Net movement in funds	At 31.12.24
	£	£	£
<b>Unrestricted funds</b>			
General fund	7,853,055	(287,641)	7,565,414
	7,853,055	(287,641)	7,565,414

Net movement in funds, included in the above are as follows:

	Incoming resources	Resources expended	Gains and losses	Movement in funds
	£	£	£	£
<b>Unrestricted funds</b>				
General fund	971,046	(1,742,773)	484,086	(287,641)
	971,046	(1,742,773)	484,086	(287,641)

**Comparatives for movement in funds**

	At 1.1.23	Net movement in funds	At 31.12.23
	£	£	£
<b>Unrestricted funds</b>			
General fund	8,426,887	(573,832)	7,853,055
	8,426,887	(573,832)	7,853,055

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**NOTES TO THE FINANCIAL STATEMENTS - continued**  
**for the year ended 31 December 2024**

**17. MOVEMENT IN FUNDS - continued**

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Gains and losses £	Movement in funds £
<b>Unrestricted funds</b>				
General fund	1,034,792	(1,832,265 )	223,641	(573,832)
<b>TOTAL FUNDS</b>	<u>1,034,792</u>	<u>(1,832,265 )</u>	<u>223,641</u>	<u>(573,832)</u>

**18. RELATED PARTY TRANSACTIONS**

**Remuneration of key management personnel**

The remuneration of key management personnel is as follows.

	2024 £	2023 £
Aggregate compensation	100,811	152,905

The above amounts include payments to the Royal College of Pathologists for the use of 2 (2023: 3) of their employees for administrative management of the society. As part of the agreement between the two entities, in the event of the Royal College of Pathologists being required to contribute to the pension scheme that it belongs to, the society could be liable to meet the obligations of the pension costs in respect of these individuals.

**19. SUBSIDIARIES**

There were no subsidiaries controlled by the charity as at 31 December 2024.

**THE PATHOLOGICAL SOCIETY OF GREAT BRITAIN AND IRELAND**

England & Wales - Charity number 1154851

---

# Accounts

---

REGISTERED COMPANY NUMBER: 08759028 (England and Wales)  
REGISTERED CHARITY NUMBER: 1154851  
REGISTERED CHARITY (SCOTLAND) NUMBER: SC045004

**REPORT OF THE TRUSTEES AND**  
**FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2023**  
**FOR**  
**THE PATHOLOGICAL SOCIETY OF GREAT**  
**BRITAIN AND IRELAND**

Raffingers LLP, Statutory Auditor  
Chartered Certified Accountants  
19-20 Bourne Court  
Southend Road  
Woodford Green  
Essex  
IG8 8HD

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**CONTENTS OF THE FINANCIAL STATEMENTS  
for the year ended 31 December 2023**

	<b>Page</b>
<b>Report of the Trustees</b>	1 to 10
<b>Report of the Independent Auditors</b>	11 to 14
<b>Statement of Financial Activities</b>	15
<b>Balance Sheet</b>	16
<b>Cash Flow Statement</b>	17
<b>Notes to the Cash Flow Statement</b>	18
<b>Notes to the Financial Statements</b>	19 to 27
<b>Detailed Statement of Financial Activities</b>	28 to 29

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**REPORT OF THE TRUSTEES  
for the year ended 31 December 2023**

The trustees present their report and accounts for the year ended 31 December 2023.

The accounts have been prepared in accordance with the accounting policies set out in note 1 to the accounts and comply with the charitable company's governing document, the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005, regulations applicable to those two Acts and Statement of recommended Practice, "Accounting and Reporting by Charities" issued in March 2015.

**PUBLIC BENEFIT**

The trustees have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing the aim and objectives and in planning the charity's future activities. The aims of the charity for the public benefit are detailed in the 'Objectives and Activities' section of this report.

**OBJECTIVES AND ACTIVITIES**

The Pathological Society is dedicated to the "Understanding of Disease-Guiding Therapy" in the medical scientific and lay communities. It provides a forum for the presentation of new scientific and medical research findings with the aim of improving knowledge and understanding of human disease. As stated in the constitution; "The objectives of the Society shall be to advance pathology and facilitate communications between pathologists" but this has expanded to recognise its role in the wider community. The Society conforms to its stated objectives by the publication of its Journals, The Journal of Pathology and The Journal of Pathology: Clinical Research, by the organisation of meetings of the Society, by support of other scientific meetings and of a variety of educational and research schemes (see below).

The Society is also a Scottish registered charity and operates in Scotland.

In setting the objectives and activities for the year, the Society has referred to the guidance issued by the Charity Commission on public benefit. In particular, the Society considers how planned activities contribute to the objectives and activities they have set and how these provide public benefit. Some of the Society's normal activities such as meetings and grant activities continue to take place online after the pandemic however the Winter and Summer meetings have resumed with in person meetings.

The Pathological Society serves the public in a variety of ways. Through its scientific and educational meetings (the largest Pathology meeting in the UK and Ireland), the doctors and scientists who manage patients are kept up to date in the latest knowledge about the causes of diseases and its diagnosis. Our flagship journal, The Journal of Pathology, now in its 130th year of publication continues to enjoy very high international esteem and is widely recognised as the first choice journal in which to publish scientific papers on the mechanisms of disease. Our more recent journal, The Journal of Pathology: Clinical Research (JPCR) now in its 10th year of publication, publishes papers on the application of investigations, biomarkers and trials in clinical scenarios. Together they keep our members, pathologists worldwide and clinicians in other disciplines, apprised of developments in our understanding of the nature and causes of disease and in the resultant current expansion of new methods in diagnosis and treatment. This has immediate significance for patients, in helping to ensure that their management is supported by pathology based on the best diagnostic methods. The Society's provision of grants schemes for research training for its trainee (Concessionary) members will help to ensure that successive cohorts of young UK pathologists will have opportunities to contribute to these advances in medical care. We are hopeful that research will be able to recommence having been halted by the Pandemic.

The Pathological Society is also committed to enhancing the understanding of medical science by the general public and to this end runs Public Lectures; the most recent was given at the Virtual Joint Meeting with the British Division of the International Academy of Pathology (BDIAP) in June 2023; Professor Sir Munir Pirmohamed gave an enlightening talk on "Developing and making medicines safer". The next Public Lecture is planned for the Sheffield Pathology 2024 Meeting (18-20 June, 2024). The Public Lectures are filmed, with the permission of the lecturer, the videos are available on the Society's website. We also run the Public Engagement grant scheme which will fund a wide range of activities that help the public to understand disease, the pathology underlying the disease and the work of pathologists in the investigation, diagnosis and clinical management of disease. This has been expanded to accommodate applications for virtual events.

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**REPORT OF THE TRUSTEES  
for the year ended 31 December 2023**

The Society continues to explore additional means of informing the public about research into human disease and the practice of pathology; it is envisaged that some of this will be conducted in association with other learned societies.

The Society normally runs two major scientific meetings per year. These meetings are open to the entire medical and scientific community and not restricted to Society members. Both Winter and Summer meetings include sessions dedicated to those in training. Summer meetings are usually run jointly with the BDIAP. As this has become established as the major pathology meeting in the UK and Ireland other specialist societies are increasingly collaborating in the development and delivery of these meetings. The format of these meetings will change with an increasing on-line element within the programme. This will allow more delegates to attend without the added expense of travel & accommodation.

The attendance at the most recent summer meetings averages approximately 600. The Society underwrites all these meetings on a 50/50 basis with the BDIAP in order to maintain registration fees at affordable levels. In 2023 the Winter meeting was held in person and was the first in person meeting since the pandemic. The Winter meeting was exceptionally held over 3 days. Winter Meetings are usually held in London, jointly with the Royal Society of Medicine. The Society holds a monthly online Pathology Grand Round Lecture series supported by The Jean Shanks Foundation which are open to members and non-members to attend free of charge.

Our current schemes include:

**RESEARCH GRANTS:**

Best Trainee Research Impact & Best Trainee Research Paper Awards

- **Research Impact Award** to encourage pathology trainees to highlight the most impactful research in the last 36 months and offer £500 and a Medal.

- Research Paper Award to encourage pathology trainees to highlight their best published single research paper relevant to pathology in the last 12 months and offers £500 and a certificate. Our current annual allocation is £1,000 for each Award.

**Cuthbert Dukes Medium Grant Scheme**

This scheme was launched in 2019 to encourage early-mid career pathology researchers, in particular academic trainees, to undertake investigation tissue-based research and offers up to £20,000 with one deadline per annum.

**Cancer Research UK/Pathological Society Pre-Doctoral Research Bursary**

These jointly funded grants were introduced in 2018 and provide short term funding to allow clinicians to get involved in cancer research and provides funding for up to £45,000 for salary and/or research expenses for up to 12 months, with two deadlines per annum. The joint funding scheme ran for an initial period of three years up to 2020 and was then renewed for a further three years up to 2023. In August 2023 a decision was made to continue this scheme for a period of up to five years.

**Early Career Pathology Research Grant - Hodgkin & Leishman**

These were introduced in 2018 to trainees in their first few years of training to undertake investigative research, with two deadlines per annum. The Hodgkin offer up to £1,000 and Leishman up to £2,000. Our current annual allocation is £10,000.

**Equipment Scheme**

This scheme is aimed at supporting pathologists engaged in research by providing funds for multi-user equipment. Our current annual allocation for this scheme is £20,000 with two deadlines per annum.

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**REPORT OF THE TRUSTEES  
for the year ended 31 December 2023**

**International Collaborative Scheme**

This is aimed at promoting collaboration in scholarly pathological activities between pathologists from any institution outside of the UK and UK pathologists. Our current annual allocation for this scheme is £20,000 with one deadline per annum.

**Jean Shanks Foundation/Pathological Society (JSPS) Joint Research Grants**

The five-year agreement with the Jean Shanks Foundation was launched in 2018 and renewed for a further five years in 2023. This provides a jointly funded range of research schemes to facilitate trainees in pathology to develop their academic and research schemes ranging from early career support through to support for new independent investigators. This initiative will result in a significant increase in the Society's research grant spend. The trustees of the Society agreed to commit money from the Society's investment funds to support this.

Applications have been considered by the Research Sub-committee during 2023 and a range of high-quality applications were recommended for support and these recommendations were endorsed by the Finance and General Purposes Sub-committee.

**All schemes have two application deadlines per annum:**

- **JSPS Pre-Doctoral Research Bursary** - to promote research in pathology to fund short projects for early career clinical academic research trainee pathologists for a period of 3, 6, 9 or 12 months. This covers salary and/or research expenses to a maximum of £50,000.

- **JSPS Clinical PhD Fellowship** - To provide 3 years of PhD funding for clinical trainee histopathologists to increase the research skills, abilities and interests of those medically qualified trainee histopathologists working on tissue-based projects in pathology. Funding covers salary, university fees and consumables of up to £20,000 pa for 3 years.

- **JSPS Clinical Lecturer Grant** - To offer histopathology trainees post MD/PhD who wish to continue research part-time whilst completing clinical training (part-time). Covers up to £220,000 over a maximum of 4 years and covers 50% salary (with 50% of salary provided by the NHS - similar to the NIHR Clinical Lectureships) and provides up to £20,000 consumables per annum.

- **JSPS Clinical Lecturer Support Grant** - To offer support for continuing research projects over a 2 year period by academic trainee histopathologists following the award of a PhD or MD, when progressing through the final stages of histopathological training leading up to the award of CCT. Covers £60,000 per annum funding over a 2 year period to be used flexibly to fund the costs of employing a research technician or assistant and associated consumables costs.

- **JSPS Intermediate Research Fellowship** - to support newly accredited pathologists during the period between completing their training (passing FRCPath part 2/completing the Certificate of Completion of Training) and obtaining full funding for a Clinician Scientist post through MRC, The Wellcome Trust, CRUK etc. Covers up to £120,000 over a maximum of 2 years and covers 50% of salary costs (with 50% of salary provided by the NHS) and up to £20,000 of consumables per annum.

- **JSPS Multidisciplinary Research Partnership (MRP) Grant (formerly Clinical Academic Research Partnership (CARP) Grant)** - to offer support for NHS consultants who wish to undertake research. The aim is to encourage consultants with and MD or PhD (or equivalent) who are currently not research active, to participate in high quality research collaborations with established leading biomedical researchers.

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**REPORT OF THE TRUSTEES  
for the year ended 31 December 2023**

- **Joint Grant Scheme in Partnership with the UKRI MRC**- The Postdoctoral Clinical Research Fellowship is for trainee pathologists who have undertaken a PhD at some point before the start of their clinical pathology training. The aim of the Fellowship is to encourage trainees back into research to reacquire and update their research skills. The funding covers salary and consumables for up to 3 years.

**PhD Sponsorships** - supports a 3-year PhD and covers a stipend, research & training allowance, conference allowance and up to £20,000 per annum for consumables. Rates are set at MRC rates.

**Small Grant Schemes**

This is divided into four separate schemes, namely the Trainees' Small Grant, the Consultant's Pump Priming Small Grant, Postdoctoral Collaborative Small Grant and the Trainees Collaborative Small Grant. These awards are designed to support laboratory expenses for Trainees (speciality trainees or academic trainees) & consultants within their first five years of appointment to generate pilot data to support subsequent applications to major funding agencies. The maximum grant available is £10,000. The current annual allocation for these schemes is £10,000 for the Trainees Collaborative and £40,000 for all others.

**Trainee-Clinical Scientist Partnership Grant Scheme (formerly known as Trainee-Clinical Scientist Partnership in Morpho-Molecular Pathology)**

This scheme was introduced in 2019 to create long lasting scientific partnerships between trainee pathologists and clinical scientists in the pathology and genomics arenas, with funding up to £50,000 for a maximum of 3 years. This scheme has one deadline per annum.

**Visiting Fellowships**

The Fellowships are for members of the medical and allied scientific professions working in pathologically related bio-medical research to enable travel to other institutions to learn new techniques of value in their research. Applicants need not be Society members. Fellowships are available for a period of study of up to twelve months.

Preference is given to applicants wishing to learn new techniques in the fields of molecular and cell biology. A maximum sum of £5,000 is allocated to any one person. The current annual allocation to this scheme is £20,000.

**EDUCATION GRANTS:**

**Case Report Prize for Undergraduate & Concessionary (Trainees) Members**

Applicants are required to submit a case report and review of the literature of a standard suitable for publication that goes beyond basic morphological and immunohistochemical diagnostics. A prize of £100 is offered and the opportunity to present the case as an oral presentation at a Summer Meeting of the Society.

**Education Grant Scheme**

This scheme is designed to provide support to Academic staff for projects in relation to medical and scientific education (undergraduate and post-graduate) that foster the general area of understanding disease. Our current annual allocation for this scheme is £10,000 with two deadlines per annum.

The following Education grants are available. Following the introduction of Associate Undergraduate Membership, these grants are restricted to Associate Undergraduate members:

**Intercalated Degree Awards**

These awards provide fees (up to £9,000) and stipend (£5,000) and £1,800 for consumables for able medical, dental or veterinary students to intercalate a year's Science training and study for a BSc or MSc degree. We support up to 10 awards per annum. There are two deadlines per annum.

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**REPORT OF THE TRUSTEES  
for the year ended 31 December 2023**

**Vacation and Elective Bursaries for Undergraduate Students**

We will support any undergraduate medical, dental or veterinary student to a maximum of £220 per week for up to 8 weeks to undertake a project on any topic that bears on the issue of 'understanding disease' during elective or vacation periods. With two deadlines per annum, our current annual allocation for this scheme is £30,000.

**The Jean Shanks Foundation & Pathological Society Summer Joint Studentships (JSPS)**

This scheme was introduced in 2020 in order to support Year 1 & Year 2 medical and dental students to carry out a research project in pathology during vacation periods. Up to £220 per week, with a maximum of £1,100 per student. The Society would like to thank the Trustees of the Jean Shanks Foundation for co-finding this important initiative. The current annual allocation for this scheme is £50,000.

**Undergraduate Essay Prize**

We make an award of £500 every year for the best essay written by an undergraduate on a pathologically orientated title. Winning entries can be seen on our website.

**Pathological Society Meeting Bursary for Undergraduates**

This covers travel costs of up to £350 to attend a Pathological Society meeting.

**Students Society Bursary Scheme**

This scheme is to provide support for the promotion of the understanding of pathology amongst medical, dental, biomedical students. The sum requested should not exceed £500, current annual allocation £4,400.

All schemes are competitive and clear guidelines are published on our website. They are advertised on our website and in our journals where appropriate. They are awarded by the Society Committee and/or after consideration by the relevant Sub-committees.

**OTHER GRANTS:**

**Pathological Society Meetings Bursary**

Bursaries are made available to cover the cost of registration fees for Society members who are post graduate students (PhD, MD or MSc) or Pathology Trainees and wish to present their research at Society meetings. An applicant whose work is/has been selected for presentation in a plenary session will be favoured.

**Public Engagement Scheme**

This was established in order to foster and promote greater awareness by the lay public of advances in understanding disease which may include support of educational ventures with schools and further education colleges. Our current annual allocation for this scheme is £10,000.

**Open Scheme**

In addition to the above, the Open Scheme is designed to be a source of funds for other activities not covered by the above schemes but that will foster the Society's mission. Our current annual allocation for this scheme is £10,000.

**Travel & Conference Bursary**

These bursaries are to promote scientific communications at major international meetings. Applicants whose work has been selected for presentation are favoured.

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**REPORT OF THE TRUSTEES  
for the year ended 31 December 2023**

**Society Lectures & Awards**

The Society makes several awards for Academic and other achievements. These include the Oakley Lecture for achievements by a young researcher: this has been held annually at Joint Meetings with the BDIAP (in the summer). The Sir Nicholas Wright Lecture was introduced in 2017 and the first lecture was given at the Maastricht Pathology 2018 meeting. This is held in alternative years with the Oakley Lecture from 2018. The next Oakley lecture will be given at the Gent Pathology in June 2025.

The Wyllie Lecture & Medal has been established to mark the death of Professor Andrew Wyllie (2022) together with the 50 year anniversary (1972) of the seminal paper of Kerr, Wyllie and Currie that first described apoptosis, a major historical event for British pathology and the Pathological Society.

We promote the discipline among trainees (including PhD students and biomedical scientists) by offering a significantly discounted membership fee (£10 per annum) which includes all benefits as well as electronic access to the Journal of Pathology and other substantial subsidies (e.g. registration fees etc) including complimentary membership of the European Society of Pathology. On occasions, we can provide Society members with other benefits, such as reduced prices from the Society journals' publishers.

**STRATEGIC REPORT**

Achievement and performance

Charitable activities

The main source of income to the Society is from The Journal of Pathology and as scientific publication migrates to the Open Access model, there is a significant potential for loss of income from the Journal of Pathology. Professor Louise Jones, Editor-in-Chief and Wiley have been working hard to maintain the success of the Journal and its high impact factor, a major consideration for subscribers. The Impact Factor (IF) announced in June 2023 was 7.3, down from 9.883.

The budget of our regular meetings continues to fall well within the resources, representing less than 10% of annual turnover and 1% of current assets.

**Investment policy**

The Society has considerable investments held mostly in funds managed by our advisors, Cazenove Capital Management, the charities investment arm of Schroders. The investment policy is reviewed annually by the trustees bearing in mind the current income from the journals and membership subscriptions. A presentation is given by the portfolio director, Jeremy Barker, to all the trustees at the January Committee Meeting. The treasurer is in regular contact with the investment team and reviews/forwards relevant documentation to the trustees. The funds available to the Society are principally represented by the Investment portfolio held by the investment fund managers and consist of a variety of quoted investments and government stock. The trustees are aware of the level of income that is available from the investment portfolio and its ability to replace a loss of income from the journals.

The value of Listed investments has decreased from £7,374,145 to £7,134,188 the end of the current year.

The Society is faced with a potential loss of income supporting its grants whilst facing increased expenditure and will increase the reliance on its investment portfolio. Until the long-term financial position is clearer, reserves will be maintained with judicious use of the investment portfolio to replace the loss of journal income.

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**REPORT OF THE TRUSTEES  
for the year ended 31 December 2023**

**STRATEGIC REPORT**

**Financial position**

The financial results for the year to 31 December 2023 are shown in the attached financial statements.

Income has decreased for the year under review to £1,034,792 (2022: £1,173,640) due to slight decreases in subscription income and investment income from the Journal of Pathology was stable. Subscription income has marginally decreased to £70,983 (2022: £77,419) and on its own would not enable the Society to function. The Meeting and Events income has decreased to £36,315 (2022: £111,600). The main areas of expenditure continue to be charitable grants £1,173,269 (2022: £421,385), Society meetings £280,271 (2022: £150,444) and support costs of the society £178,124 (2022: £165,555).

Overall expenditure has exceeded income by £573,832 (2022: surplus of £269,512) after realised and unrealised investment gains and losses. Fund balances total £7,853,055 (2022: £8,426,887).

It is the policy of the charitable company that unrestricted funds which have not been designated for a specific use should be maintained at a level equivalent to at least three and six month's expenditure. The trustees consider that reserves at this level will ensure that, in the event of a significant drop in funding, they will be able to continue the charitable company's current activities while consideration is given to ways in which additional funds may be raised. This level of reserves has been maintained throughout the year.

The trustees have assessed the major risks to which the charitable company is exposed and are satisfied that systems are in place to mitigate exposure to the major risks.

**Securing the future of pathology**

To ensure the future success of the Society, it has modified its subscription structures to encourage recruitment and greater involvement of more junior pathologists. In addition, as noted above, the Trainees' Sub-committee continues to develop. Changes have already been reflected in a significant up-turn in membership numbers and progression from concessionary to ordinary membership. There had been an increase in membership numbers in 2023. Meetings to promote academic pathology amongst trainees have also been supported by The Society as well as the additional JSPS Summer Student bursary scheme for Year 1 & 2 medical students. The National Academic trainee network meetings continue, with 2 in-person meeting being held in 2023. The Society plans to continue these meetings, which are valued by the trainees.

To encourage applications for pathology amongst medical graduates, the Undergraduate Committee was established with funding to support attendance at conferences. We aim to promote interest in Pathology even before university, establishing careers days for sixth form students in association with the College and BDIAP.

The Society continues to support the Pathological Society Winter School, which continued to be run as a virtual event for 2023. The School trains participants in advance diagnostics and research skills and the programme now includes molecular pathology. The Society now fully underwrites this course and we need to ensure the course remains competitive with others around the UK.

The society also continues to run an online Education Workshop for Members and Non-Members. The workshop was introduced in 2021 and has been very popular amongst Consultants as well as Concessionary doctors.

**STRUCTURE, GOVERNANCE AND MANAGEMENT**

**Governing document**

The charitable company is a company limited by guarantee.

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**REPORT OF THE TRUSTEES  
for the year ended 31 December 2023**

**STRUCTURE, GOVERNANCE AND MANAGEMENT**

**Risk management**

The Society performed a risk analysis, which has identified the main areas of risk as loss of membership, litigation, loss of accommodation, loss of key staff or services, financial losses on meetings and loss of income from the Journal of Pathology.

Litigation is covered jointly with the publishers of the Journal of Pathology, Wiley, by our own insurance and, by the change of legal status of the Society to become an incorporated charitable company.

All trustees are required to inform the Society of their financial interests and those of direct family members of significant others in an annual, signed declaration. At the start of all grant awarding sessions, committee members are required to declare any conflicts of interest and withdraw from those decisions.

The Committee meets twice annually, normally a day prior to the Winter and Summer Scientific Meetings. This is the formal meeting of all Trustees at which they agree on the broad strategy and areas of activity for the Society, including consideration of grant awarding, investment strategy and risk management. The 2022 Winter and Summer Committee meetings were held in person.

The Society other sub-committees remain in place and continue to administer the activities of the Society; these are as follows:

- Research Sub-committee (chaired by Professor G Thomas) is responsible for assessing research grant applications and taking into account, where appropriate, external advice with a robust peer review process for grants which exceed £25,000.

- Education Sub-committee (chaired by Dr A Mukherjee) advises on the allocation of funds for intercalated degree students, undergraduate elective bursaries, educational grants and the Student Seminar Scheme and has recently taken on the Pathological Society Meeting Bursary and Travel & Conference Bursary awards.

- Programme Sub-committee (chaired by Professor M Ilyas), develops and approves programme content and the Society's scientific meetings strategy.

- Trainees' Sub-committee (chaired by Dr C McGenity), was established in order to encourage a greater involvement of pathologists in training and to represent their views to the Committee of the Society.

- An Undergraduate Committee has representatives on the main Committee and Trainees' Sub-committee meetings.

The Committee is aware of the Charity Commission's Governance Code and continues to apply the Code as appropriate.

**REFERENCE AND ADMINISTRATIVE DETAILS**

**Registered Company number**

08759028 (England and Wales)

**Registered Charity number**

1154851

**Registered office**

7th Floor, 6 Alie Street

London

E1 8QT

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**REPORT OF THE TRUSTEES  
for the year ended 31 December 2023**

**Trustees**

Dr M J Arends , Professor of Pathology  
Doctor R J Byers Consultant Histopathologist (appointed 29.6.23)  
Dr S E Coupland , Consultant Histopathologist  
Dr H I Grabsch , Professor Gastrointestinal Pathology (resigned 29.6.23)  
Dr M Jansen Clinician Scientist-Honorary  
Dr A Mukherjee , Honorary Consultant Histopathologist  
Prof G I Murray , Professor of Pathology  
Dr A Shaaban , Consultant Pathologist (resigned 29.6.23)  
Dr G J Thomas , Professor of Experimental Pathology  
Dr N P West Trustee  
Dr C Coyne , Consultant Histopathologist  
Dr L Moore , Consultant Histopathologist (resigned 29.6.23)  
Dr G S Petts , Clinical Lecturer in Pathology  
Dr T J Kendall , Senior Clinical Research in Pathology  
Professor J P C Le Quesne , Professor Of Molecular Pathology  
Dr N Pillay ,Group Leader/Hon Consultant Pathologist  
Dr M F C Amary , Consultant Histopathologist  
Dr D A Moore , Honorary Consultant Histopathologist  
Professor S C Burdak-Rothkamm , Consultant Histopathologist  
Professor E Soilleux , Honorary Consultant Pathologist  
Professor M Ilyas , Professor of Pathology  
Dr S D Richman Lecturer In Pathology (appointed 29.6.23)

**Auditors**

Raffingers LLP, Statutory Auditor  
Chartered Certified Accountants  
19-20 Bourne Court  
Southend Road  
Woodford Green  
Essex  
IG8 8HD

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**REPORT OF THE TRUSTEES  
for the year ended 31 December 2023**

**TRUSTEES' RESPONSIBILITY STATEMENT**

The trustees, who are also the directors of The Pathological Society of Great Britain and Ireland for the purpose of company law, are responsible for preparing the Trustees' Report and the accounts in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charitable companies in England and Wales and in Scotland requires the trustees to prepare accounts for each financial year which give a true and fair view of the state of affairs of the charitable company and of the income and expenditure of the charitable company for that year. In preparing these accounts, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the accounts; and
- prepare the accounts on the going concern basis unless it is inappropriate to presume that the charitable company will continue in operation.

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the accounts comply with the Companies Act 2006, the relevant Charity (Accounts and Reports) Regulations, the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 and the provisions of the charity's constitution. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees' report was approved by the Board of Trustees

Report of the trustees, incorporating a strategic report, approved by order of the board of trustees, as the company directors, on ..... and signed on the board's behalf by:

.....  
Prof G I Murray - Trustee

**REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF  
THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**Opinion**

We have audited the financial statements of The Pathological Society of Great Britain and Ireland (the 'charitable company') for the year ended 31 December 2023 which comprise the Statement of Financial Activities, the Balance Sheet, the Cash Flow Statement and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 December 2021 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and Regulation 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended).

**Basis for opinion**

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

**Conclusions relating to going concern**

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

**Other information**

The trustees are responsible for the other information. The other information comprises the information included in the Annual Report, other than the financial statements and our Report of the Independent Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

**Opinions on other matters prescribed by the Companies Act 2006**

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the Report of the Trustees for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Report of the Trustees has been prepared in accordance with applicable legal requirements.

**REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF  
THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**Matters on which we are required to report by exception**

In the light of the knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the Report of the Trustees.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 and the Charities Accounts (Scotland) Regulations 2006 (as amended) requires us to report to you if, in our opinion: requires us to report to you if, in our opinion:

- the information given in the accounts is inconsistent in any material respect with the Trustees' Report; or
- sufficient and proper accounting records have not been kept; or
- the accounts are not in agreement with the accounting records; or
- we have not received all the information and explanations we require for our audit.

**Responsibilities of trustees**

As explained more fully in the Trustees' Responsibilities Statement, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

**REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF  
THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**Our responsibilities for the audit of the financial statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Independent Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Our approach to identifying and assessing the risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, was as follows:

- the engagement partner ensured that the engagement team collectively had the appropriate competence, capabilities and skills to identify or recognise non-compliance with applicable laws and regulations;
- we identified the laws and regulations applicable to the charitable company through discussions with management and from our commercial knowledge and experience of the sector The Pathological Society of Great Britain and Ireland belongs to;
- we focused on specific laws and regulations which we considered may have a direct material effect on the financial statements or the operations of the association, including the Charities Act 2011, Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable to the United Kingdom and Republic of Ireland (FRS 102) (effective 1 January 2019), Trustees Act, Bribery Act and data protection;
- we assessed the extent of compliance with the laws and regulations identified above through making enquiries of management and inspecting legal correspondence; and
- identified laws and regulations were communicated within the audit team regularly and the team remained alert to instances of non-compliance throughout the audit.

We assessed the susceptibility of the charity's financial statements to material misstatement, including obtaining an understanding of how fraud might occur, by:

- making enquiries of management as to where they considered there was susceptibility to fraud, their knowledge of actual, suspected and alleged fraud; and
- considering the internal controls in place to mitigate risks of fraud and non-compliance with laws and regulations, including the ones that ensure that the grants are used for intended purposes.

To address the risk of fraud through management bias and override of controls, we:

- performed analytical procedures to identify any unusual or unexpected relationships;
- tested journal entries to identify unusual transactions;
- assessed whether judgements and assumptions made in determining the accounting estimates were indicative of potential bias; and
- investigated the rationale behind significant or unusual transactions.

In response to the risk of irregularities and non-compliance with laws and regulations, we designed procedures which included, but were not limited to:

- agreeing financial statement disclosures to underlying supporting documentation;
- reading the minutes of meetings of those charged with governance;
- enquiring of management as to actual and potential litigation and claims.

There are inherent limitations in our audit procedures described above. The more removed that laws and regulations are from financial transactions, the less likely it is that we would become aware of non-compliance. Auditing standards also limit the audit procedures required to identify non-compliance with laws and regulations to enquiry of the trustees and other management and the inspection of regulatory and legal correspondence, if any.

Material misstatements that arise due to fraud can be harder to detect than those that arise from error as they may involve deliberate concealment or collusion.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at [www.frc.org.uk/auditorsresponsibilities](http://www.frc.org.uk/auditorsresponsibilities). This description forms part of our Report of the Independent Auditors.

**REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF**  
**THE PATHOLOGICAL SOCIETY OF GREAT**  
**BRITAIN AND IRELAND**

**Use of our report**

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006 and with regulations made under section 154 of that Act and in accordance with Section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and Regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Mr Thurairatnam Sudarshan (Senior Statutory Auditor)  
for and on behalf of Raffingers LLP, Statutory Auditor  
Chartered Certified Accountants  
19-20 Bourne Court  
Southend Road  
Woodford Green  
Essex  
IG8 8HD

Date: .....

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**STATEMENT OF FINANCIAL ACTIVITIES  
for the year ended 31 December 2023**

	Notes	2023 Unrestricted fund £	2022 Total funds £
<b>INCOME AND ENDOWMENTS FROM</b>			
Donations and legacies	2	70,983	77,419
<b>Charitable activities</b>			
Journal of Pathology	4	711,388	794,406
Meetings and Events		36,315	111,600
Investment income	3	<u>216,106</u>	<u>190,215</u>
<b>Total</b>		<u>1,034,792</u>	<u>1,173,640</u>
 <b>EXPENDITURE ON</b>			
<b>Raising funds</b>			
Investment management costs	5	<u>30,409</u>	<u>32,346</u>
		30,409	32,346
<b>Charitable activities</b>			
General	6	492	-
Journal of Pathology		228,181	218,470
Grants and Award payable		1,292,912	559,560
Meetings and Events		<u>280,271</u>	<u>150,444</u>
<b>Total</b>		<u>1,832,265</u>	<u>960,820</u>
Net gains/(losses) on investments		<u>223,641</u>	<u>(482,332)</u>
<b>NET INCOME/(EXPENDITURE)</b>		(573,832)	(269,512)
 <b>RECONCILIATION OF FUNDS</b>			
Total funds brought forward		<u>8,426,887</u>	<u>8,696,399</u>
<b>TOTAL FUNDS CARRIED FORWARD</b>		<u>7,853,055</u>	<u>8,426,887</u>

**CONTINUING OPERATIONS**

All income and expenditure has arisen from continuing activities.

The notes form part of these financial statements

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**BALANCE SHEET**  
**31 December 2023**

	Notes	2023 Total funds £	2022 Total funds £
<b>FIXED ASSETS</b>			
Tangible assets	13	5,735	17,855
Investments	14	<u>7,170,377</u>	<u>7,374,145</u>
		7,176,112	7,392,000
<b>CURRENT ASSETS</b>			
Debtors	15	743,993	819,723
Cash at bank and in hand		<u>246,916</u>	<u>416,445</u>
		990,909	1,236,168
<b>CREDITORS</b>			
Amounts falling due within one year	16	(313,966)	(201,281)
		<u>676,943</u>	<u>1,034,887</u>
<b>NET CURRENT ASSETS</b>		<u>676,943</u>	<u>1,034,887</u>
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>		<u>7,853,055</u>	<u>8,426,887</u>
<b>NET ASSETS</b>		<u>7,853,055</u>	<u>8,426,887</u>
<b>FUNDS</b>	17		
Unrestricted funds:			
General fund		<u>7,853,055</u>	<u>8,426,887</u>
<b>TOTAL FUNDS</b>		<u>7,853,055</u>	<u>8,426,887</u>

The financial statements were approved by the Board of Trustees and authorised for issue on .....  
and were signed on its behalf by:

.....  
Prof G I Murray - Trustee

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**CASH FLOW STATEMENT**  
**for the year ended 31 December 2023**

	Notes	2023 £	2022 £
<b>Cash flows from operating activities</b>			
Cash generated from operations	1	<u>(813,044)</u>	<u>(114,743)</u>
Net cash used in operating activities		<u>(813,044)</u>	<u>(114,743)</u>
<b>Cash flows from investing activities</b>			
Purchase of fixed asset investments		(2,609,366)	(1,174,055)
Sale of fixed asset investments		3,001,522	1,334,429
Movement in capital accounts		35,253	-
Interest received		7,770	1,097
Dividends received		<u>208,336</u>	<u>189,118</u>
Net cash provided by investing activities		<u>643,515</u>	<u>350,589</u>
		<hr/>	<hr/>
<b>Change in cash and cash equivalents in the reporting period</b>		(169,529)	235,846
<b>Cash and cash equivalents at the beginning of the reporting period</b>		<u>416,445</u>	<u>180,599</u>
<b>Cash and cash equivalents at the end of the reporting period</b>		<u><u>246,916</u></u>	<u><u>416,445</u></u>

The notes form part of these financial statements

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**NOTES TO THE CASH FLOW STATEMENT  
for the year ended 31 December 2023**

**1. RECONCILIATION OF NET EXPENDITURE TO NET CASH FLOW FROM OPERATING ACTIVITIES**

	2023 £	2022 £
<b>Net expenditure for the reporting period (as per the Statement of Financial Activities)</b>	(573,832)	(269,512)
<b>Adjustments for:</b>		
Depreciation charges	12,120	12,128
(Gain)/losses on investments	(223,641)	482,332
Interest received	(7,770)	(1,097)
Dividends received	(208,336)	(189,118)
Decrease in debtors	75,730	29,461
Increase/(decrease) in creditors	<u>112,685</u>	<u>(178,937)</u>
<b>Net cash used in operations</b>	<u><u>(813,044)</u></u>	<u><u>(114,743)</u></u>

**2. ANALYSIS OF CHANGES IN NET FUNDS**

	At 1.1.23 £	Cash flow £	At 31.12.23 £
<b>Net cash</b>			
Cash at bank and in hand	<u>416,445</u>	<u>(169,529)</u>	<u>246,916</u>
	<u>416,445</u>	<u>(169,529)</u>	<u>246,916</u>
<b>Total</b>	<u><u>416,445</u></u>	<u><u>(169,529)</u></u>	<u><u>246,916</u></u>

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**NOTES TO THE FINANCIAL STATEMENTS  
for the year ended 31 December 2023**

**1. ACCOUNTING POLICIES**

**Basis of preparing the financial statements**

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (Charities SORP FRS 102), (effective 1 January 2015) the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

The financial statements have been prepared under the historical cost convention with the exception of investments which are included at market value, as modified by the revaluation of certain assets.

The charity constitutes a public benefit entity as defined by FRS 102.

The accounts are presented in sterling and are rounded to the nearest pound.

**Assessment of going concern**

The trustees have assessed whether the use of the going concern assumption is appropriate in preparing these accounts. The trustees have made this assessment in respect to a period of one year from the date of approval of these accounts.

The trustees of the charity have concluded that there are no material uncertainties related to events or conditions that may cast significant doubt on the ability of the charity to continue as going concern. The trustees are of the opinion that the charity will have sufficient resources to meet its liabilities as they fall due.

**Critical accounting judgements and key sources of estimation uncertainty**

Preparation of the financial statements requires the trustees and management to make significant judgements and estimates.

The items in the accounts where these judgements and estimates have been made include:

- the useful economic lives attributed to tangible fixed assets used to determine the annual depreciation charge; and
- the assumptions adopted by the trustees in determining the value of any designations required from the charity's general unrestricted funds.

**Income**

Income is recognised when the charitable company is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received. Cash donations are recognised on receipt. Other donations are recognised once the charitable company has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Deferred income is recognised for income received in advance for events and meetings taking place in future periods.

Membership subscriptions are recognised in the year to which they relate.

**Journal of Pathology**

The receipts in respect of journals supplied by the Society are credited to the financial statements in the year to which they relate. The income from journals is the proportion due to the Society under the relevant agreements and is net of direct costs met by the publishers.

**Meetings and events income**

Income and corresponding expenditure are recognised in the period the event has taken place. This results in deferred income and accruals recognised in balance sheet.

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**NOTES TO THE FINANCIAL STATEMENTS - continued**  
**for the year ended 31 December 2023**

**1. ACCOUNTING POLICIES - continued**

Investment income

**Income**

Dividends and interest on securities are credited in the financial statements when the Society is entitled to receive the funds.

**Expenditure**

Expenditure is recognised once there is a legal or constructive obligation to make a payment to a third party, it is probable that settlement will be required and the amount of the obligation can be measured reliably.

The costs of raising funds consist of investment management fees.

Journal of Pathology

The cost of distributing copies of the journal to members is recognised as a charitable activity.

Support costs for meetings

Costs incurred for the Society's events and meetings are recognised in the period in which they take place.

All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the category.

Grants payable

Grants payable are payments made to third parties in the furtherance of the charitable objects of the Society. In the case of an unconditional grant offer this is accrued once the recipient has been notified of the grant award. The notification gives the recipient a reasonable expectation that they will receive the one- year or multi-year grant. Grants awards that are subject to the recipient fulfilling performance conditions are only accrued when the recipient has been notified of the grant and any remaining unfulfilled condition attaching to that grant is outside of the control of the Society.

**Tangible fixed assets**

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Fixtures and fittings	- 15% on reducing balance
Computer equipment	- 20% on cost

**Taxation**

The charity is exempt from corporation tax on its charitable activities.

**Fund accounting**

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Designated funds comprise funds which have been set aside at the discretion of the trustees for specific purposes. The purposes and uses of the designated funds are set out in the notes to the accounts.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

**Cash at bank and in hand**

Cash at bank and in hand represents such accounts and instruments that are available on demand or have a maturity of less than three months from the date of acquisition. Deposits for more than three months but less than one year have been disclosed as short term deposits.

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**NOTES TO THE FINANCIAL STATEMENTS - continued**  
**for the year ended 31 December 2023**

**1. ACCOUNTING POLICIES - continued**

**Creditors and provision**

Creditors and provision are recognised when there is an obligation at the balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably. Creditors and provision are recognised at the moment the charity anticipates it will pay to settle the debt. They have been discounted to the present value of the future cash payments where such discounting is material.

**Investments**

Listed investments are initially recognised at their transaction value and subsequently measured at their fair value as at the balance sheet date using the closing quoted market price.

Realised and unrealised investment gains (or losses) are combined in the statement of financial activities and are credited (or debited) in the year in which they arise.

**2. DONATIONS AND LEGACIES**

	Unrestricted funds £	Restricted funds £	2023 Total funds £	2022 Total funds £
Subscriptions	<u>70,983</u>	<u>-</u>	<u>70,983</u>	<u>77,419</u>

**3. INVESTMENT INCOME**

	Unrestricted funds £	Restricted funds £	2023 Total funds £	2022 Total funds £
Income from listed investments	208,336	-	208,336	189,118
Deposit account interest	<u>7,770</u>	<u>-</u>	<u>7,770</u>	<u>1,097</u>
	<u>216,106</u>	<u>-</u>	<u>216,106</u>	<u>190,215</u>

**4. INCOME FROM CHARITABLE ACTIVITIES**

	2023 £	2022 £
Journal of Pathology	711,388	794,406
Meetings and events	<u>39,506</u>	111,600
	750,894	<u>906,006</u>

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**NOTES TO THE FINANCIAL STATEMENTS - continued  
for the year ended 31 December 2023**

**5. INVESTMENT MANAGEMENT COSTS**

	Unrestricted funds £	Restricted funds £	2023 Total funds £	2022 Total funds £
Investment management	<u>30,409</u>	<u>-</u>	<u>30,409</u>	<u>32,346</u>

**6. CHARITABLE ACTIVITIES COSTS**

	Direct Costs £	Grant funding of activities (see note 7) £	Support costs (see note 8) £	Totals £
General	-	-	492	492
Journal of Pathology	228,181	-	-	228,181
Grants and Award payable	-	1,163,269	129,643	1,292,912
Meetings and Events	<u>132,695</u>	<u>10,000</u>	<u>137,576</u>	<u>280,271</u>
	<u>360,876</u>	<u>1,173,269</u>	<u>267,711</u>	<u>1,801,856</u>

**7. GRANTS PAYABLE**

	2023 £	2022 £
Grants and Award payable	1,163,269	421,385
Meetings and Events	<u>10,000</u>	<u>-</u>
	<u>1,173,269</u>	<u>421,385</u>

**8. SUPPORT COSTS**

	Management £	Finance £	Governance costs £	Totals £
General	492	-	-	492
Grants and Award payable	60,809	2,620	66,214	129,643
Meetings and Events	<u>116,823</u>	<u>-</u>	<u>20,753</u>	<u>137,576</u>
	<u>178,124</u>	<u>2,620</u>	<u>86,967</u>	<u>267,711</u>

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**NOTES TO THE FINANCIAL STATEMENTS - continued  
for the year ended 31 December 2023**

**8. SUPPORT COSTS - continued**

Support costs, included in the above, are as follows:

	2023	2022
	Total activities £	Total activities £
General £		
Grants and Award payable £		
Meetings and Events £		
Wages	69,000	48,037
Social security	6,094	2,899
Pensions	6,774	3,239
Rent and insurance	35,155	26,196
Postage and stationery	122	3,350
Sundries	6,507	10,862
Website & computer	42,352	58,844
Depreciation of tangible and heritage assets	12,120	12,128
Bank charges	2,620	1,525
Wages	29,580	20,600
Auditors' remuneration	7,000	7,000
Committee meetings	20,753	13,951
Accountancy fees	26,296	8,363
Professional and legal fees	3,338	18,853
	<u>492</u>	<u>235,847</u>
	<u>129,643</u>	<u>137,576</u>
	<u>267,711</u>	<u>267,711</u>

**9. NET INCOME/(EXPENDITURE)**

Net income/(expenditure) is stated after charging/(crediting):

	2023	2022
	£	£
Auditors' remuneration	7,000	7,000
Depreciation - owned assets	<u>12,120</u>	<u>12,128</u>

**10. TRUSTEES' REMUNERATION AND BENEFITS**

**Trustees' expenses**

None of the trustees (or any persons connected with them) received any remuneration during the year, there were also no travelling costs reimbursed this year.

No grants were received by trustees from the Society in the year.

No committee advisors (non-trustee) received grants from the Society in the year.

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**NOTES TO THE FINANCIAL STATEMENTS - continued  
for the year ended 31 December 2023**

**11. STAFF COSTS**

	2023 £	2022 £
Wages and salaries	129,800	119,649
Social security costs	9,775	9,077
Other pension costs	<u>13,330</u>	<u>12,218</u>
	<u>152,905</u>	<u>140,944</u>

The average monthly number of employees during the year was as follows:

	2023	2022
Administrative staff	<u>2</u>	<u>2</u>

No employees received emoluments in excess of £60,000.

**12. FINANCIAL COMMITMENTS, GUARANTEES AND CONTINGENT LIABILITIES**

The company is limited by guarantee - all members having a liability not exceeding £1 per member.

**13. TANGIBLE FIXED ASSETS**

	Fixtures and fittings £	Computer equipment £	Totals £
<b>COST</b>			
At 1 January 2023 and 31 December 2023	<u>12,374</u>	<u>65,774</u>	<u>78,148</u>
<b>DEPRECIATION</b>			
At 1 January 2023	12,071	48,222	60,293
Charge for year	<u>45</u>	<u>12,075</u>	<u>12,120</u>
At 31 December 2023	<u>12,116</u>	<u>60,297</u>	<u>72,413</u>
<b>NET BOOK VALUE</b>			
At 31 December 2023	<u>258</u>	<u>5,477</u>	<u>5,735</u>
At 31 December 2022	<u>303</u>	<u>17,552</u>	<u>17,855</u>

**14. FIXED ASSET INVESTMENTS**

	2023 £	2022 £
Shares	7,134,188	7,302,703
Other	<u>36,189</u>	<u>71,442</u>
	<u>7,170,377</u>	<u>7,374,145</u>

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**NOTES TO THE FINANCIAL STATEMENTS - continued  
for the year ended 31 December 2023**

**14. FIXED ASSET INVESTMENTS - continued**

Additional information as follows:

	Listed investments £
<b>MARKET VALUE</b>	
At 1 January 2023	7,302,703
Additions	2,609,366
Disposals	(3,001,522)
Revaluations	<u>223,641</u>
At 31 December 2023	<u>7,134,188</u>
<b>NET BOOK VALUE</b>	
At 31 December 2023	<u><u>7,134,188</u></u>
At 31 December 2022	<u><u>7,302,703</u></u>

There were no investment assets outside the UK.

Investments (neither listed nor unlisted) were as follows:

	2023	2022
	£	£
Cash in portfolio	<u>36,189</u>	<u>71,442</u>

**15. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	2023	2022
	£	£
Other debtors	733,371	808,552
Prepayments	<u>10,622</u>	<u>11,171</u>
	<u><u>743,993</u></u>	<u><u>819,723</u></u>

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**NOTES TO THE FINANCIAL STATEMENTS - continued**  
**for the year ended 31 December 2023**

**16. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	2023	2022
	£	£
Trade creditors	40,728	17,354
VAT	-	1,000
Other creditors	666	615
Accruals and deferred income	<u>272,572</u>	<u>182,312</u>
	<u>313,966</u>	<u>201,281</u>

**17. MOVEMENT IN FUNDS**

	At 1.1.23	Net movement in funds	At 31.12.23
	£	£	£
<b>Unrestricted funds</b>			
General fund	8,426,887	(573,832)	7,853,055
	<u>8,426,887</u>	<u>(573,832)</u>	<u>7,853,055</u>
<b>TOTAL FUNDS</b>	<u>8,426,887</u>	<u>(573,832)</u>	<u>7,853,055</u>

Net movement in funds, included in the above are as follows:

	Incoming resources	Resources expended	Gains and losses	Movement in funds
	£	£	£	£
<b>Unrestricted funds</b>				
General fund	1,034,792	(1,832,265)	223,641	(573,832)
	<u>1,034,792</u>	<u>(1,832,265)</u>	<u>223,641</u>	<u>(573,832)</u>
<b>TOTAL FUNDS</b>	<u>1,034,792</u>	<u>(1,832,265)</u>	<u>223,641</u>	<u>(573,832)</u>

**Comparatives for movement in funds**

	At 1.1.22	Net movement in funds	At 31.12.22
	£	£	£
<b>Unrestricted funds</b>			
General fund	8,696,399	(269,512)	8,426,887
	<u>8,696,399</u>	<u>(269,512)</u>	<u>8,426,887</u>
<b>TOTAL FUNDS</b>	<u>8,696,399</u>	<u>(269,512)</u>	<u>8,426,887</u>

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**NOTES TO THE FINANCIAL STATEMENTS - continued**  
**for the year ended 31 December 2023**

**17. MOVEMENT IN FUNDS - continued**

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Gains and losses £	Movement in funds £
<b>Unrestricted funds</b>				
General fund	1,173,640	(960,820)	(482,332)	(269,512)
	<u>                    </u>	<u>                    </u>	<u>                    </u>	<u>                    </u>
<b>TOTAL FUNDS</b>	<u>1,173,640</u>	<u>(960,820)</u>	<u>(482,332)</u>	<u>(269,512)</u>

**18. RELATED PARTY TRANSACTIONS**

**Remuneration of key management personnel**

The remuneration of key management personnel is as follows.

	2023 £	2022 £
Aggregate compensation	152,905	140,944

The above amounts include payments to the Royal College of Pathologists for the use of 3 (2022: 3) of their employees for administrative management of the society. As part of the agreement between the two entities, in the event of the Royal College of Pathologists being required to contribute to the pension scheme that it belongs to, the society could be liable to meet the obligations of the pension costs in respect of these individuals.

**19. SUBSIDIARIES**

There were no subsidiaries controlled by the charity as at 31 December 2023.

**THE PATHOLOGICAL SOCIETY OF GREAT BRITAIN AND IRELAND**

England & Wales - Charity number 1154851

---

# Accounts

---

REGISTERED COMPANY NUMBER: 08759028 (England and Wales)  
REGISTERED CHARITY NUMBER: 1154851

**REPORT OF THE TRUSTEES AND**  
**FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2022**  
**FOR**  
**THE PATHOLOGICAL SOCIETY OF GREAT**  
**BRITAIN AND IRELAND**

Raffingers LLP, Statutory Auditor  
Chartered Certified Accountants  
19-20 Bourne Court  
Southend Road  
Woodford Green  
Essex  
IG8 8HD

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**CONTENTS OF THE FINANCIAL STATEMENTS  
for the year ended 31 December 2022**

	<b>Page</b>
<b>Report of the Trustees</b>	1 to 10
<b>Report of the Independent Auditors</b>	11 to 14
<b>Statement of Financial Activities</b>	15
<b>Balance Sheet</b>	16
<b>Cash Flow Statement</b>	17
<b>Notes to the Cash Flow Statement</b>	18
<b>Notes to the Financial Statements</b>	19 to 27

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND (REGISTERED NUMBER: 08759028)**

**REPORT OF THE TRUSTEES  
for the year ended 31 December 2022**

The trustees present their report and accounts for the year ended 31 December 2022.

The accounts have been prepared in accordance with the accounting policies set out in note 1 to the accounts and comply with the charitable company's governing document, the Companies Act 2006 and the Statement of Recommended Practice, "Accounting and Reporting by Charities", issued in March 2015.

**PUBLIC BENEFIT**

The trustees have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing the aim and objectives and in planning the charity's future activities. The aims of the charity for the public benefit are detailed in the 'Objectives and Activities' section of this report.

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND (REGISTERED NUMBER: 08759028)**

**REPORT OF THE TRUSTEES  
for the year ended 31 December 2022**

**OBJECTIVES AND ACTIVITIES**

The Pathological Society is dedicated to the "Understanding of Disease-Guiding Therapy" in the medical scientific and lay communities. It provides a forum for the presentation of new scientific and medical research findings with the aim of improving knowledge and understanding of human disease. As stated in the constitution; "The objectives of the Society shall be to advance pathology and facilitate communications between pathologists" but this has expanded to recognise its role in the wider community. The Society conforms to its stated objectives by the publication of its Journals, The Journal of Pathology and The Journal of Pathology: Clinical Research, by the organisation of meetings of the Society, by support of other scientific meetings and of a variety of educational and research schemes (see below).

The Society is also a Scottish registered charity and operates in Scotland.

In setting the objectives and activities for the year, the Society has referred to the guidance issued by the Charity Commission on public benefit. In particular, the Society considers how planned activities contribute to the objectives and activities they have set and how these provide public benefit. For the past year, due to the ongoing Covid-19 pandemic, the Society's normal activities have had to adapt accordingly, especially in relation to scientific meetings as well as some grant activities.

The Pathological Society serves the public in a variety of ways. Through its scientific and educational meetings (the largest Pathology meeting in the UK and Ireland), the doctors and scientists who manage patients are kept up to date in the latest knowledge about the causes of diseases and its diagnosis. Our flagship journal, The Journal of Pathology, now in its 130th year of publication continues to enjoy very high international esteem and is widely recognised as the first choice journal in which to publish scientific papers on the mechanisms of disease. Our more recent journal, The Journal of Pathology: Clinical Research (JPCR) now in its 9th year of publication, publishes papers on the application of investigations, biomarkers and trials in clinical scenarios. Together they keep our members, pathologists worldwide and clinicians in other disciplines, apprised of developments in our understanding of the nature and causes of disease and in the resultant current expansion of new methods in diagnosis and treatment. This has immediate significance for patients, in helping to ensure that their management is supported by pathology based on the best diagnostic methods. The Society's provision of grants schemes for research training for its trainee (Concessionary) members will help to ensure that successive cohorts of young UK pathologists will have opportunities to contribute to these advances in medical care. We are hopeful that research will be able to recommence having been halted by the Pandemic.

The Pathological Society is also committed to enhancing the understanding of medical science by the general public and to this end runs Public Lectures; the most recent was given at the Virtual Joint Meeting with the British Division of the International Academy of Pathology (BDIAP) in July 2021; Dame Nancy Rothwell gave an enlightening talk on the "A Stroke of Bad Luck". The next Public Lecture is planned for the Liverpool Pathology 2023 Meeting (27-29 June, 2023). The Public Lectures are filmed, with the permission of the lecturer, the videos are available on the Society's website. We also run the Public Engagement grant scheme which will fund a wide range of activities that help the public to understand disease, the pathology underlying the disease and the work of pathologists in the investigation, diagnosis and clinical management of disease. This has been expanded to accommodate applications for virtual events.

The Society continues to explore additional means of informing the public about research into human disease and the practice of pathology; it is envisaged that some of this will be conducted in association with other learned societies.

The Society normally runs two major scientific meetings per year. These meetings are open to the entire medical and scientific community and not restricted to Society members. Both Winter and Summer meetings include sessions dedicated to those in training. All our summer meetings are run jointly with the BDIAP. As this has become established as the major pathology meeting in the UK and Ireland other specialist societies are increasingly collaborating in the development and delivery of these meetings. The format of these meetings will change with an increasing on-line element within the programme. This will allow more delegates to attend without the added expense of travel & accommodation.

The attendance at the most recent summer meetings averages approximately 500. The Society underwrites all these meetings on a 50/50 basis with the BDIAP in order to maintain registration fees at affordable levels. In 2022 the Winter meeting was held online as a fully virtual meeting. Winter Meetings are usually held in London, jointly with the Royal Society of Medicine. Whilst no face to face educational events were possible over the last year, the Society holds a monthly online Pathology Grand Round Lecture series supported by The Jean Shanks Foundation which are open to members and non-members to attend free of charge.

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND (REGISTERED NUMBER: 08759028)**

**REPORT OF THE TRUSTEES  
for the year ended 31 December 2022**

Our current schemes include:

**RESEARCH GRANTS:**

Best Trainee Research Impact & Best Trainee Research Paper Awards

- **Research Impact Award** to encourage pathology trainees to highlight the most impactful research in the last 36 months and offer £500 and a Medal.

- **Research Paper Award** to encourage pathology trainees to highlight their best published single research paper relevant to pathology in the last 12 months and offers £500 and a certificate.

Our current annual allocation is £1,000 for each Award.

Cuthbert Dukes Medium Grant Scheme

This scheme was launched in 2019 to encourage early-mid career pathology researchers, in particular academic trainees, to undertake investigation tissue-based research and offers up to £20,000 with one deadline per annum.

Cancer Research UK/Pathological Society Pre-Doctoral Research Bursary

These jointly funded grants were introduced in 2018 and provide short term funding to allow clinicians to get involved in cancer research and provides funding for up to £45,000 for salary and/or research expenses for up to 12 months, with two deadlines per annum. The initial 3 year agreement with CRUK ended in 2020 and has been extended for a further 3 year period.

**Early Career Pathology Research Grant - Hodgkin & Leishman**

These were introduced in 2018 to trainees in their first few years of training to undertake investigative research, with two deadlines per annum. The Hodgkin offer up to £1,000 and Leishman up to £2,000. Our current annual allocation is £10,000

**Equipment Scheme**

This scheme is aimed at supporting pathologists engaged in research by providing funds for multi-user equipment. Our current annual allocation for this scheme is £20,000 with two deadlines per annum

**International Collaborative Scheme**

This is aimed at promoting collaboration in scholarly pathological activities between pathologists from any institution outside of the UK and UK pathologists. Our current annual allocation for this scheme is £20,000 with one deadline per annum.

**Jean Shanks Foundation/Pathological Society (JSPS) Joint Research Grants**

The five-year agreement with the Jean Shanks Foundation launched in 2018 provides a jointly funded range of research schemes to facilitate trainees in pathology to develop their academic and research schemes ranging from early career support through to support for new independent investigators. This initiative will result in a significant increase in the Society's research grant spend. The trustees of the Society agreed to commit money from the Society's investment funds to support this.

Applications have been considered by the Research Sub-committee during 2022 and a range of high-quality applications were recommended for support and these recommendations were endorsed by the Finance and General Purposes Sub-committee.

**All schemes have two application deadlines per annum:**

- **JSPS Pre-Doctoral Research Bursary** - to promote research in pathology to fund short projects for early career clinical academic research trainee pathologists for a period of 3, 6, 9 or 12 months. This covers salary and/or research expenses to a maximum of £50,000.

- **JSPS Clinical PhD Fellowship** - To provide 3 years of PhD funding for clinical trainee histopathologists to increase the research skills, abilities and interests of those medically qualified trainee histopathologists working on tissue-based projects in pathology. Funding covers salary, university fees and consumables of up to £20,000 pa for 3 years.

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND (REGISTERED NUMBER: 08759028)**

**REPORT OF THE TRUSTEES  
for the year ended 31 December 2022**

- **JSPS Clinical Lecturer Grant** - To offer histopathology trainees post MD/PhD who wish to continue research part-time whilst completing clinical training (part-time). Covers up to £220,000 over a maximum of 4 years and covers 50% salary (with 50% of salary provided by the NHS - similar to the NIHR Clinical Lectureships) and provides up to £20,000 consumables per annum.
- **JSPS Clinical Lecturer Support Grant** - To offer support for continuing research projects over a 2 year period by academic trainee histopathologists following the award of a PhD or MD, when progressing through the final stages of histopathological training leading up to the award of CCT. Covers £60,000 per annum funding over a 2 year period to be used flexibly to fund the costs of employing a research technician or assistant and associated consumables costs.
- **JSPS Intermediate Research Fellowship** - to support newly accredited pathologists during the period between completing their training (passing FRCPath part 2/completing the Certificate of Completion of Training) and obtaining full funding for a Clinician Scientist post through MRC, The Wellcome Trust, CRUK etc. Covers up to £120,000 over a maximum of 2 years and covers 50% of salary costs (with 50% of salary provided by the NHS) and up to £20,000 of consumables per annum.
- **JSPS Clinical Academic Research Partnership** - to offer support for NHS consultants who wish to undertake research. The aim is to encourage consultants with and MD or PhD (or equivalent) who are currently not research active, to participate in high quality research collaborations with established leading biomedical researchers.
- **Joint Grant Scheme in Partnership with the UKRI MRC**- The Postdoctoral Clinical Research Fellowship is for trainee pathologists who have undertaken a PhD at some point before the start of their clinical pathology training. The aim of the Fellowship is to encourage trainees back into research to reacquire and update their research skills. The funding covers salary and consumables for up to 3 years.

**PhD Sponsorships** - supports a 3-year PhD and covers a stipend, research & training allowance, conference allowance and up to £20,000 per annum for consumables. Rates are set at MRC rates.

#### Small Grant Schemes

This is divided into four separate schemes, namely the Trainees' Small Grant, the Consultant's Pump Priming Small Grant, Postdoctoral Collaborative Small Grant and the Trainees Collaborative Small Grant. These awards are designed to support laboratory expenses for Trainees (speciality trainees or academic trainees) & consultants within their first five years of appointment to generate pilot data to support subsequent applications to major funding agencies. The maximum grant available is £10,000. The current annual allocation for these schemes is £10,000 for the Trainees Collaborative and £40,000 for all others.

#### **Trainee-Clinical Scientist Partnership Grant Scheme (formerly known as Trainee-Clinical Scientist Partnership in Morpho-Molecular Pathology)**

This scheme was introduced in 2019 to create long lasting scientific partnerships between trainee pathologists and clinical scientists in the pathology and genomics arenas, with funding up to £50,000 for a maximum of 3 years. This scheme has one deadline per annum.

#### **Visiting Fellowships**

The Fellowships are for members of the medical and allied scientific professions working in pathologically related bio-medical research to enable travel to other institutions to learn new techniques of value in their research. Applicants need not be Society members. Fellowships are available for a period of study of up to twelve months.

Preference is given to applicants wishing to learn new techniques in the fields of molecular and cell biology. A maximum sum of £5,000 is allocated to any one person. The current annual allocation to this scheme is £20,000.

#### EDUCATION GRANTS:

##### **Case Report Prize for Undergraduate & Concessionary (Trainees) Members**

Applicants are required to submit a case report and review of the literature of a standard suitable for publication that goes beyond basic morphological and immunohistochemical diagnostics. A prize of £100 is offered and the opportunity to present the case as an oral presentation at a Summer Meeting of the Society.

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND (REGISTERED NUMBER: 08759028)**

**REPORT OF THE TRUSTEES  
for the year ended 31 December 2022**

**Education Grant Scheme**

This scheme is designed to provide support to Academic staff for projects in relation to medical and scientific education (undergraduate and post-graduate) that foster the general area of understanding disease. Our current annual allocation for this scheme is £10,000 with two deadlines per annum

The following Education grants are available. Following the introduction of Associate Undergraduate Membership, these grants are restricted to Associate Undergraduate members:

**Intercalated Degree Awards**

These awards provide fees (up to £9,000) and stipend (£5,000) and £1,800 for consumables for able medical, dental or veterinary students to intercalate a year's Science training and study for a BSc or MSc degree. We support up to 10 awards per annum. There are two deadlines per annum.

**Vacation and Elective Bursaries for Undergraduate Students**

We will support any undergraduate medical, dental or veterinary student to a maximum of £220 per week for up to 8 weeks to undertake a project on any topic that bears on the issue of 'understanding disease' during elective or vacation periods. With two deadlines per annum, our current annual allocation for this scheme is £30,000.

**The Jean Shanks Foundation & Pathological Society Summer Joint Studentships (JSPS)**

This scheme was introduced in 2020 in order to support Year 1 & Year 2 medical and dental students to carry out a research project in pathology during vacation periods. Up to £220 per week, with a maximum of £1,100 per student.

The Society would like to thank the Trustees of the Jean Shanks Foundation for co-finding this important initiative. The current annual allocation for this scheme is £50,000.

**Undergraduate Essay Prize**

We make an award of £500 every year for the best essay written by an undergraduate on a pathologically orientated title. Winning entries can be seen on our website.

**Pathological Society Meeting Bursary for Undergraduates**

This covers travel costs of up to £350 to attend a Pathological Society meeting.

**Students Society Bursary Scheme**

This scheme is to provide support for the promotion of the understanding of pathology amongst medical, dental, biomedical students. The sum requested should not exceed £500, current annual allocation £4,400

All schemes are competitive and clear guidelines are published on our website. They are advertised on our website and in our journals where appropriate. They are awarded by the Society Committee and/or after consideration by the relevant Sub-committees.

**OTHER GRANTS:**

**Pathological Society Meetings Bursary**

Bursaries are made available to cover the cost of registration fees for Society members who are post graduate students (PhD, MD or MSc) or Pathology Trainees and wish to present their research at Society meetings. An applicant whose work is/has been selected for presentation in a plenary session will be favoured.

**Public Engagement Scheme**

This was established in order to foster and promote greater awareness by the lay public of advances in understanding disease which may include support of educational ventures with schools and further education colleges. Our current annual allocation for this scheme is £10,000.

**Open Scheme**

In addition to the above, the Open Scheme is designed to be a source of funds for other activities not covered by the above schemes but that will foster the Society's mission. Our current annual allocation for this scheme is £10,000.

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND (REGISTERED NUMBER: 08759028)**

**REPORT OF THE TRUSTEES  
for the year ended 31 December 2022**

**Travel & Conference Bursary**

These bursaries are to promote scientific communications at major international meetings. Applicants whose work has been selected for presentation are favoured.

**Society Lectures & Awards**

The Society makes several awards for Academic and other achievements. These include the Oakley Lecture for achievements by a young researcher: this has been held annually at Joint Meetings with the BDIAP (in the summer). The Sir Nicholas Wright Lecture was introduced in 2017 and the first lecture was given at the Maastricht Pathology 2018 meeting. This is held in alternative years with the Oakley Lecture from 2018. The next Oakley lecture will be given at the Liverpool Pathology meeting in June 2023.

We promote the discipline among trainees (including PhD students and biomedical scientists) by offering a significantly discounted membership fee (£10 per annum) which includes all benefits as well as electronic access to the Journal of Pathology and other substantial subsidies (e.g. registration fees etc) including complimentary membership of the European Society of Pathology. On occasions, we can provide Society members with other benefits, such as reduced prices from the Society journals' publishers.

**STRATEGIC REPORT**

**Achievement and performance**

**Charitable activities**

The main source of income to the Society is from The Journal of Pathology and as scientific publication migrates to the Open Access model, there is a significant potential for loss of income from the Journal of Pathology. Prof Simon Herrington, Editor-in-Chief, Professor Louise Jones, Editor-in-Chief elect (Editor-in-Chief from January 2023) and Wiley have been working hard to maintain the success of the Journal and its high impact factor, a major consideration for subscribers. The 2022 impact factor of 9.883 was the highest the Journal of Pathology had attained.

The budget of our regular meetings continues to fall well within the resources, representing less than 10% of annual turnover and 1% of current assets.

**Investment policy**

The Society has considerable investments held mostly in funds managed by our advisors, Cazenove Capital Management, the charities investment arm of Schroders. The investment policy is reviewed annually by the trustees bearing in mind the current income from the journals and membership subscriptions. A presentation is given by the portfolio director, Jeremy Barker, to all the trustees at the January Committee Meeting. The treasurer is in regular contact with the investment team and reviews/forwards relevant documentation to the trustees. The funds available to the Society are principally represented by the Investment portfolio held by the investment fund managers and consist of a variety of quoted investments and government stock. The trustees are aware of the level of income that is available from the investment portfolio and its ability to replace a loss of income from the journals.

The value of Listed investments has decreased from £8,016,851 to £7,374,145 the end of the current year. This reflects the volatile performance of financial markets in 2022.

The Society is faced with a potential loss of income supporting its grants whilst facing increased expenditure and will increase the reliance on its investment portfolio. Until the long-term financial position is clearer, reserves will be maintained with judicious use of the investment portfolio to replace the loss of journal income.

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND (REGISTERED NUMBER: 08759028)**

**REPORT OF THE TRUSTEES  
for the year ended 31 December 2022**

**STRATEGIC REPORT**

**Financial position**

The financial results for the year to 31 December 2022 are shown in the attached financial statements.

Income has increased for the year under review to £1,173,640 (2021: £1,153,236) due to slight increases in subscription income and investment income from the Journal of Pathology was stable. Subscription income has marginally increased to £77,419 (2021: £76,987) and on its own would not enable the Society to function. The Meeting and Events income has increased to £111,600 (2021: £73,925). The main areas of expenditure continue to be charitable grants £421,385 (2021: 967,686), Society meetings £150,444 (2021: £208,298) and support costs of the society £165,55 (2021: £235,412).

Overall expenditure has exceeded income by £269,512 (2021: surplus of £358,372) after realised and unrealised investment gains and losses. Fund balances total £8,426,887 (2021: £8,696,399).

It is the policy of the charitable company that unrestricted funds which have not been designated for a specific use should be maintained at a level equivalent to at least three and six month's expenditure. The trustees consider that reserves at this level will ensure that, in the event of a significant drop in funding, they will be able to continue the charitable company's current activities while consideration is given to ways in which additional funds may be raised. This level of reserves has been maintained throughout the year.

The trustees have assessed the major risks to which the charitable company is exposed and are satisfied that systems are in place to mitigate exposure to the major risks.

**Securing the future of pathology**

To ensure the future success of the Society, it has modified its subscription structures to encourage recruitment and greater involvement of more junior pathologists. In addition, as noted above, the Trainees' Sub-committee continues to develop. Changes have already been reflected in a significant up-turn in membership numbers and progression from concessionary to ordinary membership. There had been a drop in membership numbers in 2021 largely due to lack of Undergraduate activity due to the pandemic. Meetings to promote academic pathology amongst trainees have also been supported by The Society as well as the additional JSPS Summer Student bursary scheme for Year 1 & 2 medical students. The National Academic trainee network meetings continue, with 1 hybrid and 1 in-person meeting being held in 2022. The Society plans to continue these meetings, which are valued by the trainees.

To encourage applications for pathology amongst medical graduates, the Undergraduate Committee was established with funding to support attendance at conferences. We aim to promote interest in Pathology even before university, establishing careers days for sixth form students in association with the College and BDIAP. Unfortunately, it was not possible to hold a meeting in 2022, however the Society supported several Undergraduate initiatives for virtual events.

The Society continues to support the Pathological Society Winter School, which continued to be run as a virtual event for 2022. The School trains participants in advance diagnostics and research skills and the programme now includes molecular pathology. The Society now fully underwrites this course and we need to ensure the course remains competitive with others around the UK.

The society also continues to run an online Education Workshop for Members and Non-Members. The workshop was been introduced in 2021 and has been very popular amongst Consultants as well as Concessionary doctors.

**STRUCTURE, GOVERNANCE AND MANAGEMENT**

**Governing document**

The charitable company is a company limited by guarantee.

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND (REGISTERED NUMBER: 08759028)**

**REPORT OF THE TRUSTEES  
for the year ended 31 December 2022**

**STRUCTURE, GOVERNANCE AND MANAGEMENT**

**Risk management**

The Society performed a risk analysis, which has identified the main areas of risk as loss of membership, litigation, loss of accommodation, loss of key staff or services, financial losses on meetings and loss of income from the Journal of Pathology.

Litigation is covered jointly with the publishers of the Journal of Pathology, Wiley, by our own insurance and, by the change of legal status of the Society to become an incorporated charitable company.

All trustees are required to inform the Society of their financial interests and those of direct family members of significant others in an annual, signed declaration. At the start of all grant awarding sessions, committee members are required to declare any conflicts of interest and withdraw from those decisions.

The Committee meets twice annually, normally a day prior to the Winter and Summer Scientific Meetings. This is the formal meeting of all Trustees at which they agree on the broad strategy and areas of activity for the Society, including consideration of grant awarding, investment strategy and risk management. The 2022 Winter and Summer Committee meetings were held as virtual meetings.

The 2022 Away day was held in person in London.

The Society other sub-committees remain in place and continue to administer the activities of the Society; these are as follows:

- Research Sub-committee (chaired by Professor G Thomas) is responsible for assessing research grant applications and taking into account, where appropriate, external advice with a robust peer review process for grants which exceed £25,000.
- Education Sub-committee (chaired by Dr A Mukherjee) advises on the allocation of funds for intercalated degree students, undergraduate elective bursaries, educational grants and the Student Seminar Scheme and has recently taken on the Pathological Society Meeting Bursary and Travel & Conference Bursary awards.
- Molecular Pathology Sub-committee was formed in 2018 and is chaired by Dr M Jansen. However, it was recommended at the Society away day held in October 2022 that this sub-committee be terminated.
- Programme Sub-committee (chaired by Professor HI Grabsch, Professor M Ilyas was elected as meeting secretary elect from July 2022 and will take over from Professor Grabsch in June 2023), develops and approves programme content and the Society's scientific meetings strategy.
- Trainees' Sub-committee (chaired by Dr K Marks), was established in order to encourage a greater involvement of pathologists in training and to represent their views to the Committee of the Society.
- An Undergraduate Committee has representatives on the main Committee and Trainees' Sub-committee meetings.

The Committee is aware of the Charity Commission's Governance Code and continues to apply the Code as appropriate.

**REFERENCE AND ADMINISTRATIVE DETAILS**

**Registered Company number**  
08759028 (England and Wales)

**Registered Charity number**  
1154851

**Registered office**  
7th Floor, 6 Alie Street  
London  
E1 8QT

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND (REGISTERED NUMBER: 08759028)**

**REPORT OF THE TRUSTEES  
for the year ended 31 December 2022**

**Trustees**

Dr M J Arends , Professor of Pathology  
Dr S E Coupland , Consultant Histopathologist  
Dr H I Grabsch , Professor Gastrointestinal Pathology  
Dr M Jansen Clinician Scientist-Honorary  
Dr A Mukherjee , Honorary Consultant Histopathologist  
Prof G I Murray , Professor of Pathology  
Dr A Shaaban , Consultant Pathologist  
Dr G J Thomas , Professor of Experimental Pathology  
Dr N P West Trustee  
Dr A Winstanley , Consultant Cellular Pathologist (resigned 6.7.22)  
Dr K D Hunter , Professor of Head & Neck Pathology (resigned 6.7.22)  
Dr C Coyne , Consultant Histopathologist  
Professor N Coleman , Professor of Histopathology (resigned 6.7.22)  
Dr L Moore , Consultant Histopathologist  
Dr G S Petts , Clinical Lecturer in Pathology  
Dr T J Kendall , Senior Clinical Research in Pathology  
Professor J P C Le Quesne , Professor Of Molecular Pathology  
Dr N Pillay ,Group Leader/Hon Consultant Pathologist  
Dr M F C Amary , Consultant Histopathologist  
Dr D A Moore , Honorary Consultant Histopathologist (appointed 6.7.22)  
Professor S C Burdak-Rothkamm , Consultant Histopathologist (appointed 6.7.22)  
Professor E Scilleux , Honorary Consultant Pathologist (appointed 6.7.22)  
Professor M Ilyas , Professor of Pathology (appointed 6.7.22)

**Auditors**

Raffingers LLP, Statutory Auditor  
Chartered Certified Accountants  
19-20 Bourne Court  
Southend Road  
Woodford Green  
Essex  
IG8 8HD

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND (REGISTERED NUMBER: 08759028)**

**REPORT OF THE TRUSTEES  
for the year ended 31 December 2022**

**TRUSTEES' RESPONSIBILITY STATEMENT**

The trustees, who are also the directors of The Pathological Society of Great Britain and Ireland for the purpose of company law, are responsible for preparing the Trustees' Report and the accounts in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charitable companies in England and Wales and in Scotland requires the trustees to prepare accounts for each financial year which give a true and fair view of the state of affairs of the charitable company and of the income and expenditure of the charitable company for that year. In preparing these accounts, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the accounts; and
- prepare the accounts on the going concern basis unless it is inappropriate to presume that the charitable company will continue in operation.

The trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the accounts comply with the Companies Act 2006 and the Charities and Trustee Investment (Scotland) Act 2005, the applicable Charities (Accounts and Reports) Regulations. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees' report was approved by the Board of Trustees

Report of the trustees, incorporating a strategic report, approved by order of the board of trustees, as the company directors, on 22 June 2023 and signed on the board's behalf by:

Prof G I Murray - Trustee

**REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF**  
**THE PATHOLOGICAL SOCIETY OF GREAT**  
**BRITAIN AND IRELAND**

**Opinion**

We have audited the financial statements of The Pathological Society of Great Britain and Ireland (the 'charitable company') for the year ended 31 December 2022 which comprise the Statement of Financial Activities, the Balance Sheet, the Cash Flow Statement and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 December 2021 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and Regulation 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended).

**Basis for opinion**

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

**Conclusions relating to going concern**

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

**Other information**

The trustees are responsible for the other information. The other information comprises the information included in the Annual Report, other than the financial statements and our Report of the Independent Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

**Opinions on other matters prescribed by the Companies Act 2006**

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the Report of the Trustees for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Report of the Trustees has been prepared in accordance with applicable legal requirements.

**REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF**  
**THE PATHOLOGICAL SOCIETY OF GREAT**  
**BRITAIN AND IRELAND**

**Matters on which we are required to report by exception**

In the light of the knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the Report of the Trustees.

We have nothing to report in respect of the following matters in relation to which the Charities (Accounts and Reports) Regulations 2008 and the Charities Accounts (Scotland) Regulations 2006 (as amended) require us to report to you if, in our opinion:

- the information given in the accounts is inconsistent in any material respect with the Trustees' Report; or
- sufficient and proper accounting records have not been kept; or
- the accounts are not in agreement with the accounting records; or
- we have not received all the information and explanations we require for our audit.

**Responsibilities of trustees**

As explained more fully in the Trustees' Responsibilities Statement, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

**REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF**  
**THE PATHOLOGICAL SOCIETY OF GREAT**  
**BRITAIN AND IRELAND**

**Our responsibilities for the audit of the financial statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Independent Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Our approach to identifying and assessing the risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, was as follows:

- the engagement partner ensured that the engagement team collectively had the appropriate competence, capabilities and skills to identify or recognise non-compliance with applicable laws and regulations;
- we identified the laws and regulations applicable to the charitable company through discussions with management and from our commercial knowledge and experience of the sector The Pathological Society of Great Britain and Ireland belongs to;
- we focused on specific laws and regulations which we considered may have a direct material effect on the financial statements or the operations of the association, including the Charities Act 2011, Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable to the United Kingdom and Republic of Ireland (FRS 102) (effective 1 January 2019), Trustees Act, Bribery Act and data protection;
- we assessed the extent of compliance with the laws and regulations identified above through making enquiries of management and inspecting legal correspondence; and
- identified laws and regulations were communicated within the audit team regularly and the team remained alert to instances of non-compliance throughout the audit.

We assessed the susceptibility of the charity's financial statements to material misstatement, including obtaining an understanding of how fraud might occur, by:

- making enquiries of management as to where they considered there was susceptibility to fraud, their knowledge of actual, suspected and alleged fraud; and
- considering the internal controls in place to mitigate risks of fraud and non-compliance with laws and regulations, including the ones that ensure that the grants are used for intended purposes.

To address the risk of fraud through management bias and override of controls, we:

- performed analytical procedures to identify any unusual or unexpected relationships;
- tested journal entries to identify unusual transactions;
- assessed whether judgements and assumptions made in determining the accounting estimates were indicative of potential bias; and
- investigated the rationale behind significant or unusual transactions.

In response to the risk of irregularities and non-compliance with laws and regulations, we designed procedures which included, but were not limited to:

- agreeing financial statement disclosures to underlying supporting documentation;
- reading the minutes of meetings of those charged with governance;
- enquiring of management as to actual and potential litigation and claims.

There are inherent limitations in our audit procedures described above. The more removed that laws and regulations are from financial transactions, the less likely it is that we would become aware of non-compliance. Auditing standards also limit the audit procedures required to identify non-compliance with laws and regulations to enquiry of the trustees and other management and the inspection of regulatory and legal correspondence, if any.

Material misstatements that arise due to fraud can be harder to detect than those that arise from error as they may involve deliberate concealment or collusion.

**REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF**  
**THE PATHOLOGICAL SOCIETY OF GREAT**  
**BRITAIN AND IRELAND**

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at [www.frc.org.uk/auditorsresponsibilities](http://www.frc.org.uk/auditorsresponsibilities). This description forms part of our Report of the Independent Auditors.

**Use of our report**

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Mr Thuraiatnam Sudarshan (Senior Statutory Auditor)  
for and on behalf of Raffingers LLP, Statutory Auditor  
Chartered Certified Accountants  
19-20 Bourne Court  
Southend Road  
Woodford Green  
Essex  
IG8 8HD

22 June 2023

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**STATEMENT OF FINANCIAL ACTIVITIES  
for the year ended 31 December 2022**

	Notes	2022 Unrestricted fund £	2021 Total funds £
<b>INCOME AND ENDOWMENTS FROM</b>			
Donations and legacies	2	77,419	76,987
<b>Charitable activities</b>			
Journal of Pathology	4	794,406	818,290
Meetings and Events		111,600	73,925
Investment income	3	190,215	184,034
<b>Total</b>		<u>1,173,640</u>	<u>1,153,236</u>
<b>EXPENDITURE ON</b>			
<b>Raising funds</b>			
Investment management costs	5	32,346	30,658
		32,346	30,658
<b>Charitable activities</b>			
Journal of Pathology	6	218,470	149,595
Grants and Award payable		559,560	1,134,298
Meetings and Events		150,444	222,186
<b>Total</b>		<u>960,820</u>	<u>1,536,737</u>
Net gains/(losses) on investments		<u>(482,332)</u>	<u>741,873</u>
<b>NET INCOME/(EXPENDITURE)</b>		(269,512)	358,372
<b>RECONCILIATION OF FUNDS</b>			
Total funds brought forward		8,696,399	8,338,027
<b>TOTAL FUNDS CARRIED FORWARD</b>		<u>8,426,887</u>	<u>8,696,399</u>

**CONTINUING OPERATIONS**

All income and expenditure has arisen from continuing activities.

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND (REGISTERED NUMBER: 08759028)**

**BALANCE SHEET**  
**31 December 2022**

	Notes	2022 Total funds £	2021 Total funds £
<b>FIXED ASSETS</b>			
Tangible assets	13	17,855	29,983
Investments	14	<u>7,374,145</u>	<u>8,016,851</u>
		7,392,000	8,046,834
<b>CURRENT ASSETS</b>			
Debtors	15	819,723	849,184
Cash at bank and in hand		<u>416,445</u>	<u>180,599</u>
		1,236,168	1,029,783
<b>CREDITORS</b>			
Amounts falling due within one year	16	(201,281)	(380,218)
<b>NET CURRENT ASSETS</b>		<u>1,034,887</u>	<u>649,565</u>
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>		8,426,887	8,696,399
<b>NET ASSETS</b>		<u>8,426,887</u>	<u>8,696,399</u>
<b>FUNDS</b>			
Unrestricted funds:	17		
General fund		<u>8,426,887</u>	<u>8,696,399</u>
<b>TOTAL FUNDS</b>		<u>8,426,887</u>	<u>8,696,399</u>

The financial statements were approved by the Board of Trustees and authorised for issue on 22 June 2023 and were signed on its behalf by:

Prof G I Murray - Trustee

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**CASH FLOW STATEMENT**  
**for the year ended 31 December 2022**

Notes	2022 £	2021 £
<b>Cash flows from operating activities</b>		
Cash generated from operations	1 (114,743)	(516,246)
Net cash used in operating activities	<u>(114,743)</u>	<u>(516,246)</u>
<b>Cash flows from investing activities</b>		
Purchase of fixed asset investments	(1,174,055)	(1,640,850)
Sale of fixed asset investments	1,334,429	1,968,594
Movement in capital accounts	-	32,586
Interest received	1,097	57
Dividends received	189,118	183,976
Net cash provided by investing activities	<u>350,589</u>	<u>544,363</u>
<b>Change in cash and cash equivalents in the reporting period</b>	<u>235,846</u>	<u>28,117</u>
<b>Cash and cash equivalents at the beginning of the reporting period</b>	<u>180,599</u>	<u>152,482</u>
<b>Cash and cash equivalents at the end of the reporting period</b>	<u>416,445</u>	<u>180,599</u>

The notes form part of these financial statements

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**NOTES TO THE CASH FLOW STATEMENT  
for the year ended 31 December 2022**

**1. RECONCILIATION OF NET (EXPENDITURE)/INCOME TO NET CASH FLOW FROM OPERATING ACTIVITIES**

	2022 £	2021 £
<b>Net (expenditure)/income for the reporting period (as per the Statement of Financial Activities)</b>	(269,512)	358,372
<b>Adjustments for:</b>		
Depreciation charges	12,128	12,138
Losses/(gain) on investments	482,332	(741,873)
Interest received	(1,097)	(57)
Dividends received	(189,118)	(183,976)
Decrease in debtors	29,461	63,488
Decrease in creditors	(178,937)	(24,338)
<b>Net cash used in operations</b>	<u>(114,743)</u>	<u>(516,246)</u>

**2. ANALYSIS OF CHANGES IN NET FUNDS**

	At 1.1.22 £	Cash flow £	At 31.12.22 £
<b>Net cash</b>			
Cash at bank and in hand	180,599	235,846	416,445
	<u>180,599</u>	<u>235,846</u>	<u>416,445</u>
<b>Total</b>	<u>180,599</u>	<u>235,846</u>	<u>416,445</u>

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**NOTES TO THE FINANCIAL STATEMENTS  
for the year ended 31 December 2022**

**1. ACCOUNTING POLICIES**

**Basis of preparing the financial statements**

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (Charities SORP FRS 102) , (effective 1 January 2015) the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

The financial statements have been prepared under the historical cost convention with the exception of investments which are included at market value, as modified by the revaluation of certain assets.

The charity constitutes a public benefit entity as defined by FRS 102.

The accounts are presented in sterling and are rounded to the nearest pound.

**Assessment of going concern**

The trustees have assessed whether the use of the going concern assumption is appropriate in preparing these accounts. The trustees have made this assessment in respect to a period of one year from the date of approval of these accounts.

The trustees of the charity have concluded that there are no material uncertainties related to events or conditions that may cast significant doubt on the ability of the charity to continue as going concern. The trustees are of the opinion that the charity will have sufficient resources to meet its liabilities as they fall due.

**Critical accounting judgements and key sources of estimation uncertainty**

Preparation of the financial statements requires the trustees and management to make significant judgements and estimates.

The items in the accounts where these judgements and estimates have been made include:

- the useful economic lives attributed to tangible fixed assets used to determine the annual depreciation charge; and
- the assumptions adopted by the trustees in determining the value of any designations required from the charity's general unrestricted funds.

**Income**

Income is recognised when the charitable company is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charitable company has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Deferred income is recognised for income received in advance for events and meetings taking place in future periods.

Membership subscriptions are recognised in the year to which they relate.

**Journal of Pathology**

The receipts in respect of journals supplied by the Society are credited to the financial statements in the year to which they relate. The income from journals is the proportion due to the Society under the relevant agreements and is net of direct costs met by the publishers.

**Meetings and events income**

Income and corresponding expenditure are recognised in the period the event has taken place. This results in deferred income and accruals recognised in balance sheet.

**Investment income**

Dividends and interest on securities are credited in the financial statements when the Society is entitled to receive the funds.

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**NOTES TO THE FINANCIAL STATEMENTS - continued**  
**for the year ended 31 December 2022**

**1. ACCOUNTING POLICIES - continued**

**Expenditure**

Expenditure is recognised once there is a legal or constructive obligation to make a payment to a third party, it is probable that settlement will be required and the amount of the obligation can be measured reliably.

The costs of raising funds consist of investment management fees.

**Journal of Pathology**

The cost of distributing copies of the journal to members is recognised as a charitable activity.

**Support costs for meetings**

Costs incurred for the Society's events and meetings are recognised in the period in which they take place.

All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the category.

**Grants payable**

Grants payable are payments made to third parties in the furtherance of the charitable objects of the Society. In the case of an unconditional grant offer this is accrued once the recipient has been notified of the grant award. The notification gives the recipient a reasonable expectation that they will receive the one- year or multi-year grant. Grants awards that are subject to the recipient fulfilling performance conditions are only accrued when the recipient has been notified of the grant and any remaining unfulfilled condition attaching to that grant is outside of the control of the Society.

**Tangible fixed assets**

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Fixtures and fittings	- 15% on reducing balance
Computer equipment	- 20% on cost

**Taxation**

The charity is exempt from corporation tax on its charitable activities.

**Fund accounting**

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Designated funds comprise funds which have been set aside at the discretion of the trustees for specific purposes. The purposes and uses of the designated funds are set out in the notes to the accounts.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

**Cash at bank and in hand**

Cash at bank and in hand represents such accounts and instruments that are available on demand or have a maturity of less than three months from the date of acquisition. Deposits for more than three months but less than one year have been disclosed as short term deposits.

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**NOTES TO THE FINANCIAL STATEMENTS - continued**  
**for the year ended 31 December 2022**

**1. ACCOUNTING POLICIES - continued**

**Creditors and provision**

Creditors and provision are recognised when there is an obligation at the balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably. Creditors and provision are recognised at the moment the charity anticipates it will pay to settle the debt. They have been discounted to the present value of the future cash payments where such discounting is material.

**Investments**

Listed investments are initially recognised at their transaction value and subsequently measured at their fair value as at the balance sheet date using the closing quoted market price.

Realised and unrealised investment gains (or losses) are combined in the statement of financial activities and are credited (or debited) in the year in which they arise.

**2. DONATIONS AND LEGACIES**

	Unrestricted funds £	Restricted funds £	2022 Total funds £	2021 Total funds £
Subscriptions	<u>77,419</u>	<u>-</u>	<u>77,419</u>	<u>76,987</u>

**3. INVESTMENT INCOME**

	Unrestricted funds £	Restricted funds £	2022 Total funds £	2021 Total funds £
Income from listed investments	189,118	-	189,118	183,977
Deposit account interest	<u>1,097</u>	<u>-</u>	<u>1,097</u>	<u>57</u>
	<u>190,215</u>	<u>-</u>	<u>190,215</u>	<u>184,034</u>

**4. INCOME FROM CHARITABLE ACTIVITIES**

	2022 £	2021 £
Journal of Pathology	794,406	818,290
Meetings and events	<u>111,600</u>	<u>73,925</u>
	906,006	<u>892,215</u>

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**NOTES TO THE FINANCIAL STATEMENTS - continued**  
**for the year ended 31 December 2022**

**5. INVESTMENT MANAGEMENT COSTS**

	Unrestricted funds £	Restricted funds £	2022 Total funds £	2021 Total funds £
Investment management	<u>32,346</u>	<u>-</u>	<u>32,346</u>	<u>30,658</u>

**6. CHARITABLE ACTIVITIES COSTS**

	Direct Costs £	Grant funding of activities (see note 7) £	Support costs (see note 8) £	Totals £
Journal of Pathology	218,470	-	-	218,470
Grants and Award payable	-	421,385	138,175	559,560
Meetings and Events	<u>52,772</u>	<u>-</u>	<u>97,672</u>	<u>150,444</u>
	<u>271,242</u>	<u>421,385</u>	<u>235,847</u>	<u>928,474</u>

**7. GRANTS PAYABLE**

		2022 £	2021 £
Grants and Award payable		<u>421,385</u>	<u>967,686</u>

**8. SUPPORT COSTS**

	Management £	Finance £	Governance costs £	Totals £
Grants and Award payable	81,834	1,525	54,816	138,175
Meetings and Events	<u>83,721</u>	<u>-</u>	<u>13,951</u>	<u>97,672</u>
	<u>165,555</u>	<u>1,525</u>	<u>68,767</u>	<u>235,847</u>

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**NOTES TO THE FINANCIAL STATEMENTS - continued**  
**for the year ended 31 December 2022**

**8. SUPPORT COSTS - continued**

Support costs, included in the above, are as follows:

	Grants and Award payable £	Meetings and Events £	2022 Total activities £	2021 Total activities £
Wages	-	48,037	48,037	70,255
Social security	-	2,899	2,899	11,413
Pensions	-	3,239	3,239	15,942
Rent and insurance	-	26,196	26,196	26,632
Postage and stationery	-	3,350	3,350	3,519
Sundries	10,862	-	10,862	4,788
Website & computer	58,844	-	58,844	90,725
Depreciation of tangible and heritage assets	12,128	-	12,128	12,138
Bank charges	1,525	-	1,525	2,640
Wages	20,600	-	20,600	30,100
Auditors' remuneration	7,000	-	7,000	6,500
Committee meetings	-	13,951	13,951	-
Accountancy fees	8,363	-	8,363	7,853
Professional and legal fees	18,853	-	18,853	11,868
	<u>138,175</u>	<u>97,672</u>	<u>235,847</u>	<u>294,373</u>

**9. NET INCOME/(EXPENDITURE)**

Net income/(expenditure) is stated after charging/(crediting):

	2022 £	2021 £
Auditors' remuneration	7,000	6,500
Depreciation - owned assets	<u>12,128</u>	<u>12,138</u>

**10. TRUSTEES' REMUNERATION AND BENEFITS**

**Trustees' expenses**

None of the trustees (or any persons connected with them) received any remuneration during the year, there were also no travelling costs reimbursed this year.

No grants were received by trustees from the Society in the year.

No committee advisors (non-trustee) received grants from the Society in the year.

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**NOTES TO THE FINANCIAL STATEMENTS - continued**  
**for the year ended 31 December 2022**

**11. STAFF COSTS**

	2022	2021
	£	£
Wages and salaries	119,649	128,268
Social security costs	9,077	14,656
Other pension costs	<u>12,218</u>	<u>20,408</u>
	<u>140,944</u>	<u>163,332</u>

The average monthly number of employees during the year was as follows:

	2022	2021
Administrative staff	<u>2</u>	<u>3</u>

No employees received emoluments in excess of £60,000.

**12. FINANCIAL COMMITMENTS, GUARANTEES AND CONTINGENT LIABILITIES**

The company is limited by guarantee - all members having a liability not exceeding £1 per member.

**13. TANGIBLE FIXED ASSETS**

	Fixtures and fittings £	Computer equipment £	Totals £
<b>COST</b>			
At 1 January 2022 and 31 December 2022	<u>12,374</u>	<u>65,774</u>	<u>78,148</u>
<b>DEPRECIATION</b>			
At 1 January 2022	12,018	36,147	48,165
Charge for year	<u>53</u>	<u>12,075</u>	<u>12,128</u>
At 31 December 2022	<u>12,071</u>	<u>48,222</u>	<u>60,293</u>
<b>NET BOOK VALUE</b>			
At 31 December 2022	<u>303</u>	<u>17,552</u>	<u>17,855</u>
At 31 December 2021	<u>356</u>	<u>29,627</u>	<u>29,983</u>

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**NOTES TO THE FINANCIAL STATEMENTS - continued  
for the year ended 31 December 2022**

**14. FIXED ASSET INVESTMENTS**

	2022	2021
	£	£
Shares	7,302,703	7,982,827
Other	71,442	34,024
	<u>7,374,145</u>	<u>8,016,851</u>

Additional information as follows:

		Listed investments £
<b>MARKET VALUE</b>		
At 1 January 2022		7,982,827
Additions		1,136,637
Disposals		(1,334,429)
Revaluations		<u>(482,332)</u>
At 31 December 2022		<u>7,302,703</u>
<b>NET BOOK VALUE</b>		
At 31 December 2022		<u>7,302,703</u>
At 31 December 2021		<u>7,982,827</u>

There were no investment assets outside the UK.

Investments (neither listed nor unlisted) were as follows:

	2022	2021
	£	£
Cash in portfolio	<u>71,442</u>	<u>34,024</u>

**15. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	2022	2021
	£	£
Other debtors	808,552	840,010
Prepayments	11,171	9,174
	<u>819,723</u>	<u>849,184</u>

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**NOTES TO THE FINANCIAL STATEMENTS - continued  
for the year ended 31 December 2022**

**16. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	2022	2021
	£	£
Trade creditors	17,354	9,595
VAT	1,000	-
Other creditors	615	500
Accruals and deferred income	<u>182,312</u>	<u>370,123</u>
	<u>201,281</u>	<u>380,218</u>

**17. MOVEMENT IN FUNDS**

	At 1.1.22	Net movement in funds	At 31.12.22
	£	£	£
<b>Unrestricted funds</b>			
General fund	8,696,399	(269,512)	8,426,887
<b>TOTAL FUNDS</b>	<u>8,696,399</u>	<u>(269,512)</u>	<u>8,426,887</u>

Net movement in funds, included in the above are as follows:

	Incoming resources	Resources expended	Gains and losses	Movement in funds
	£	£	£	£
<b>Unrestricted funds</b>				
General fund	1,173,640	(960,820)	(482,332)	(269,512)
<b>TOTAL FUNDS</b>	<u>1,173,640</u>	<u>(960,820)</u>	<u>(482,332)</u>	<u>(269,512)</u>

**Comparatives for movement in funds**

	At 1.1.21	Net movement in funds	At 31.12.21
	£	£	£
<b>Unrestricted funds</b>			
General fund	8,338,027	358,372	8,696,399
<b>TOTAL FUNDS</b>	<u>8,338,027</u>	<u>358,372</u>	<u>8,696,399</u>

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**NOTES TO THE FINANCIAL STATEMENTS - continued**  
**for the year ended 31 December 2022**

**17. MOVEMENT IN FUNDS - continued**

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Gains and losses £	Movement in funds £
<b>Unrestricted funds</b>				
General fund	1,153,236	(1,536,737)	741,873	358,372
<b>TOTAL FUNDS</b>	<u>1,153,236</u>	<u>(1,536,737)</u>	<u>741,873</u>	<u>358,372</u>

**18. RELATED PARTY TRANSACTIONS**

**Remuneration of key management personnel**

The remuneration of key management personnel is as follows.

	£	£	2022	2021
Aggregate compensation			140,944	163,332

The above amounts include payments to the Royal College of Pathologists for the use of 3 (2021: 3) of their employees for administrative management of the society. As part of the agreement between the two entities, in the event of the Royal College of Pathologists being required to contribute to the pension scheme that it belongs to, the society could be liable to meet the obligations of the pension costs in respect of these individuals.

**19. SUBSIDIARIES**

There were no subsidiaries controlled by the charity as at 31 December 2022.

**THE PATHOLOGICAL SOCIETY OF GREAT BRITAIN AND IRELAND**

England & Wales - Charity number 1154851

---

# Accounts

---

REGISTERED COMPANY NUMBER: 08759028 (England and Wales)  
REGISTERED CHARITY NUMBER: 1154851  
REGISTERED CHARITY (SCOTLAND) NUMBER: SC045004

**REPORT OF THE TRUSTEES AND**  
**FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2021**  
**FOR**  
**THE PATHOLOGICAL SOCIETY OF GREAT**  
**BRITAIN AND IRELAND**

Raffingers LLP, Statutory Auditor  
Chartered Certified Accountants  
19-20 Bourne Court  
Southend Road  
Woodford Green  
Essex  
IG8 8HD

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**CONTENTS OF THE FINANCIAL STATEMENTS  
for the year ended 31 December 2021**

	<b>Page</b>
<b>Report of the Trustees</b>	1 to 11
<b>Report of the Independent Auditors</b>	12 to 15
<b>Statement of Financial Activities</b>	16
<b>Balance Sheet</b>	17
<b>Cash Flow Statement</b>	18
<b>Notes to the Cash Flow Statement</b>	19
<b>Notes to the Financial Statements</b>	20 to 29
<b>Detailed Statement of Financial Activities</b>	30

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**REPORT OF THE TRUSTEES  
for the year ended 31 December 2021**

The trustees present their report and accounts for the year ended 31 December 2021.

The accounts have been prepared in accordance with the accounting policies set out in note 1 to the accounts and comply with the charitable company's governing document, the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005, regulations applicable to those two Acts and Statement of recommended Practice, "Accounting and Reporting by Charities" issued in March 2015.

**PUBLIC BENEFIT**

The trustees have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing the aim and objectives and in planning the charity's future activities. The aims of the charity for the public benefit are detailed in the 'Objectives and Activities' section of this report.

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**REPORT OF THE TRUSTEES  
for the year ended 31 December 2021**

**OBJECTIVES AND ACTIVITIES**

The Pathological Society is dedicated to the "Understanding of Disease-Guiding Therapy" in the medical scientific and lay communities. It provides a forum for the presentation of new scientific and medical research findings with the aim of improving knowledge and understanding of human disease. As stated in the constitution; "The objectives of the Society shall be to advance pathology and facilitate communications between pathologists" but this has expanded to recognise its role in the wider community. The Society conforms to its stated objectives by the publication of its Journals, The Journal of Pathology and The Journal of Pathology: Clinical Research, by the organisation of meetings of the Society, by support of other scientific meetings and of a variety of educational and research schemes (see below).

The Society is also a Scottish registered charity and operates in Scotland.

In setting the objectives and activities for the year, the Society has referred to the guidance issued by the Charity Commission on public benefit. In particular, the Society considers how planned activities contribute to the objectives and activities they have set and how these provide public benefit. For the past year, due to the Covid-19 pandemic, the Society's normal activities have had to adapt accordingly, especially in relation to scientific meetings as well as some grant activities.

The Pathological Society serves the public in a variety of ways. Through its scientific and educational meetings (the largest Pathology meeting in the UK and Ireland), the doctors and scientists who manage patients are kept up to date in the latest knowledge about the causes of diseases and its diagnosis. Our flagship journal, The Journal of Pathology, now in its 129th year of publication continues to enjoy high international esteem and is widely recognised as the preferred journal in which to publish scientific papers on the mechanisms of disease. Our more recent journal, The Journal of Pathology: Clinical Research (JPCR), publishes papers on the application of investigations and trials in clinical scenarios. Together they keep our members, pathologists worldwide and clinicians in other disciplines, apprised of developments in our understanding of the nature and causes of disease and in the resultant current expansion of new methods in diagnosis and treatment. This has immediate significance for patients, in helping to ensure that their management is supported by pathology based on the best diagnostic methods. In June 2021 we were pleased to announce that JPCR had increased its Impact Factor to 5.638 which has resulted in a significant increase in submissions. The Society's provision of grants schemes for research training for its trainee (Concessionary) members will help to ensure that successive cohorts of young UK pathologists will have opportunities to contribute to these advances in medical care. We are hopeful that research will be able to recommence having been halted by the Pandemic.

The Pathological Society is also committed to enhancing the understanding of medical science by the general public and to this end runs Public Lectures; the most recent was given at the Virtual Joint Meeting with the British Division of the International Academy of Pathology (BDIAP) in July 2021; Dame Nancy Rothwell gave an enlightening talk on the "A Stroke of Bad Luck". The next Public Lecture is planned for the Liverpool Pathology 2023 Conference (27-29 June). The Public Lectures are filmed, with the permission of the lecturer, the videos are available on the Society's website. We also run the Public Engagement grant scheme which will fund a wide range of activities that help the public to understand disease, the pathology underlying the disease and the work of pathologists in the investigation, diagnosis and clinical management of disease. This has been expanded to accommodate applications for virtual events.

The Society continues to explore additional means of informing the public about research into human disease and the practice of pathology; it is envisaged that some of this will be conducted in association with other learned societies.

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**REPORT OF THE TRUSTEES  
for the year ended 31 December 2021**

The Society normally runs two major scientific meetings per year. These meetings are open to the entire medical and scientific community and not restricted to Society members. Both Winter and Summer meetings include sessions dedicated to those in training. All our summer meetings are run jointly with the BDIAP. As this has become established as the major pathology meeting in the UK and Ireland other specialist societies are increasingly collaborating in the development and delivery of these meetings. The format of these meetings will change with an increasing on-line element within the programme. This will allow more delegates to attend without the added expense of travel and accommodation.

The attendance at the most recent summer meetings averages approximately 500. The Society underwrites all these meetings on a 50/50 basis with the BDIAP in order to maintain registration fees at affordable levels. In 2021 there was no Winter meeting due to the Covid-19 pandemic restrictions. Winter Meetings are usually held in London, jointly with the Royal Society of Medicine. Whilst no face to face educational events were possible over the last year, the Society has introduced on-line sessions for trainees as well as our monthly Pathology Grand Round Lecture series over the past year.

Our current schemes include:

**RESEARCH GRANTS:**

**Best Trainee Research Impact & Best Trainee Research Paper Awards**

- **Research Impact Award** to encourage pathology trainees to highlight the most impactful research in the last 36 months and offer £500 and a Medal.

- **Research Paper Award** to encourage pathology trainees to highlight their best published single research paper relevant to pathology in the last 12 months and offers £500 and a certificate. Our current annual allocation is £1,000 for each Award.

**Cuthbert Dukes Medium Grant Scheme**

This scheme was launched in 2019 to encourage early-mid career pathology researchers, in particular academic trainees, to undertake investigation tissue-based research and offers up to £20,000 with one deadline per annum.

**Cancer Research UK/Pathological Society Pre-Doctoral Research Bursary**

These jointly funded grants were introduced in 2018 and provide short term funding to allow clinicians to get involved in cancer research and provides funding for up to £45,000 for salary and/or research expenses for up to 12 months, with two deadlines per annum. The initial 3 year agreement with CRUK ended in 2020 and has been extended for a further 3 year period.

**Early Career Pathology Research Grant - Hodgkin & Leishman**

These were introduced in 2018 to trainees in their first few years of training to undertake investigative research, with two deadlines per annum. The Hodgkin offer up to £1,000 and Leishman up to £2,000. Our current annual allocation is £10,000.

**Equipment Scheme**

This scheme is aimed at supporting pathologists engaged in research by providing funds for multi-user equipment. Our current annual allocation for this scheme is £20,000 with two deadlines per annum.

**International Collaborative Scheme**

This is aimed at promoting collaboration in scholarly pathological activities between pathologists from any institution outside of the UK and UK pathologists. Our current annual allocation for this scheme is £20,000 with one deadline per annum.

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**REPORT OF THE TRUSTEES  
for the year ended 31 December 2021**

**Jean Shanks Foundation/Pathological Society (JSPS) Joint Research Grants**

The five-year agreement with the Jean Shanks Foundation launched in 2018 provides a jointly funded range of research schemes to facilitate trainees in pathology to develop their academic and research schemes ranging from early career support through to support for new independent investigators. This initiative will result in a significant increase in the Society's research grant spend. The trustees of the Society agreed to commit money from the Society's investment funds to support this.

Applications have been considered by the Research Sub-committee during 2021 and a range of high-quality applications were recommended for support and these recommendations were endorsed by the Finance and General Purposes Sub-committee.

Further grant schemes are planned for introduction in 2022.

**All schemes have two application deadlines per annum:**

- **JSPS Pre-Doctoral Research Bursary** - to promote research in pathology to fund short projects for early career clinical academic research trainee pathologists for a period of 3, 6, 9 or 12 months. This covers salary and/or research expenses to a maximum of £40,000.

- **JSPS Clinical PhD Fellowship** - to provide 3 years of PhD funding for clinical trainee histopathologists to increase the research skills, abilities and interests of those medically qualified trainee histopathologists working on tissue-based projects in pathology. Funding covers salary, university fees and consumables of up to £15,000 pa for 3 years.

- **JSPS Clinical Lecturer Grant** - to offer histopathology trainees post MD/PhD who wish to continue research part-time whilst completing clinical training (part-time). Covers up to £200,000 over a maximum of 4 years and covers 50% salary (with 50% of salary provided by the NHS - similar to the NIHR Clinical Lectureships) and provides up to £15,000 consumables per annum.

- **JSPS Clinical Lecturer Support Grant** - to offer support for continuing research projects over a 2 year period by academic trainee histopathologists following the award of a PhD or MD, when progressing through the final stages of histopathological training leading up to the award of CCT. Covers £50,000 per annum funding over a 2 year period to be used flexibly to fund the costs of employing a research technician or assistant and associated consumables costs.

- **JSPS Intermediate Research Fellowship** - to support newly accredited pathologists during the period between completing their training (passing FRCPath part 2/completing the Certificate of Completion of Training) and obtaining full funding for a Clinician Scientist post through MRC, The Wellcome Trust, CRUK etc. Covers up to £100,000 over a maximum of 2 years and covers 50% of salary costs (with 50% of salary provided by the NHS) and up to £15,000 of consumables per annum.

- **JSPS Clinical Academic Research Partnership** - to offer support for NHS consultants who wish to undertake research. The aim is to encourage consultants with and MD or PhD (or equivalent) who are currently not research active, to participate in high quality research collaborations with established leading biomedical researchers.

**PhD Sponsorships** - supports a 3-year PhD and covers a stipend, research and training allowance, conference allowance and up to £15,000 per annum for consumables. Rates are set at MRC rates. Current annual allocation for this is £210,300.

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**REPORT OF THE TRUSTEES  
for the year ended 31 December 2021**

**Small Grant Schemes**

This is divided into four separate schemes, namely the Trainees' Small Grant, the Consultant's Pump Priming Small Grant, Postdoctoral Collaborative Small Grant and the Trainees Collaborative Small Grant. These awards are designed to support laboratory expenses for Trainees (speciality trainees or academic trainees) and consultants within their first five years of appointment to generate pilot data to support subsequent applications to major funding agencies. The maximum grant available is £10,000. The current annual allocation for these schemes is £10,000 for the Trainees Collaborative and £40,000 for all others.

**Trainee-Clinical Scientist Partnership Grant Scheme (formerly known as Trainee-Clinical Scientist Partnership in Morpho-Molecular Pathology)**

This scheme was introduced in 2019 to create long lasting scientific partnerships between trainee pathologists and clinical scientists in the pathology and genomics arenas, with funding up to £50,000 for a maximum of 3 years. This scheme has one deadline per annum.

**Visiting Fellowships**

The Fellowships are for members of the medical and allied scientific professions working in pathologically related bio-medical research to enable travel to other institutions to learn new techniques of value in their research. Applicants need not be Society members. Fellowships are available for a period of study of up to twelve months.

Preference is given to applicants wishing to learn new techniques in the fields of molecular and cell biology. A maximum sum of £5,000 is allocated to any one person. The current annual allocation to this scheme is £20,000.

**EDUCATION GRANTS:**

Case Report Prize for Undergraduate & Concessionary (Trainees) Members

Applicants are required to submit a case report and review of the literature of a standard suitable for publication that goes beyond basic morphological and immunohistochemical diagnostics. A prize of £100 is offered and the opportunity to present the case as an oral presentation at a Summer Meeting of the Society.

**Education Grant Scheme**

This scheme is designed to provide support to Academic staff for projects in relation to medical and scientific education (undergraduate and post-graduate) that foster the general area of understanding disease. Our current annual allocation for this scheme is £10,000 with two deadlines per annum.

The following Education grants are available. Following the introduction of Associate Undergraduate Membership, these grants are restricted to Associate Undergraduate members:

**Intercalated Degree Awards**

These awards provide fees (up to £9,000) and stipend (£4,500) and £1,500 for consumables for able medical, dental or veterinary students to intercalate a year's Science training and study for a BSc or MSc degree. We support up to 10 awards per annum. There are now two deadlines per annum.

**Vacation and Elective Bursaries for Undergraduate Students**

We will support any undergraduate medical, dental or veterinary student to a maximum of £200 per week for up to 8 weeks to undertake a project on any topic that bears on the issue of 'understanding disease' during elective or vacation periods. With two deadlines per annum, our current annual allocation for this scheme is £30,000.

**The Jean Shanks Foundation & Pathological Society Summer Joint Studentships (JSPS)**

This scheme was introduced in 2020 in order to support Year 1 and Year 2 medical and dental students to carry out a research project in pathology during vacation periods. Up to £200 per week, with a maximum of £1,000 per student.

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**REPORT OF THE TRUSTEES  
for the year ended 31 December 2021**

The Society would like to thank the Trustees of the Jean Shanks Foundation for co-funding this important initiative. The current annual allocation for this scheme is £50,000.

**Undergraduate Essay Prize**

We make an award of £500 every year for the best essay written by an undergraduate on a pathologically orientated title. Winning entries can be seen on our website.

**Pathological Society Meeting Bursary for Undergraduates**

This covers travel costs of up to £250 to attend a Pathological Society meeting.

**Students Society Bursary Scheme**

This scheme is to provide support for the promotion of the understanding of pathology amongst medical, dental, biomedical students. The sum requested should not exceed £500, current annual allocation £4,400.

All schemes are competitive and clear guidelines are published on our website. They are advertised on our website and in our journals where appropriate. They are awarded by the Society Committee and/or after consideration by the relevant Sub-committees.

**OTHER GRANTS:**

**Pathological Society Meetings Bursary**

Bursaries are made available to cover the cost of registration fees for Society members who are post graduate students (PhD, MD or MSc) or Pathology Trainees and wish to present their research at Society meetings. An applicant whose work is/has been selected for presentation in a plenary session will be favoured.

**Public Engagement Scheme**

This was established in order to foster and promote greater awareness by the lay public of advances in understanding disease which may include support of educational ventures with schools and further education colleges. Our current annual allocation for this scheme is £10,000.

**Open Scheme**

In addition to the above, the Open Scheme is designed to be a source of funds for other activities not covered by the above schemes but that will foster the Society's mission. Our current annual allocation for this scheme is £10,000.

**Travel & Conference Bursary**

These bursaries are to promote scientific communications at major international meetings. Applicants whose work has been selected for presentation are favoured.

**Society Lectures & Awards**

The Society makes several awards for Academic and other achievements. These include the Oakley Lecture for achievements by a young researcher: this has been held annually at Joint Meetings with the BDIAP (in the summer). The Sir Nicholas Wright Lecture introduced in 2017 and the first lecture was given at the Maastricht Pathology 2018 meeting. This is held in alternative years with the Oakley Lecture from 2018.

We promote the discipline among trainees (including PhD students and biomedical scientists) by offering a significantly discounted membership fee (£10 per annum) which includes all benefits as well as electronic access to the Journal of Pathology and other substantial subsidies (e.g. registration fees etc) including complimentary membership of the European Society of Pathology. On occasions we can provide Society members with other benefits, such as reduced prices from the Society journals' publishers.

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**REPORT OF THE TRUSTEES  
for the year ended 31 December 2021**

**STRATEGIC REPORT**

**Achievement and performance**

**Charitable activities**

The main source of income to the Society is from The Journal of Pathology and as scientific publication migrates to the Open Access model, there is a significant potential for loss of income from the Journal of Pathology. Prof Simon Herrington, Editor-in-Chief and Wiley-Blackwell have been working hard to maintain the success of the Journal and its high impact factor, a major consideration for subscribers.

The budget of our regular meetings continues to fall well within the resources, representing less than 10% of annual turnover and 1% of current assets.

**Investment policy**

The Society has considerable investments held mostly in funds managed by our advisors, Cazenove Capital Management, the charities investment arm of Schroders. The investment policy is reviewed annually by the trustees bearing in mind the current income from the journals and membership subscriptions. A presentation is given by the portfolio director, Jeremy Barker, to all the trustees at the January Committee Meeting. The treasurer is in regular contact with the investment team and reviews/forwards relevant documentation to the trustees. The funds available to the Society are principally represented by the Investment portfolio held by the investment fund managers and consist of a variety of quoted investments and government stock. The trustees are aware of the level of income that is available from the investment portfolio and its ability to replace loss of income from the journals.

The value of Listed investments has increased from £7,568,698 to £7,982,827 at the end of the current year. This increase is due to unrealised gains on the revaluation of the investment.

The Society is faced with a potential loss of income supporting its grants whilst facing increased expenditure and will increase the reliance on its investment portfolio. Until the long-term financial position is clearer, reserves will be maintained with judicious use of the investment portfolio to replace the loss of journal income.

**STRATEGIC REPORT**

**Financial position**

The financial results for the year to 31 December 2021 are shown in the attached financial statements.

Income has decreased for the year under review to £1,153,236 (2020: £1,168,754) primarily due to an decrease in income from the Journal of Pathology. Subscription income has also decreased to £76,987 (2020: £86,857) and on its own would not enable the Society to function. The Meeting and Events income has increased to £73,925 (2020: £24,600). The main areas of expenditure continue to be charitable grants £1,134,298 (2020: £744,872), Society meetings £222,186 (2020: £157,006) and support costs of the society £235,412 (2020: £208,092).

Overall income has exceeded expenditure by £358,372 (2020: £19,442) after realised and unrealised investment gains and losses. Fund balances total £8,696,399 (2020: £8,338,027).

It is the policy of the charitable company that unrestricted funds which have not been designated for a specific use should be maintained at a level equivalent to between three and six month's expenditure. The trustees consider that reserves at this level will ensure that, in the event of a significant drop in funding, they will be able to continue the charitable company's current activities while consideration is given to ways in which additional funds may be raised. This level of reserves has been maintained throughout the year.

The trustees have assessed the major risks to which the charitable company is exposed, and are satisfied that systems are in place to mitigate exposure to the major risks.

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**REPORT OF THE TRUSTEES  
for the year ended 31 December 2021**

**STRATEGIC REPORT**

**Securing the future of pathology**

To ensure the future success of the Society, it has modified its subscription structures to encourage recruitment and greater involvement of more junior pathologists. In addition, as noted above, the Trainees' Sub-committee continues to develop. Changes have already been reflected in a significant up-turn in membership numbers and progression from concessionary to ordinary membership. There had been a drop in membership numbers in 2021 largely due to lack of Undergraduate activity due to the pandemic. Meetings to promote academic pathology amongst trainees have also been supported by The Society as well as the additional JSPS Summer Student bursary scheme for Year 1 and 2 medical students. The National Academic trainee network meetings continue, with 3 virtual meetings being held in 2021. Other stand-alone meetings had to be postponed, cancelled or held on line due to Social Distancing regulations. The Society plans to continue these meetings, which are valued by the trainees.

To encourage applications for pathology amongst medical graduates, the Undergraduate Committee was established with funding to support attendance at conferences. We aim to promote interest in Pathology even before university, establishing careers days for sixth form students in association with the College and BDIAP. Unfortunately, it was not possible to hold a meeting in 2021 however the Society supported several Undergraduate initiatives for virtual events.

The Society continues to support the Pathological Society Winter School, which was run as a virtual event for 2021 and potentially this format will be retained in future years. The School trains participants in advance diagnostics and research skills and the programme now includes molecular pathology. The Society now fully underwrites the course and we need to ensure the course remains competitive with others around the UK.

**STRUCTURE, GOVERNANCE AND MANAGEMENT**

**Governing document**

The charitable company is a company limited by guarantee.

**Risk management**

The Society performed a risk analysis, which has identified the main areas of risk as loss of membership, litigation, loss of accommodation, loss of key staff or services, financial losses on meetings and loss of income from the Journal of Pathology.

Litigation is covered jointly with the publishers of the Journal of Pathology, Wiley-Blackwell, by our own insurance and, by the change of legal status of the Society to become an incorporated charitable company.

All trustees are required to inform the Society of their financial interests and those of family members of significant others in an annual, signed declaration. At the start of all grant awarding sessions, committee members are required to declare any conflicts of interest and withdraw from those decisions.

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**REPORT OF THE TRUSTEES  
for the year ended 31 December 2021**

**STRUCTURE, GOVERNANCE AND MANAGEMENT**

**Trustees and other committees**

The Committee meets twice annually, normally immediately prior to the Winter and Summer Scientific Meetings. This is the formal meeting of all Trustees at which they agree the broad strategy and areas of activity for the Society, including consideration of grant awarding, investment strategy and risk management. The 2021 Winter and Summer Committee meetings were held as virtual meetings.

An Awayday originally scheduled for March 2020 had to be cancelled and will be held at a later date.

The Society other sub-committees remain in place and continue to administer the activities of the Society; these are as follows:

- Research Sub-committee (chaired by Prof G Thomas) is responsible for assessing research grant applications and taking into account, where appropriate, external advice with a robust a peer review process for grants which exceed £25,000. Prof Thomas' had stood for a further term of office and was re-elected at the AGM on 8 July 2021.
- Education Sub-committee (chaired by Dr A Mukherjee). This Sub-committee advises on the allocation of funds for intercalated degree students, undergraduate elective bursaries, educational grants and the Student Seminar Scheme and has recently taken on the Pathological Society Meeting Bursary and Travel & Conference Bursary awards.
- Molecular Pathology Sub-committee was formed in 2018 and is chaired by Dr M Jansen.
- Programme Sub-committee (chaired by Prof HI Grabsch), approves programme content and the Society's scientific meetings strategy.
- Trainees' Sub-committee (chaired by Dr K Marks), was established in order to encourage a greater involvement of pathologists in training and to represent their views to the Committee of the Society.
- An Undergraduate Committee has representatives on the main Committee and Trainees' Sub - committee meetings.

The Committee is aware of the Charity Commission's Governance Code and continues to apply the Code as appropriate.

**REFERENCE AND ADMINISTRATIVE DETAILS**

**Registered Company number**

08759028 (England and Wales)

**Registered Charity number**

1154851

**Registered office**

7th Floor, 6 Alie Street  
London  
E1 8QT

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**REPORT OF THE TRUSTEES  
for the year ended 31 December 2021**

**Trustees**

Dr M F C Amary (appointed 8.7.21)  
Professor M J Arends , Professor of Pathology  
Dr G N J Betts , Consultant Histopathologist (resigned 8.7.21)  
Professor S E Coupland , Consultant Histopathologist  
Dr C Coyne , Consultant Histopathologist  
Dr N Coleman , Professor of Histopathology  
Professor A M Flanagan , Medical Doctor (resigned 8.7.21)  
Professor H I Grabsch , Professor Gastrointestinal Pathology  
Professor K D Hunter , Professor of Head & Neck Pathology  
Professor M Ilyas , Professor of Pathology (resigned 8.7.21)  
Dr M Jansen Clinician Scientist-Honorary  
Dr T J Kendall , Senior Clinical Research in Pathology (appointed 8.7.21)  
Professor J P C Le Quesne , Professor Of Molecular Pathology (appointed 8.7.21)  
Dr A Mukherjee , Honorary Consultant Histopathologist  
Dr L Moore , Research Fellow Histopathologist  
Professor G I Murray , Professor of Pathology  
Professor M Salto-Tellez Director Of Molecular Diagnostics, (resigned 25.1.21)  
Dr G S Petts , Clinical Lecturer in Pathology  
Dr N Pillay , Clinical Associate of Patholog (appointed 8.7.21)  
Dr A Shaaban , Consultant Pathologist  
Dr E J Soilleux , University Lecturer (resigned 8.7.21)  
Professor G J Thomas , Professor of Experimental Pathology  
Dr N P West Trustee (appointed 8.7.21)  
Dr A Winstanley , Consultant Cellular Pathologist

**Auditors**

Raffingers LLP, Statutory Auditor  
Chartered Certified Accountants  
19-20 Bourne Court  
Southend Road  
Woodford Green  
Essex  
IG8 8HD

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**REPORT OF THE TRUSTEES  
for the year ended 31 December 2021**

**TRUSTEES' RESPONSIBILITY STATEMENT**

The trustees, who are also the directors of The Pathological Society of Great Britain and Ireland for the purpose of company law, are responsible for preparing the Trustees' Report and the accounts in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).


The law applicable to charitable companies in England and Wales and in Scotland requires the trustees to prepare accounts for each financial year which give a true and fair view of the state of affairs of the charitable company and of the income and expenditure of the charitable company for that year. In preparing these accounts, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the accounts; and
- prepare the accounts on the going concern basis unless it is inappropriate to presume that the charitable company will continue in operation.

The trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the accounts comply with the Companies Act 2006 and the Charities and Trustee Investment (Scotland) Act 2005, the applicable Charities (Accounts and Reports) Regulations. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees' report was approved by the Board of Trustees

Report of the trustees, incorporating a strategic report, approved by order of the board of trustees, as the company directors, on, 17 May 2022 and signed on the board's behalf by:



Prof Graeme I Murray, Trustee

**REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF  
THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**Opinion**

We have audited the financial statements of The Pathological Society of Great Britain and Ireland (the 'charitable company') for the year ended 31 December 2021 which comprise the Statement of Financial Activities, the Balance Sheet, the Cash Flow Statement and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 December 2021 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and Regulation 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended).

**Basis for opinion**

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

**Conclusions relating to going concern**

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

**Other information**

The trustees are responsible for the other information. The other information comprises the information included in the Annual Report, other than the financial statements and our Report of the Independent Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

**REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF  
THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**Opinions on other matters prescribed by the Companies Act 2006**

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the Report of the Trustees for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Report of the Trustees has been prepared in accordance with applicable legal requirements.

**Matters on which we are required to report by exception**

In the light of the knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the Report of the Trustees.

We have nothing to report in respect of the following matters in relation to which the Charities (Accounts and Reports) Regulations 2008 and the Charities Accounts (Scotland) Regulations 2006 (as amended) require us to report to you if, in our opinion:

- the information given in the accounts is inconsistent in any material respect with the Trustees' Report; or
- sufficient and proper accounting records have not been kept; or
- the accounts are not in agreement with the accounting records; or
- we have not received all the information and explanations we require for our audit.

**Responsibilities of trustees**

As explained more fully in the Trustees' Responsibilities Statement, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

**REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF  
THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**Our responsibilities for the audit of the financial statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Independent Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

**The extent to which the audit was considered capable of detecting irregularities including fraud:**

Our approach to identifying and assessing the risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, was as follows:

- the engagement partner ensured that the engagement team collectively had the appropriate competence, capabilities and skills to identify or recognise non-compliance with applicable laws and regulations;
- we identified the laws and regulations applicable to the charitable company through discussions with management and from our commercial knowledge and experience of the sector The Pathological Society of Great Britain and Ireland belongs to;
- we focused on specific laws and regulations which we considered may have a direct material effect on the financial statements or the operations of the association, including the Charities Act 2011, Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable to the United Kingdom and Republic of Ireland (FRS 102) (effective 1 January 2019), Trustees Act, Bribery Act and data protection;
- we assessed the extent of compliance with the laws and regulations identified above through making enquiries of management and inspecting legal correspondence; and
- identified laws and regulations were communicated within the audit team regularly and the team remained alert to instances of non-compliance throughout the audit.

We assessed the susceptibility of the charity's financial statements to material misstatement, including obtaining an understanding of how fraud might occur, by:

- making enquiries of management as to where they considered there was susceptibility to fraud, their knowledge of actual, suspected and alleged fraud; and
- considering the internal controls in place to mitigate risks of fraud and non-compliance with laws and regulations, including the ones that ensure that the grants are used for intended purposes.

To address the risk of fraud through management bias and override of controls, we:

- performed analytical procedures to identify any unusual or unexpected relationships;
- tested journal entries to identify unusual transactions;
- assessed whether judgements and assumptions made in determining the accounting estimates were indicative of potential bias; and
- investigated the rationale behind significant or unusual transactions.

In response to the risk of irregularities and non-compliance with laws and regulations, we designed procedures which included, but were not limited to:

- agreeing financial statement disclosures to underlying supporting documentation;
- reading the minutes of meetings of those charged with governance;
- enquiring of management as to actual and potential litigation and claims.

**REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF**  
**THE PATHOLOGICAL SOCIETY OF GREAT**  
**BRITAIN AND IRELAND**

There are inherent limitations in our audit procedures described above. The more removed that laws and regulations are from financial transactions, the less likely it is that we would become aware of non-compliance. Auditing standards also limit the audit procedures required to identify non-compliance with laws and regulations to enquiry of the trustees and other management and the inspection of regulatory and legal correspondence, if any.

Material misstatements that arise due to fraud can be harder to detect than those that arise from error as they may involve deliberate concealment or collusion.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at [www.frc.org.uk/auditorsresponsibilities](http://www.frc.org.uk/auditorsresponsibilities). This description forms part of our Report of the Independent Auditors.

**Use of our report**

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's members as a body, for our audit work, for this report, or for the opinions we have formed.



Mr Thurairatnam Sudarshan (Senior Statutory Auditor)  
for and on behalf of Raffingers LLP, Statutory Auditor  
Chartered Certified Accountants  
19-20 Bourne Court  
Southend Road  
Woodford Green  
Essex  
IG8 8HD

17 May 2022

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**STATEMENT OF FINANCIAL ACTIVITIES  
for the year ended 31 December 2021**

	Notes	2021 Unrestricted fund £	2020 Total funds £
<b>INCOME AND ENDOWMENTS FROM</b>			
Donations and legacies	2	76,987	86,857
<b>Charitable activities</b>			
Journal of Pathology	4	818,290	860,340
Meetings and Events		73,925	24,600
Investment income	3	<u>184,034</u>	<u>196,957</u>
<b>Total</b>		1,153,236	1,168,754
 <b>EXPENDITURE ON</b>			
<b>Raising funds</b>			
Investment management costs	5	<u>30,658</u>	<u>30,457</u>
		30,658	30,457
<b>Charitable activities</b>			
Journal of Pathology	6	149,595	144,780
Grants and Award payable		1,134,298	744,872
Meetings and Events		222,186	157,006
<b>Total</b>		1,536,737	1,077,115
Net gains/(losses) on investments		<u>741,873</u>	<u>(72,197)</u>
<b>NET INCOME</b>		358,372	19,442
 <b>RECONCILIATION OF FUNDS</b>			
<b>Total funds brought forward</b>		<u>8,338,027</u>	<u>8,318,585</u>
<b>TOTAL FUNDS CARRIED FORWARD</b>		<u><u>8,696,399</u></u>	<u><u>8,338,027</u></u>

**CONTINUING OPERATIONS**

All income and expenditure has arisen from continuing activities.

The notes form part of these financial statements

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**BALANCE SHEET**  
**31 December 2021**

	Notes	2021 Total funds £	2020 Total funds £
<b>FIXED ASSETS</b>			
Tangible assets	13	29,983	42,121
Investments	14	<u>8,016,851</u>	<u>7,635,309</u>
		8,046,834	7,677,430
<b>CURRENT ASSETS</b>			
Debtors	15	849,184	912,672
Cash at bank and in hand		<u>180,599</u>	<u>152,482</u>
		1,029,783	1,065,154
<b>CREDITORS</b>			
Amounts falling due within one year	16	(380,218)	(404,557)
<b>NET CURRENT ASSETS</b>		<u>649,565</u>	<u>660,597</u>
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>		8,696,399	8,338,027
<b>NET ASSETS</b>		<u>8,696,399</u>	<u>8,338,027</u>
<b>FUNDS</b>	17		
Unrestricted funds:			
General fund		<u>8,696,399</u>	<u>8,338,027</u>
<b>TOTAL FUNDS</b>		<u>8,696,399</u>	<u>8,338,027</u>

The financial statements were approved by the Board of Trustees and authorised for issue on 17 May 2022 and were signed on its behalf by:



Prof Graeme I Murray, Trustee

The notes form part of these financial statements

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**CASH FLOW STATEMENT  
for the year ended 31 December 2021**

	Notes	2021 £	2020 £
<b>Cash flows from operating activities</b>			
Cash generated from operations	1	<u>(516,246)</u>	<u>(334,424)</u>
Net cash used in operating activities		<u>(516,246)</u>	<u>(334,424)</u>
<b>Cash flows from investing activities</b>			
Purchase of fixed asset investments		(1,640,850)	(863,894)
Sale of fixed asset investments		1,968,594	992,594
Movement in capital accounts		32,586	(38,167)
Interest received		57	545
Dividends received		<u>183,976</u>	<u>196,413</u>
Net cash provided by investing activities		<u>544,363</u>	<u>287,491</u>
<b>Change in cash and cash equivalents in the reporting period</b>			
		28,117	(46,933)
<b>Cash and cash equivalents at the beginning of the reporting period</b>		<u>152,482</u>	<u>199,415</u>
<b>Cash and cash equivalents at the end of the reporting period</b>		<u><u>180,599</u></u>	<u><u>152,482</u></u>

The notes form part of these financial statements

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**NOTES TO THE CASH FLOW STATEMENT  
for the year ended 31 December 2021**

**1. RECONCILIATION OF NET INCOME TO NET CASH FLOW FROM OPERATING ACTIVITIES**

	2021	2020
	£	£
<b>Net income for the reporting period (as per the Statement of Financial Activities)</b>	358,372	19,442
<b>Adjustments for:</b>		
Depreciation charges	12,138	12,149
(Gain)/losses on investments	(741,873)	72,197
Interest received	(57)	(545)
Dividends received	(183,976)	(196,413)
Decrease/(increase) in debtors	63,488	(18,111)
Decrease in creditors	<u>(24,338)</u>	<u>(223,143)</u>
<b>Net cash used in operations</b>	<u><u>(516,246)</u></u>	<u><u>(334,424)</u></u>

**2. ANALYSIS OF CHANGES IN NET FUNDS**

	At 1.1.21	Cash flow	At 31.12.21
	£	£	£
<b>Net cash</b>			
Cash at bank and in hand	<u>152,482</u>	<u>28,117</u>	<u>180,599</u>
	<u>152,482</u>	<u>28,117</u>	<u>180,599</u>
<b>Total</b>	<u><u>152,482</u></u>	<u><u>28,117</u></u>	<u><u>180,599</u></u>

The notes form part of these financial statements

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**NOTES TO THE FINANCIAL STATEMENTS  
for the year ended 31 December 2021**

**1. ACCOUNTING POLICIES**

**Basis of preparing the financial statements**

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (Charities SORP FRS 102) , (effective 1 January 2015) the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

The financial statements have been prepared under the historical cost convention with the exception of investments which are included at market value, as modified by the revaluation of certain assets.

The charity constitutes a public benefit entity as defined by FRS 102.

The accounts are presented in sterling and are rounded to the nearest pound.

Pathology London 2014 Limited, a 100% controlled subsidiary trading company, was dissolved during 2020.

**Assessment of going concern**

The trustees have assessed whether the use of the going concern assumption is appropriate in preparing these accounts. The trustees have made this assessment in respect to a period of one year from the date of approval of these accounts.

The trustees of the charity have concluded that there are no material uncertainties related to events or conditions that may cast significant doubt on the ability of the charity to continue as going concern. The trustees are of the opinion that the charity will have sufficient resources to meet its liabilities as they fall due.

**Critical accounting judgements and key sources of estimation uncertainty**

Preparation of the financial statements requires the trustees and management to make significant judgements and estimates.

The items in the accounts where these judgements and estimates have been made include:

- the useful economic lives attributed to tangible fixed assets used to determine the annual depreciation charge; and
- the assumptions adopted by the trustees in determining the value of any designations required from the charity's general unrestricted funds.

**Income**

Income is recognised when the charitable company is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charitable company has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Deferred income is recognised for income received in advance for events and meetings taking place in future periods.

Membership subscriptions are recognised in the year to which they relate.

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**NOTES TO THE FINANCIAL STATEMENTS - continued  
for the year ended 31 December 2021**

**1. ACCOUNTING POLICIES - continued**

**Income**

**Journal of Pathology**

The receipts in respect of journals supplied by the Society are credited to the financial statements in the year to which they relate. The income from journals is the proportion due to the Society under the relevant agreements and is net of direct costs met by the publishers.

**Meetings and events income**

Income and corresponding expenditure are recognised in the period the event has taken place. This results in deferred income and accruals recognised in balance sheet.

**Investment income**

Dividends and interest on securities are credited in the financial statements when the Society is entitled to receive the funds.

**Expenditure**

Expenditure is recognised once there is a legal or constructive obligation to make a payment to a third party, it is probable that settlement will be required and the amount of the obligation can be measured reliably.

The costs of raising funds consist of investment management fees.

**Journal of Pathology**

The cost of distributing copies of the journal to members is recognised as a charitable activity.

**Support costs for meetings**

Costs incurred for the Society's events and meetings are recognised in the period in which they take place.

All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the category.

Support and governance costs relating to charitable activities have been apportioned as follows:

Grants and awards payable 14%

Support costs for meetings 77%

Journal of Pathology 9%

**Grants payable**

Grants payable are payments made to third parties in the furtherance of the charitable objects of the Society. In the case of an unconditional grant offer this is accrued once the recipient has been notified of the grant award. The notification gives the recipient a reasonable expectation that they will receive the one- year or multi-year grant. Grants awards that are subject to the recipient fulfilling performance conditions are only accrued when the recipient has been notified of the grant and any remaining unfulfilled condition attaching to that grant is outside of the control of the Society.

**Tangible fixed assets**

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Fixtures and fittings - 15% on reducing balance

Computer equipment - 20% on cost

**Taxation**

The charity is exempt from corporation tax on its charitable activities.

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**NOTES TO THE FINANCIAL STATEMENTS - continued**  
**for the year ended 31 December 2021**

**1. ACCOUNTING POLICIES - continued**

**Fund accounting**

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Designated funds comprise funds which have been set aside at the discretion of the trustees for specific purposes. The purposes and uses of the designated funds are set out in the notes to the accounts.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

**Cash at bank and in hand**

Cash at bank and in hand represents such accounts and instruments that are available on demand or have a maturity of less than three months from the date of acquisition. Deposits for more than three months but less than one year have been disclosed as short term deposits.

**Creditors and provision**

Creditors and provision are recognised when there is an obligation at the balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably. Creditors and provision are recognised at the moment the charity anticipates it will pay to settle the debt. They have been discounted to the present value of the future cash payments where such discounting is material.

**Investments**

Listed investments are initially recognised at their transaction value and subsequently measured at their fair value as at the balance sheet date using the closing quoted market price.

Realised and unrealised investment gains (or losses) are combined in the statement of financial activities and are credited (or debited) in the year in which they arise.

**2. DONATIONS AND LEGACIES**

	Unrestricted funds	Restricted funds	2021 Total funds	2020 Total funds
Subscriptions	£ <u>76,987</u>	£ <u>-</u>	£ <u>76,987</u>	£ <u>86,857</u>

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**NOTES TO THE FINANCIAL STATEMENTS - continued  
for the year ended 31 December 2021**

**3. INVESTMENT INCOME**

	Unrestricted funds £	Restricted funds £	2021 Total funds £	2020 Total funds £
Income from listed investments	183,977	-	183,977	196,412
Deposit account interest	<u>57</u>	<u>-</u>	<u>57</u>	<u>545</u>
	<u>184,034</u>	<u>-</u>	<u>184,034</u>	<u>196,957</u>

**4. INCOME FROM CHARITABLE ACTIVITIES**

	2021 £	2020 £
Journal of Pathology	782,864	860,340
Meetings and events	<u>73,925</u>	<u>24,600</u>
	<u>856,789</u>	<u>884,940</u>

**5. INVESTMENT MANAGEMENT COSTS**

	Unrestricted funds £	Restricted funds £	2021 Total funds £	2020 Total funds £
Investment management	<u>30,658</u>	<u>-</u>	<u>30,658</u>	<u>30,457</u>

**6. CHARITABLE ACTIVITIES COSTS**

	Direct Costs £	Grant funding of activities (see note 7) £	Support costs (see note 8) £	Totals £
Journal of Pathology	149,595	-	-	149,595
Grants and Award payable	-	967,686	166,612	1,134,298
Meetings and Events	<u>94,425</u>	<u>-</u>	<u>127,761</u>	<u>222,186</u>
	<u>244,020</u>	<u>967,686</u>	<u>294,373</u>	<u>1,506,079</u>

**7. GRANTS PAYABLE**

	2021 £	2020 £
Grants and Award payable	<u>967,686</u>	<u>616,207</u>

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**NOTES TO THE FINANCIAL STATEMENTS - continued  
for the year ended 31 December 2021**

**8. SUPPORT COSTS**

	Management Finance		Governance costs	Totals
	£	£	£	£
Grants and Award payable	107,651	2,640	56,321	166,612
Meetings and Events	<u>127,761</u>	-	-	<u>127,761</u>
	<u>235,412</u>	<u>2,640</u>	<u>56,321</u>	<u>294,373</u>

Support costs, included in the above, are as follows:

	Grants and Award payable £	Meetings and Events £	2021 Total activities £	2020 Total activities £
Wages	-	70,255	70,255	59,104
Social security	-	11,413	11,413	13,580
Pensions	-	15,942	15,942	19,244
Rent and insurance	-	26,632	26,632	25,249
Postage and stationery	-	3,519	3,519	5,280
Sundries	4,788	-	4,788	8,614
Website and computer	90,725	-	90,725	62,076
Staff travel	-	-	-	2,796
Depreciation of tangible and heritage assets	12,138	-	12,138	12,149
Bank charges	2,640	-	2,640	2,182
Wages	30,100	-	30,100	25,500
Auditors' remuneration	6,500	-	6,500	6,000
Committee meetings	-	-	-	16,328
Accountancy fees	7,853	-	7,853	8,318
Professional and legal fees	<u>11,868</u>	-	<u>11,868</u>	<u>3,826</u>
	<u>166,612</u>	<u>127,761</u>	<u>294,373</u>	<u>270,246</u>

**9. NET INCOME/(EXPENDITURE)**

Net income/(expenditure) is stated after charging/(crediting):

	2021 £	2020 £
Auditors' remuneration	6,500	6,000
Depreciation - owned assets	<u>12,138</u>	<u>12,149</u>

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**NOTES TO THE FINANCIAL STATEMENTS - continued  
for the year ended 31 December 2021**

**10. TRUSTEES' REMUNERATION AND BENEFITS**

**Trustees' expenses**

None of the trustees (or any persons connected with them) received any remuneration during the year, there were also no travelling costs reimbursed this year.

No grants were received by trustees from the Society in the year.

No committee advisors (non-trustee) received grants from the Society in the year.

**11. STAFF COSTS**

	2021	2020
	£	£
Wages and salaries	128,268	107,430
Social security costs	14,656	18,672
Other pension costs	<u>20,408</u>	<u>26,548</u>
	<u>163,332</u>	<u>152,650</u>

The average monthly number of employees during the year was as follows:

	2021	2020
Administrative staff	<u>3</u>	<u>3</u>

No employees received emoluments in excess of £60,000.

**12. FINANCIAL COMMITMENTS, GUARANTEES AND CONTINGENT LIABILITIES**

The company is limited by guarantee - all members having a liability not exceeding £1 per member.

**13. TANGIBLE FIXED ASSETS**

	Fixtures and fittings £	Computer equipment £	Totals £
<b>COST</b>			
At 1 January 2021 and 31 December 2021	<u>12,374</u>	<u>65,774</u>	<u>78,148</u>
<b>DEPRECIATION</b>			
At 1 January 2021	11,955	24,072	36,027
Charge for year	<u>63</u>	<u>12,075</u>	<u>12,138</u>
At 31 December 2021	<u>12,018</u>	<u>36,147</u>	<u>48,165</u>
<b>NET BOOK VALUE</b>			
At 31 December 2021	<u>356</u>	<u>29,627</u>	<u>29,983</u>
	<u>          </u>	<u>          </u>	<u>          </u>

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**NOTES TO THE FINANCIAL STATEMENTS - continued  
for the year ended 31 December 2021**

**14. FIXED ASSET INVESTMENTS**

	2021	2020
	£	£
Shares	7,982,827	7,568,699
Other	<u>34,024</u>	<u>66,610</u>
	<u>8,016,851</u>	<u>7,635,309</u>

Additional information as follows:

	Shares in group undertakings	Listed investments	Totals
	£	£	£
<b>MARKET VALUE</b>			
At 1 January 2021	1	7,568,698	7,568,699
Additions	-	1,640,850	1,640,850
Disposals	-	(1,968,594)	(1,968,594)
Revaluations	-	741,873	741,873
Impairments	<u>(1)</u>	<u>-</u>	<u>(1)</u>
At 31 December 2021	<u>-</u>	<u>7,982,827</u>	<u>7,982,827</u>
<b>NET BOOK VALUE</b>			
At 31 December 2021	<u>-</u>	<u>7,982,827</u>	<u>7,982,827</u>
At 31 December 2020	<u>1</u>	<u>7,568,698</u>	<u>7,568,699</u>

There were no investment assets outside the UK.

Investments (neither listed nor unlisted) were as follows:

	2021	2020
	£	£
Cash in portfolio	<u>34,024</u>	<u>66,610</u>

**15. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	2021	2020
	£	£
Other debtors	840,010	903,993
Prepayments	<u>9,174</u>	<u>8,679</u>
	<u>849,184</u>	<u>912,672</u>

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**NOTES TO THE FINANCIAL STATEMENTS - continued  
for the year ended 31 December 2021**

**16. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	2021	2020
	£	£
Trade creditors	9,595	4,050
VAT	-	15
Other creditors	500	940
Accrued expenses	<u>370,123</u>	<u>399,552</u>
	<u>380,218</u>	<u>404,557</u>

**17. MOVEMENT IN FUNDS**

	At 1.1.21	Net movement in funds	At 31.12.21
	£	£	£
<b>Unrestricted funds</b>			
General fund	8,338,027	358,372	8,696,399
	<u>8,338,027</u>	<u>358,372</u>	<u>8,696,399</u>
<b>TOTAL FUNDS</b>	<u>8,338,027</u>	<u>358,372</u>	<u>8,696,399</u>

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Gains and losses £	Movement in funds £
<b>Unrestricted funds</b>				
General fund	1,153,236	(1,536,737)	741,873	358,372
	<u>1,153,236</u>	<u>(1,536,737)</u>	<u>741,873</u>	<u>358,372</u>
<b>TOTAL FUNDS</b>	<u>1,153,236</u>	<u>(1,536,737)</u>	<u>741,873</u>	<u>358,372</u>

**Comparatives for movement in funds**

	At 1.1.20	Net movement in funds	At 31.12.20
	£	£	£
<b>Unrestricted funds</b>			
General fund	8,318,585	19,442	8,338,027
	<u>8,318,585</u>	<u>19,442</u>	<u>8,338,027</u>
<b>TOTAL FUNDS</b>	<u>8,318,585</u>	<u>19,442</u>	<u>8,338,027</u>

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**NOTES TO THE FINANCIAL STATEMENTS - continued  
for the year ended 31 December 2021**

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Gains and losses £	Movement in funds £
<b>Unrestricted funds</b>				
General fund	1,168,754	(1,077,115)	(72,197)	19,442
	<hr/>	<hr/>	<hr/>	<hr/>
<b>TOTAL FUNDS</b>	<u>1,168,754</u>	<u>(1,077,115)</u>	<u>(72,197)</u>	<u>19,442</u>

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**NOTES TO THE FINANCIAL STATEMENTS - continued  
for the year ended 31 December 2021**

**18. RELATED PARTY TRANSACTIONS**

**Remuneration of key management personnel**

The remuneration of key management personnel is as follows.

	2021	2020
	£	£
Aggregate compensation	163,332	152,650

The above amounts were paid to the Royal College of Pathologists for the use of 3 (2020: 3) of their employees for administrative management of the society. As part of the agreement between the two entities, in the event of the Royal College of Pathologists being required to contribute to the pension scheme that it belongs to, the society could be liable to meet the obligations of the pension costs in respect of these individuals.

**19. SUBSIDIARIES**

There were no subsidiaries controlled by the charity as at 31 December 2021.

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**DETAILED STATEMENT OF FINANCIAL ACTIVITIES  
for the year ended 31 December 2021**

	2021 £	2020 £
<b>INCOME AND ENDOWMENTS</b>		
<b>Donations and legacies</b>		
Subscriptions	76,987	86,857
<b>Investment income</b>		
Income from listed investments	183,977	196,412
Deposit account interest	57	545
	184,034	196,957
<b>Charitable activities</b>		
Journal of Pathology	818,290	860,340
Meetings and events	73,925	24,600
	892,215	884,940
<b>Total incoming resources</b>	1,153,236	1,168,754
<b>EXPENDITURE</b>		
<b>Investment management costs</b>		
Investment management	30,658	30,457
<b>Charitable activities</b>		
Wages	27,913	22,826
Social security	3,243	5,092
Pensions	4,466	7,304
Charitable expenditure	208,398	124,983
Grants to individuals	967,686	616,207
	1,211,706	776,412
<b>Support costs</b>		
<b>Management</b>		
Wages	70,255	59,104
Social security	11,413	13,580
Pensions	15,942	19,244
Rent and insurance	26,632	25,249
Postage and stationery	3,519	5,280
Sundries	4,788	8,614
Website and computer	90,725	62,076
Staff travel	-	2,796
Fixtures and fittings	63	74
Computer equipment	12,075	12,075
	235,412	208,092
<b>Finance</b>		

This page does not form part of the statutory financial statements

Bank charges	2,640	2,182
<b>Governance costs</b>		
Wages	30,100	25,500
Auditors' remuneration	6,500	6,000
Committee meetings	-	16,328
Accountancy fees	7,853	8,318
Professional and legal fees	<u>11,868</u>	<u>3,826</u>
	<u>56,321</u>	<u>59,972</u>
Total resources expended	<u>1,536,737</u>	<u>1,077,115</u>
<b>Net (expenditure)/income before gains and losses</b>	(383,501)	91,639
<b>Net (losses) gains on investments</b>		
Realised gains/(losses) on fixed asset investments	<u>741,873</u>	<u>(72,197)</u>
<b>Net income</b>	<u><u>358,372</u></u>	<u><u>19,442</u></u>

This page does not form part of the statutory financial statements

**THE PATHOLOGICAL SOCIETY OF GREAT BRITAIN AND IRELAND**

England & Wales - Charity number 1154851

---

# Accounts

---

REGISTERED COMPANY NUMBER: 08759028 (England and Wales)  
REGISTERED CHARITY NUMBER: 1154851  
REGISTERED CHARITY (SCOTLAND) NUMBER: SC045004

**REPORT OF THE TRUSTEES AND**  
**FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2020**  
**FOR**  
**THE PATHOLOGICAL SOCIETY OF GREAT**  
**BRITAIN AND IRELAND**

Raffingers LLP  
19-20 Bourne Court  
Southend Road  
Woodford Green  
Essex  
IG8 8HD

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**CONTENTS OF THE FINANCIAL STATEMENTS  
for the year ended 31 December 2020**

	<b>Page</b>
<b>Report of the Trustees</b>	1 to 10
<b>Report of the Independent Auditors</b>	11 to 14
<b>Statement of Financial Activities</b>	15
<b>Balance Sheet</b>	16
<b>Cash Flow Statement</b>	17
<b>Notes to the Cash Flow Statement</b>	18
<b>Notes to the Financial Statements</b>	19 to 28

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**REPORT OF THE TRUSTEES  
for the year ended 31 December 2020**

The trustees present their report and accounts for the year ended 31 December 2020.

The accounts have been prepared in accordance with the accounting policies set out in note 1 to the accounts and comply with the charitable company's governing document, the Companies Act 2006 and the Statement of Recommended Practice, "Accounting and Reporting by Charities", issued in March 2015.

**PUBLIC BENEFIT**

The trustees have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing the aim and objectives and in planning the charity's future activities. The aims of the charity for the public benefit are detailed in the 'Objectives and Activities' section of this report.

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**REPORT OF THE TRUSTEES  
for the year ended 31 December 2020**

**OBJECTIVES AND ACTIVITIES**

The Pathological Society is dedicated to the "Understanding of Disease-Guiding Therapy" in the medical scientific and lay communities. It provides a forum for the presentation of new scientific and medical research findings with the aim of improving knowledge and understanding of human disease. As stated in the constitution; "The objectives of the Society shall be to advance pathology and facilitate communications between pathologists" but this has expanded to recognise its role in the wider community. The Society conforms to its stated objectives by the publication of its Journals, The Journal of Pathology and The Journal of Pathology: Clinical Research, by the organisation of meetings of the Society, by support of other scientific meetings and of a variety of educational and research schemes (see below).

The Society is also a Scottish registered charity and operates in Scotland.

In setting the objectives and activities for the year, the Society has referred to the guidance issued by the Charity Commission on public benefit. In particular, the Society considers how planned activities contribute to the objectives and activities they have set and how these provide public benefit. For the past year, due to the Covid-19 pandemic, the Society's normal activities have had to adapt accordingly, especially in relation to scientific meetings as well as some grant activities.

The Pathological Society serves the public in a variety of ways. Through its scientific and educational meetings (the largest Pathology meeting in the UK and Ireland), the doctors and scientists who manage patients are kept up to date in the latest knowledge about the causes of diseases and its diagnosis. Our flagship journal, The Journal of Pathology, now in its 128th year of publication continues to enjoy high international esteem and is widely recognised as the preferred journal in which to publish scientific papers on the mechanisms of disease. Our more recent journal, The Journal of Pathology: Clinical Research (JPCR), publishes papers on the application of investigations and trials in clinical scenarios. Together they keep our members, pathologists worldwide and clinicians in other disciplines, apprised of developments in our understanding of the nature and causes of disease and in the resultant current expansion of new methods in diagnosis and treatment. This has immediate significance for patients, in helping to ensure that their management is supported by pathology based on the best diagnostic methods. In June 2020 we were pleased to announce that JPCR has its first Impact Factor, 3.489 which has resulted in a significant increase in submissions. The Society's provision of grants schemes for research training for its trainee (Concessionary) members will help to ensure that successive cohorts of young UK pathologists will have opportunities to contribute to these advances in medical care. We are hopeful that research will be able to recommence having been halted by the Pandemic.

The Pathological Society is also committed to enhancing the understanding of medical science by the general public and to this end runs Public Lectures; the most recent was given at the joint meeting with the British Division of the International Academy of Pathology (BDIAP) held in Harrogate, UK in July 2019; Prof Louise Jones gave an enlightening talk on the 100,000 Genomes Project and Cancer. The next Public Lecture is planned for the Manchester Pathology 2021 Virtual Conference (6-8 July). The Public Lectures are filmed, with the permission of the lecturer, the videos are available on the Society's website. We also run the Public Engagement grant scheme which will fund a wide range of activities that help the public to understand disease, the pathology underlying the disease and the work of pathologists in the investigation, diagnosis and clinical management of disease. This has been expanded to accommodate applications for virtual events.

The Society continues to explore additional means of informing the public about research into human disease and the practice of pathology; it is envisaged that some of this will be conducted in association with other learned societies.

The Society normally runs two major scientific meetings per year. These meetings are open to the entire medical and scientific community and not restricted to Society members. Both Winter and Summer meetings include sessions dedicated to those in training. All our summer meetings are run jointly with the BDIAP. As this has become established as the major pathology meeting in the UK and Ireland other specialist societies are increasingly collaborating in the development and delivery of these meetings. The format of these meetings will change with an increasing on-line element within the programme. This will allow more delegates to attend without the added expense of travel and accommodation.

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**REPORT OF THE TRUSTEES  
for the year ended 31 December 2020**

The attendance at the most recent summer meetings averages approximately 500. The Society underwrites all these meetings on a 50/50 basis with the BDIAP in order to maintain registration fees at affordable levels. In 2020 there was a winter meeting, held in London, which was the 3rd Joint Meeting with the Royal Society of Medicine. There was no summer (Joint Meeting with the BDIAP) in 2020 as the BDIAP were co-organisers of the ECP 2020 which became a fully virtual event. Whilst no face to face educational events were possible over the last year, the Society has introduced on-line sessions for trainees over the past year.

Our current schemes include:

**RESEARCH GRANTS:**

**Best Trainee Research Impact & Best Trainee Research Paper Awards - introduced in 2017**

- **Research Impact Award** to encourage pathology trainees to highlight the most impactful research in the last 36 months and offer £500 and a Medal.

- **Research Paper Award** to encourage pathology trainees to highlight their best published single research paper relevant to pathology in the last 12 months and offers £500 and a certificate. Our current annual allocation is £1,000 for each Award.

**Cuthbert Dukes Medium Grant Scheme**

This scheme was launched in 2019 to encourage early-mid career pathology researchers, in particular academic trainees, to undertake investigation tissue-based research and offers up to £20,000 with one deadline per annum.

**Cancer Research UK/Pathological Society Pre-Doctoral Research Bursary**

These jointly funded grants were introduced in 2018 and provide short term funding to allow clinicians to get involved in cancer research and provides funding for up to £45,000 for salary and/or research expenses for up to 12 months, with two deadlines per annum. The initial 3 year agreement with CRUK ended in 2020 and has been extended for a further 3 year period.

**Early Career Pathology Research Grant - Hodgkin & Leishman**

These were introduced in 2018 to trainees in their first few years of training to undertake investigative research, with two deadlines per annum. The Hodgkin offer up to £1,000 and Leishman up to £2,000. Our current annual allocation is £10,000.

**Equipment Scheme**

This scheme is aimed at supporting pathologists engaged in research by providing funds for multi-user equipment. Our current annual allocation for this scheme is £20,000 with two deadlines per annum.

**International Collaborative Scheme**

This is aimed at promoting collaboration in scholarly pathological activities between pathologists from any institution outside of the UK and UK pathologists. Our current annual allocation for this scheme is £20,000 with one deadline per annum.

**Jean Shanks Foundation/Pathological Society (JSPS) Joint Research Grants**

The five-year agreement with the Jean Shanks Foundation launched in 2018 provides a jointly funded range of research schemes to facilitate trainees in pathology to develop their academic and research schemes ranging from early career support through to support for new independent investigators. This initiative will result in a significant increase in the Society's research grant spend. The trustees of the Society agreed to commit money from the Society's investment funds to support this.

Applications have been considered by the Research Sub-committee during 2020 and a range of high-quality applications were recommended for support and these recommendations were endorsed by the Finance and General Purposes Sub-committee.

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**REPORT OF THE TRUSTEES  
for the year ended 31 December 2020**

**All schemes have two application deadlines per annum:**

- **JSPS Pre-Doctoral Research Bursary** - to promote research in pathology to fund short projects for early career clinical academic research trainee pathologists for a period of 3, 6, 9 or 12 months. This covers salary and/or research expenses to a maximum of £40,000.

- **JSPS Clinical PhD Fellowship** - To provide 3 years of PhD funding for clinical trainee histopathologists to increase the research skills, abilities and interests of those medically qualified trainee histopathologists working on tissue-based projects in pathology. Funding covers salary, university fees and consumables of up to £15,000 pa for 3 years.

- **JSPS Clinical Lecturer Grant** - To offer histopathology trainees post MD/PhD who wish to continue research part-time whilst completing clinical training (part-time). Covers up to £200,000 over a maximum of 4 years and covers 50% salary (with 50% of salary provided by the NHS - similar to the NIHR Clinical Lectureships) and provides up to £15,000 consumables per annum.

- **JSPS Clinical Lecturer Support Grant** - To offer support for continuing research projects over a 2 year period by academic trainee histopathologists following the award of a PhD or MD, when progressing through the final stages of histopathological training leading up to the award of CCT. Covers £50,000 per annum funding over a 2 year period to be used flexibly to fund the costs of employing a research technician or assistant and associated consumables costs.

- **JSPS Intermediate Research Fellowship** - to support newly accredited pathologists during the period between completing their training (passing FRCPath part 2/completing the Certificate of Completion of Training) and obtaining full funding for a Clinician Scientist post through MRC, The Wellcome Trust, CRUK etc. Covers up to £100,000 over a maximum of 2 years and covers 50% of salary costs (with 50% of salary provided by the NHS) and up to £15,000 of consumables per annum.

- **JSPS Clinical Academic Research Partnership** - to offer support for NHS consultants who wish to undertake research. The aim is to encourage consultants with and MD or PhD (or equivalent) who are currently not research active, to participate in high quality research collaborations with established leading biomedical researchers.

**PhD Sponsorships** - supports a 3-year PhD and covers a stipend, research & training allowance, conference allowance and up to £15,000 per annum for consumables. Rates are set at MRC rates. Current annual allocation for this is £210,300.

**Small Grant Schemes**

This is divided into four separate schemes, namely the Trainees' Small Grant, the Consultant's Pump Priming Small Grant, Postdoctoral Collaborative Small Grant and the Trainees Collaborative Small Grant. These awards are designed to support laboratory expenses for Trainees (speciality trainees or academic trainees) and consultants within their first five years of appointment to generate pilot data to support subsequent applications to major funding agencies. The maximum grant available is £10,000. The current annual allocation for these schemes is £10,000 for the Trainees Collaborative and £40,000 for all others.

**Trainee-Clinical Scientist Partnership in Morpho-Molecular Pathology**

This new scheme was introduced in 2019 to create long lasting scientific partnerships between trainee pathologists and clinical scientists in the pathology and genomics arenas, with funding up to £50,000 for a maximum of 3 years. This scheme has one deadline per annum.

**Visiting Fellowships**

The Fellowships are for members of the medical and allied scientific professions working in pathologically related bio-medical research to enable travel to other institutions to learn new techniques of value in their research. Applicants need not be Society members. Fellowships are available for a period of study of up to twelve months.

Preference is given to applicants wishing to learn new techniques in the fields of molecular and cell biology. A maximum sum of £5,000 is allocated to any one person. The current annual allocation to this scheme is £20,000.

**EDUCATION GRANTS:**

**Case Report Prize for Undergraduate & Concessionary (Trainees) Members**

Applicants are required to submit a case report and review of the literature of a standard suitable for publication that goes beyond basic morphological and immunohistochemical diagnostics. A prize of £100 is offered and the opportunity to present the case as an oral presentation at a Summer Meeting of the Society.

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**REPORT OF THE TRUSTEES  
for the year ended 31 December 2020**

**Educational Grant Scheme**

This scheme is designed to provide support to Academic staff for projects in relation to medical and scientific education (undergraduate and post-graduate) that foster the general area of understanding disease. Our current annual allocation for this scheme is £10,000 with two deadlines per annum.

The following Education grants are available. Following the introduction of Associate Undergraduate Membership, these grants are restricted to Associate Undergraduate members:

**Intercalated Degree Awards**

These awards provide fees (up to £9,000) and stipend (£4,500) and £1,500 for consumables for able medical, dental or veterinary students to intercalate a year's Science training and study for a BSc or MSc degree. We support up to 10 awards per annum.

**Vacation and Elective Bursaries for Undergraduate Students**

We will support any undergraduate medical, dental or veterinary student to a maximum of £150 per week for up to 8 weeks to undertake a project on any topic that bears on the issue of 'understanding disease' during elective or vacation periods. With two deadlines per annum, our current annual allocation for this scheme is £30,000.

**The Jean Shanks Foundation & Pathological Society Summer Joint Studentships (JSPS)**

This scheme was introduced in 2020 in order to support Year 1 & Year 2 medical and dental students to carry out a research project in pathology during vacation periods. Up to £200 per week, with a maximum of £1,000 per student. The Society would like to thank the Trustees of the Jean Shanks Foundation for co-finding this important initiative. The current annual allocation for this scheme is £50,000.

**Undergraduate Essay Prize**

We make an award of £500 every year for the best essay written by an undergraduate on a pathologically orientated title. Winning entries can be seen on our website.

**Pathological Society Meeting Bursary for Undergraduates**

This covers travel costs of up to £250 to attend a Pathological Society meeting.

**Students Society Bursary Scheme**

This scheme is to provide support for the promotion of the understanding of pathology amongst medical, dental, biomedical students. The sum requested should not exceed £500, current annual allocation £4,400.

All schemes are competitive and clear guidelines are published on our website. They are advertised on our website and in our journals where appropriate. They are awarded by the Society Committee and/or after consideration by the relevant Sub-committees.

**OTHER GRANTS:**

**Pathological Society Meetings Bursary**

Bursaries are made available to cover the cost of registration fees for Society members who are post graduate students (PhD, MD or MSc) or Pathology Trainees and wish to present their research at Society meetings. An applicant whose work is/has been selected for presentation in a plenary session will be favoured.

**Public Engagement Scheme**

This was established in order to foster and promote greater awareness by the lay public of advances in understanding disease which may include support of educational ventures with schools and further education colleges. Our current annual allocation for this scheme is £10,000.

**Open Scheme**

In addition to the above, the Open Scheme is designed to be a source of funds for other activities not covered by the above schemes but that will foster the Society's mission. Our current annual allocation for this scheme is £10,000.

**Travel & Conference Bursary**

These bursaries are to promote scientific communications at major international meetings. Applicants whose work has been selected for presentation are favoured.

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**REPORT OF THE TRUSTEES  
for the year ended 31 December 2020**

**Society Lectures & Awards**

The Society makes several awards for Academic and other achievements. These include the Oakley Lecture for achievements by a young researcher: this has been held annually at Joint Meetings with the BDIAP (in the summer). The Sir Nicholas Wright Lecture introduced in 2017 and the first lecture was given at the Maastricht Pathology 2018 meeting. This is held in alternative years with the Oakley Lecture from 2018.

We promote the discipline among trainees (including PhD students and biomedical scientists) by offering a significantly discounted membership fee (£10 per annum) which includes all benefits as well as electronic access to the Journal of Pathology and other substantial subsidies (e.g. registration fees etc) including complimentary membership of the European Society of Pathology. On occasions we can provide Society members with other benefits, such as reduced prices from the Society journals' publishers.

**STRATEGIC REPORT**

**Achievement and performance**

**Charitable activities**

The main source of income to the Society is from The Journal of Pathology and as scientific publication migrates to the Open Access model, there is a significant potential for loss of income from the Journal of Pathology. Prof Simon Herrington, Editor-in-Chief and Wiley-Blackwell have been working hard to maintain the success of the Journal and its high impact factor, a major consideration for subscribers.

The budget of our regular meetings continues to fall well within the resources, representing less than 10% of annual turnover and 1% of current assets. A separate trading company "Pathology London 2014 Ltd" was set up to manage the Society's involvement in the joint meeting with the European Society of Pathology in London. This is a wholly owned subsidiary of the Society and its directors are Professor Sir Nicholas Wright and Dr Nicholas Rooney and, since 2016, Professor Graeme Murray, current treasurer of the Society and a decision was taken to close this company as had not been utilised since 2014. Pathology London 2014 was closed on 29 September 2020.

**Investment policy**

The Society has considerable investments held mostly in funds managed by our advisors, Cazenove Capital Management, the charities investment arm of Schrodgers. The investment policy is reviewed annually by the trustees bearing in mind the current income from the journals and membership subscriptions. A presentation is given by the portfolio director, Jeremy Barker, to all the trustees at the January Committee Meeting. The treasurer is in regular contact with the investment team and reviews/forwards relevant documentation to the trustees. The funds available to the Society are principally represented by the Investment portfolio held by the investment fund managers and consist of a variety of quoted investments and government stock. The trustees are aware of the level of income that is available from the investment portfolio and its ability to replace loss of income from the journals.

The value of Listed investments has decreased from £7,798,039 to £7,635,309 at the end of the current year. This decrease is due to unrealised losses on the revaluation of the investment due to volatile stock market conditions. The trustees believe that this downturn will be corrected in the long run.

The Society is faced with a potential loss of income supporting its grants whilst facing increased expenditure. However, the cost of accommodation has stabilised since the Society entered an agreement with The Royal College of Pathologists to lease office accommodation within the new Royal College of Pathologists building at 6 Alie Street. The Society moved to its new office in April 2019. and will increase the reliance on investment and journal income. Until the long-term financial position is clearer, reserves will be maintained to allow investment income to replace the loss of journal income.

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**REPORT OF THE TRUSTEES  
for the year ended 31 December 2020**

**STRATEGIC REPORT**

**Financial review**

**Financial position**

The financial results for the year to 31 December 2020 are shown in the attached financial statements.

Income has decreased for the year under review to £1,168,755 (2019: £1,369,508) primarily due to an decrease in income from the listed investments and the lack of meetings and events. Subscription income is relatively stable at £86,857 (2019: £83,232) but on its own would not enable the Society to function. The main areas of expenditure continue to be charitable grants £616,207 (2019: £861,662), Society meetings £157,006 (2019: £467,322) and support costs of the society £270,246 (2019: £288,318).

Overall income has exceeded expenditure by £19,443 (2019: £586,935) after realised and unrealised investment gains and losses. Fund balances total £8,338,027 (2019: £8,318,584).

It is the policy of the charitable company that unrestricted funds which have not been designated for a specific use should be maintained at a level equivalent to between three and six month's expenditure. The trustees consider that reserves at this level will ensure that, in the event of a significant drop in funding, they will be able to continue the charitable company's current activities while consideration is given to ways in which additional funds may be raised. This level of reserves has been maintained throughout the year.

The trustees have assessed the major risks to which the charitable company is exposed, and are satisfied that systems are in place to mitigate exposure to the major risks.

**Securing the future of pathology**

To ensure the future success of the Society, it has modified its subscription structures to encourage recruitment and greater involvement of more junior pathologists. In addition, as noted above, the Trainees' Sub-committee continues to develop. Changes have already been reflected in a significant up-turn in membership numbers and progression from concessionary to ordinary membership. There had been a drop in membership numbers in recent months largely due to lack of Undergraduate activity due to the pandemic. Meetings to promote academic pathology amongst trainees have also been supported by The Society as well as the additional JSPS Summer Student bursary scheme for Year 1 & 2 medical students. The National Academic trainee network meetings continue, with 2 being held in 2020 (the October meeting was held on-as a virtual event), in conjunction with the Winter Society meetings. Other stand alone meetings had to be postponed, cancelled or held on line due to Social Distancing regulations. The Society plans to continue these meetings, which are valued by the trainees.

To encourage applications for pathology amongst medical graduates, the Undergraduate Committee was established with funding to support attendance at conferences. We aim to promote interest in Pathology even before university, establishing careers days for sixth form students in association with the College and BDIAP. Unfortunately, it was not possible to hold a meeting in 2020.

The Society continues to support the Pathological Society Winter School, which trains participants in advance diagnostics and research skills and the programme now includes molecular pathology. The Society now fully underwrites the course and we need to ensure the course remains competitive with others around the UK.

**STRUCTURE, GOVERNANCE AND MANAGEMENT**

**Governing document**

The charitable company is a company limited by guarantee.

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**REPORT OF THE TRUSTEES  
for the year ended 31 December 2020**

**STRUCTURE, GOVERNANCE AND MANAGEMENT**

**Risk management**

The Society performed a risk analysis, which has identified the main areas of risk as loss of membership, litigation, loss of accommodation, loss of key staff or services, financial losses on meetings and loss of income from the Journal of Pathology.

To protect the membership database and members confidential information, an external company was contracted to manage and secure our data off-site.

Litigation is covered jointly with the publishers of the Journal of Pathology, Wiley-Blackwell, by our own insurance and, by the change of legal status of the Society to become an incorporated charitable company.

All trustees are required to inform the Society of their financial interests and those of family members of significant others in an annual, signed declaration. At the start of all grant awarding sessions, committee members are required to declare any conflicts of interest and withdraw from those decisions.

**Trustees and other committees**

The Committee meets twice annually, normally immediately prior to the Winter and Summer Scientific Meetings. This is the formal meeting of all Trustees at which they agree the broad strategy and areas of activity for the Society, including consideration of grant awarding, investment strategy and risk management. The summer 2020 Committee meeting was held as a virtual meeting on 2 September 2020.

An Awayday was scheduled for March 2020 but this was cancelled due to the Covid-19 pandemic and will be held at a later date.

The Society other sub-committees remain in place and continue to administer the activities of the Society; these are as follows:

- Research Sub-committee (chaired by Prof G Thomas) is responsible for assessing research grant applications and taking into account, where appropriate, external advice with a robust a peer review process for grants which exceed £25,000.

- Education Sub-committee (chaired by Dr EW Benbow from 1 January - 2 September 2020. Dr A Mukherjee took up Chair on 2 September 2020). This Sub-committee advises on the allocation of funds for intercalated degree students, undergraduate elective bursaries, educational grants and the Student Seminar Scheme and has recently taken on the Pathological Society Meeting Bursary and Travel & Conference Bursary awards.

- Molecular Pathology Sub-committee was formed in 2018 and is chaired by Professor M Salto-Tellez.

- Programme Sub-committee (chaired by Prof HI Grabsch), approves programme content and the Society's scientific meetings strategy.

- Trainees' Sub-committee (chaired by Dr C Young from 1 January - 2 September 2020. Dr K Marks took up Chair on 2 September 2020), was established in order to encourage a greater involvement of pathologists in training and to represent their views to the Committee of the Society.

- An Undergraduate Committee has representatives on the main Committee and Trainees' Sub - committee meetings.

The Committee is aware of the Charity Commission's Governance Code and continues to apply the Code as appropriate.

**REFERENCE AND ADMINISTRATIVE DETAILS**

**Registered Company number**

08759028 (England and Wales)

**Registered Charity number**

1154851

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**REPORT OF THE TRUSTEES  
for the year ended 31 December 2020**

**Registered Charity (Scotland) number**  
SC045004

**Registered office**  
7th Floor, 6 Alie Street  
London  
E1 8QT

**Trustees**

Professor M J Arends Professor Of Pathology  
Dr E W Benbow Senior Lecturer In Pathology (resigned 2.9.20)  
Dr G N J Betts Consultant Histopathologist  
Professor S E Coupland Consultant Histopathologist (appointed 2.9.20)  
Professor M Du Professor of Oncological Pathology (resigned 2.9.20)  
Professor A M Flanagan Medical Doctor  
Professor H I Grabsch Professor In Gastrointestinal Pathology  
Professor M Ilyas Professor of Pathology  
Dr M Jansen Clinician Scientist-Hon Consultant Histo  
Dr A Mukherjee Honorary Consultant Histopathologist  
Professor G I Murray Professor Of Pathology  
Dr A M Quinn Consultant Histopathologist (resigned 2.9.20)  
Professor M Salto-Tellez Director Of Molecular Diagnostics, Molec  
Dr A Shaaban Consultant Pathologist (appointed 2.9.20)  
Doctor E J Soilleux University Lecturer  
Professor G J Thomas Professor of Experimental Pathology  
Dr A Winstanley Consultant Cellular Pathologist  
Professor K D Hunter Professor of Head & Neck Pathology  
Dr C Coyne Consultant Histopathologist  
Professor N Coleman Professor of Histopathology  
Dr L Moore Research Fellow/consultant Histopatholog (appointed 2.9.20)  
Dr G S Petts Clinical Lecturer In Pathology (appointed 20.2.20)

**Auditors**

Raffingers LLP  
19-20 Bourne Court  
Southend Road  
Woodford Green  
Essex  
IG8 8HD

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**REPORT OF THE TRUSTEES  
for the year ended 31 December 2020**

**TRUSTEES' RESPONSIBILITY STATEMENT**

The trustees, who are also the directors of The Pathological Society of Great Britain and Ireland for the purpose of company law, are responsible for preparing the Trustees' Report and the accounts in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charitable companies in England and Wales and in Scotland requires the trustees to prepare accounts for each financial year which give a true and fair view of the state of affairs of the charitable company and of the income and expenditure of the charitable company for that year. In preparing these accounts, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the accounts; and
- prepare the accounts on the going concern basis unless it is inappropriate to presume that the charitable company will continue in operation.

The trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the accounts comply with the Companies Act 2006 and the Charities and Trustee Investment (Scotland) Act 2005, the applicable Charities (Accounts and Reports) Regulations. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees' report was approved by the Board of Trustees

Report of the trustees, incorporating a strategic report, approved by order of the board of trustees, as the company directors, on 21 May 2021 and signed on the board's behalf by:

Prof Graeme I Murray, Trustee

**REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF  
THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**Opinion**

We have audited the financial statements of The Pathological Society of Great Britain and Ireland (the 'charitable company') for the year ended 31 December 2020 which comprise the Statement of Financial Activities, the Balance Sheet, the Cash Flow Statement and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 December 2020 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and Regulation 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended).

**Basis for opinion**

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

**Conclusions relating to going concern**

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

**Other information**

The trustees are responsible for the other information. The other information comprises the information included in the Annual Report, other than the financial statements and our Report of the Independent Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

**Opinions on other matters prescribed by the Companies Act 2006**

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the Report of the Trustees for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Report of the Trustees has been prepared in accordance with applicable legal requirements.

**REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF**  
**THE PATHOLOGICAL SOCIETY OF GREAT**  
**BRITAIN AND IRELAND**

**Matters on which we are required to report by exception**

In the light of the knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the Report of the Trustees.

We have nothing to report in respect of the following matters where the Companies Act 2006 and the Charities Accounts (Scotland) regulations 2006 require us to report to you if, in our opinion:

- adequate and proper accounting records have not been kept or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the trustees directors were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies' exemptions in preparing the trustees' report and from the requirement to prepare a strategic report.

**Responsibilities of trustees**

As explained more fully in the Trustees' Responsibilities Statement, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

**REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF  
THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**Our responsibilities for the audit of the financial statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Independent Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

**The extent to which the audit was considered capable of detecting irregularities including fraud:**

Our approach to identifying and assessing the risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, was as follows:

- the engagement partner ensured that the engagement team collectively had the appropriate competence, capabilities and skills to identify or recognise non-compliance with applicable laws and regulations;
- we identified the laws and regulations applicable to the charitable company through discussions with management and from our commercial knowledge and experience of the sector The Pathological Society of Great Britain and Ireland belongs to;
- we focused on specific laws and regulations which we considered may have a direct material effect on the financial statements or the operations of the association, including the Companies Act 2006, Charities Act 2011, Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable to the United Kingdom and Republic of Ireland (FRS 102) (effective 1 January 2019), Charities Accounts (Scotland) Regulations 2006, By-Laws and Articles of Association of the Pathological Society of Great Britain and Ireland, data protection, employment, health and safety legislation and laws;
- we assessed the extent of compliance with the laws and regulations identified above through making enquiries of management and inspecting legal correspondence; and
- identified laws and regulations were communicated within the audit team regularly and the team remained alert to instances of non-compliance throughout the audit.

We assessed the susceptibility of the charitable company's financial statements to material misstatement, including obtaining an understanding of how fraud might occur, by:

- making enquiries of management as to where they considered there was susceptibility to fraud, their knowledge of actual, suspected and alleged fraud; and
- considering the internal controls in place to mitigate risks of fraud and non-compliance with laws and regulations.

To address the risk of fraud through management bias and override of controls, we:

- performed analytical procedures to identify any unusual or unexpected relationships;
- tested journal entries to identify unusual transactions;
- assessed whether judgements and assumptions made in determining the accounting estimates were indicative of potential bias; and
- investigated the rationale behind significant or unusual transactions.

In response to the risk of irregularities and non-compliance with laws and regulations, we designed procedures which included, but were not limited to:

- agreeing financial statement disclosures to underlying supporting documentation;
- reading the minutes of meetings of those charged with governance;
- enquiring of management as to actual and potential litigation and claims.

There are inherent limitations in our audit procedures described above. The more removed that laws and regulations are from financial transactions, the less likely it is that we would become aware of non-compliance. Auditing standards also limit the audit procedures required to identify non-compliance with laws and regulations to enquiry of the trustees and other management and the inspection of regulatory and legal correspondence, if any.

**REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF**  
**THE PATHOLOGICAL SOCIETY OF GREAT**  
**BRITAIN AND IRELAND**

Material misstatements that arise due to fraud can be harder to detect than those that arise from error as they may involve deliberate concealment or collusion.

We did not identify any irregularities, including fraud.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at [www.frc.org.uk/auditorsresponsibilities](http://www.frc.org.uk/auditorsresponsibilities). This description forms part of our Report of the Independent Auditors.

**Use of our report**

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006 and with regulations made under section 154 of that Act and in accordance with Section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and Regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Mr Thurairatnam Sudarshan (Senior Statutory Auditor)  
for and on behalf of Raffingers LLP  
19-20 Bourne Court  
Southend Road  
Woodford Green  
Essex  
IG8 8HD

21 May 2021

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**STATEMENT OF FINANCIAL ACTIVITIES**  
**for the year ended 31 December 2020**

	Notes	Unrestricted fund £	Designated funds £	2020 Total funds £	2019 Total funds £
<b>INCOME AND ENDOWMENTS FROM</b>					
Donations and legacies	2	86,857	-	86,857	83,232
<b>Charitable activities</b>					
Journal of Pathology	4	-	860,340	860,340	848,064
Meetings and Events		24,600	-	24,600	157,441
Investment income	3	196,958	-	196,958	251,607
Other income	5	-	-	-	29,164
<b>Total</b>		308,415	860,340	1,168,755	1,369,508
<b>EXPENDITURE ON</b>					
<b>Raising funds</b>					
Investment management costs	6	30,457	-	30,457	32,206
		30,457	-	30,457	32,206
<b>Charitable activities</b>					
Journal of Pathology	7	144,780	-	144,780	124,506
Grants and Award payable		128,665	616,207	744,872	911,313
Meetings and Events		157,006	-	157,006	467,322
<b>Total</b>		460,908	616,207	1,077,115	1,535,347
Net (losses)/gains on investments		(72,197)	-	(72,197)	752,774
<b>NET INCOME/(EXPENDITURE)</b>		(224,690)	244,133	19,443	586,935
<b>Transfers between funds</b>	19	160,470	(160,470)	-	-
<b>Net movement in funds</b>		(64,220)	83,663	19,443	586,935
<b>RECONCILIATION OF FUNDS</b>					
<b>Total funds brought forward</b>		7,405,141	913,443	8,318,584	7,731,649
<b>TOTAL FUNDS CARRIED FORWARD</b>		<u>7,340,921</u>	<u>997,106</u>	<u>8,338,027</u>	<u>8,318,584</u>

**CONTINUING OPERATIONS**

All income and expenditure has arisen from continuing activities.

The notes form part of these financial statements

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**BALANCE SHEET**  
**31 December 2020**

	Notes	2020 £	2019 £
<b>FIXED ASSETS</b>			
Tangible assets	14	42,121	54,270
Investments	15	<u>7,635,309</u>	<u>7,798,039</u>
		7,677,430	7,852,309
<b>CURRENT ASSETS</b>			
Debtors	16	912,673	894,560
Cash at bank and in hand		<u>152,481</u>	<u>199,415</u>
		1,065,154	1,093,975
<b>CREDITORS</b>			
Amounts falling due within one year	17	(404,557)	(627,700)
		<u>660,597</u>	<u>466,275</u>
<b>NET CURRENT ASSETS</b>			
		<u>660,597</u>	<u>466,275</u>
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>			
		<u>8,338,027</u>	<u>8,318,584</u>
<b>NET ASSETS</b>			
		<u><u>8,338,027</u></u>	<u><u>8,318,584</u></u>
<b>FUNDS</b>	19		
Unrestricted funds:			
General fund		7,340,921	7,405,141
Designated funds		<u>997,106</u>	<u>913,443</u>
<b>TOTAL FUNDS</b>		<u><u>8,338,027</u></u>	<u><u>8,318,584</u></u>

The financial statements were approved by the Board of Trustees and authorised for issue on 21 May 2021 and were signed on its behalf by:

Prof Graeme I Murray, Trustee

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**CASH FLOW STATEMENT**  
**for the year ended 31 December 2020**

	Notes	2020 £	2019 £
<b>Cash flows from operating activities</b>			
Cash generated from operations	1	<u>(334,425)</u>	<u>(353,572)</u>
Net cash used in operating activities		<u>(334,425)</u>	<u>(353,572)</u>
<b>Cash flows from investing activities</b>			
Purchase of tangible fixed assets		-	(60,375)
Purchase of fixed asset investments		(863,894)	(1,806,213)
Sale of fixed asset investments		992,594	1,968,447
Interest received		545	757
Dividends received		<u>196,413</u>	<u>251,608</u>
Net cash provided by investing activities		<u>325,658</u>	<u>354,224</u>
<b>Change in cash and cash equivalents in the reporting period</b>			
		(8,767)	652
<b>Cash and cash equivalents at the beginning of the reporting period</b>			
		<u>227,858</u>	<u>227,206</u>
<b>Cash and cash equivalents at the end of the reporting period</b>			
		<u><u>219,091</u></u>	<u><u>227,858</u></u>

The notes form part of these financial statements

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**NOTES TO THE CASH FLOW STATEMENT  
for the year ended 31 December 2020**

**1. RECONCILIATION OF NET INCOME TO NET CASH FLOW FROM OPERATING ACTIVITIES**

	2020 £	2019 £
<b>Net income for the reporting period (as per the Statement of Financial Activities)</b>	19,443	586,935
<b>Adjustments for:</b>		
Depreciation charges	12,149	6,685
Losses/(gain) on investments	72,197	(752,774)
Interest received	(545)	(757)
Dividends received	(196,413)	(251,608)
Increase in debtors	(18,113)	(62,463)
(Decrease)/increase in creditors	<u>(223,143)</u>	<u>120,410</u>
<b>Net cash used in operations</b>	<u>(334,425)</u>	<u>(353,572)</u>

**2. ANALYSIS OF CHANGES IN NET FUNDS**

	At 1.1.20 £	Cash flow £	At 31.12.20 £
<b>Net cash</b>			
Cash at bank and in hand	199,415	(46,934)	152,481
Cash held by investment managers	<u>28,443</u>	<u>38,167</u>	<u>66,610</u>
	<u>227,858</u>	<u>(8,767)</u>	<u>219,091</u>
<b>Total</b>	<u>227,858</u>	<u>(8,767)</u>	<u>219,091</u>

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**NOTES TO THE FINANCIAL STATEMENTS  
for the year ended 31 December 2020**

**1. ACCOUNTING POLICIES**

**Basis of preparing the financial statements**

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (Charities SORP FRS 102) , (effective 1 January 2015) the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

The financial statements have been prepared under the historical cost convention with the exception of investments which are included at market value, as modified by the revaluation of certain assets.

The charity constitutes a public benefit entity as defined by FRS 102.

The accounts are presented in sterling and are rounded to the nearest pound.

Pathology London 2014 Limited, a 100% controlled subsidiary trading company, was dissolved during the year.

**Assessment of going concern**

The trustees have assessed whether the use of the going concern assumption is appropriate in preparing these accounts. The trustees have made this assessment in respect to a period of one year from the date of approval of these accounts.

The trustees of the charity have concluded that there are no material uncertainties related to events or conditions that may cast significant doubt on the ability of the charity to continue as going concern. The trustees are of the opinion that the charity will have sufficient resources to meet its liabilities as they fall due.

**Critical accounting judgements and key sources of estimation uncertainty**

Preparation of the financial statements requires the trustees and management to make significant judgements and estimates.

The items in the accounts where these judgements and estimates have been made include:

- the useful economic lives attributed to tangible fixed assets used to determine the annual depreciation charge; and
- the assumptions adopted by the trustees in determining the value of any designations required from the charity's general unrestricted funds.

**Income**

Income is recognised when the charitable company is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charitable company has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Deferred income is recognised for income received in advance for events and meetings taking place in future periods.

Membership subscriptions are recognised in the year to which they relate.

**Journal of Pathology**

The receipts in respect of journals supplied by the Society are credited to the financial statements in the year to which they relate. The income from journals is the proportion due to the Society under the relevant agreements and is net of direct costs met by the publishers.

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**NOTES TO THE FINANCIAL STATEMENTS - continued**  
**for the year ended 31 December 2020**

**1. ACCOUNTING POLICIES - continued**

**Income**

**Meetings and events income**

Income and corresponding expenditure are recognised in the period the event has taken place. This results in deferred income and accruals recognised in balance sheet.

**Investment income**

Dividends and interest on securities are credited in the financial statements when the Society is entitled to receive the funds.

**Expenditure**

Expenditure is recognised once there is a legal or constructive obligation to make a payment to a third party, it is probable that settlement will be required and the amount of the obligation can be measured reliably.

The costs of raising funds consist of investment management fees.

**Journal of Pathology**

The cost of distributing copies of the journal to members is recognised as a charitable activity.

**Support costs for meetings**

Costs incurred for the Society's events and meetings are recognised in the period in which they take place.

All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the category.

Support and governance costs relating to charitable activities have been apportioned as follows:

Grants and awards payable 14%

Support costs for meetings 77%

Journal of Pathology 9%

**Grants payable**

Grants payable are payments made to third parties in the furtherance of the charitable objects of the Society. In the case of an unconditional grant offer this is accrued once the recipient has been notified of the grant award. The notification gives the recipient a reasonable expectation that they will receive the one- year or multi-year grant. Grants awards that are subject to the recipient fulfilling performance conditions are only accrued when the recipient has been notified of the grant and any remaining unfulfilled condition attaching to that grant is outside of the control of the Society.

**Tangible fixed assets**

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Fixtures and fittings - 15% on reducing balance

Computer equipment - 20% on cost

**Taxation**

The charity is exempt from corporation tax on its charitable activities.

**Fund accounting**

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Designated funds comprise funds which have been set aside at the discretion of the trustees for specific purposes. The purposes and uses of the designated funds are set out in the notes to the accounts.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**NOTES TO THE FINANCIAL STATEMENTS - continued**  
**for the year ended 31 December 2020**

**1. ACCOUNTING POLICIES - continued**

**Cash at bank and in hand**

Cash at bank and in hand represents such accounts and instruments that are available on demand or have a maturity of less than three months from the date of acquisition. Deposits for more than three months but less than one year have been disclosed as short term deposits.

**Creditors and provision**

Creditors and provision are recognised when there is an obligation at the balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably. Creditors and provision are recognised at the moment the charity anticipates it will pay to settle the debt. They have been discounted to the present value of the future cash payments where such discounting is material.

**Investments**

Listed investments are initially recognised at their transaction value and subsequently measured at their fair value as at the balance sheet date using the closing quoted market price.

Realised and unrealised investment gains (or losses) are combined in the statement of financial activities and are credited (or debited) in the year in which they arise.

**2. DONATIONS AND LEGACIES**

	Unrestricted funds £	Designated funds £	2020 Total funds £	2019 Total funds £
Subscriptions	<u>86,857</u>	<u>-</u>	<u>86,857</u>	<u>83,232</u>

**3. INVESTMENT INCOME**

	Unrestricted funds £	Designated funds £	2020 Total funds £	2019 Total funds £
Income from listed investments	196,413	-	196,413	250,850
Deposit account interest	<u>545</u>	<u>-</u>	<u>545</u>	<u>757</u>
	<u>196,958</u>	<u>-</u>	<u>196,958</u>	<u>251,607</u>

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**NOTES TO THE FINANCIAL STATEMENTS - continued**  
**for the year ended 31 December 2020**

**4. INCOME FROM CHARITABLE ACTIVITIES**

	Activity	2020 £	2019 £
Journal of Pathology	Journal of Pathology	860,340	848,064
Meetings and events	Meetings and Events	<u>24,600</u>	<u>157,441</u>
		<u>884,940</u>	<u>1,005,505</u>

**5. OTHER INCOME**

	Unrestricted funds £	Designated funds £	2020 Total funds £	2019 Total funds £
Other income	-	-	-	8,751
Other income from BDIAP	<u>-</u>	<u>-</u>	<u>-</u>	<u>20,413</u>
	<u>-</u>	<u>-</u>	<u>-</u>	<u>29,164</u>

**6. INVESTMENT MANAGEMENT COSTS**

	Unrestricted funds £	Designated funds £	2020 Total funds £	2019 Total funds £
Investment management	<u>30,457</u>	<u>-</u>	<u>30,457</u>	<u>32,206</u>

**7. CHARITABLE ACTIVITIES COSTS**

	Direct Costs £	Grant funding of activities (see note 8) £	Support costs (see note 9) £	Totals £
Journal of Pathology	144,780	-	-	144,780
Grants and Award payable	-	616,207	128,665	744,872
Meetings and Events	<u>15,425</u>	<u>-</u>	<u>141,581</u>	<u>157,006</u>
	<u>160,205</u>	<u>616,207</u>	<u>270,246</u>	<u>1,046,658</u>

**8. GRANTS PAYABLE**

	2020 £	2019 £
Grants and Award payable	<u>616,207</u>	<u>861,660</u>

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**NOTES TO THE FINANCIAL STATEMENTS - continued  
for the year ended 31 December 2020**

**9. SUPPORT COSTS**

	Management £	Finance £	Governance costs £	Totals £
Grants and Award payable	82,839	2,182	43,644	128,665
Meetings and Events	<u>125,253</u>	<u>-</u>	<u>16,328</u>	<u>141,581</u>
	<u>208,092</u>	<u>2,182</u>	<u>59,972</u>	<u>270,246</u>

Support costs, included in the above, are as follows:

	Grants and Award payable £	Meetings and Events £	2020 Total activities £	2019 Total activities £
Wages	-	59,104	59,104	65,908
Social security	-	13,580	13,580	11,724
Pensions	-	19,244	19,244	15,092
Insurance	-	25,249	25,249	29,804
Postage and stationery	-	5,280	5,280	5,418
Sundries	8,614	-	8,614	10,955
Website & computer	62,076	-	62,076	52,608
Staff travel	-	2,796	2,796	8,924
Depreciation of tangible and heritage assets	12,149	-	12,149	6,685
Bank charges	2,182	-	2,182	4,241
Wages	25,500	-	25,500	27,902
Auditors' remuneration	6,000	-	6,000	5,000
Committee meetings	-	16,328	16,328	27,306
Accountancy fees	8,318	-	8,318	8,643
Professional and legal fees	<u>3,826</u>	<u>-</u>	<u>3,826</u>	<u>8,108</u>
	<u>128,665</u>	<u>141,581</u>	<u>270,246</u>	<u>288,318</u>

**10. NET INCOME/(EXPENDITURE)**

Net income/(expenditure) is stated after charging/(crediting):

	2020 £	2019 £
Auditors' remuneration	6,000	5,000
Depreciation - owned assets	<u>12,149</u>	<u>6,685</u>

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**NOTES TO THE FINANCIAL STATEMENTS - continued  
for the year ended 31 December 2020**

**11. TRUSTEES' REMUNERATION AND BENEFITS**

**Trustees' expenses**

None of the trustees (or any persons connected with them) received any remuneration during the year, there were also no travelling costs reimbursed this year (2019: £9,060).

Regarding grants received by trustees from the Society in the year: M Illyas received £10,000 (2019: £10,000) from University of Nottingham.

No committee advisors (non-trustee) received grants from the Society in the year.

**12. STAFF COSTS**

	2020	2019
	£	£
Wages and salaries	107,430	115,573
Social security costs	18,672	14,136
Other pension costs	<u>26,548</u>	<u>18,574</u>
	<u>152,650</u>	<u>148,283</u>

The average monthly number of employees during the year was as follows:

	2020	2019
Administrative staff	<u>3</u>	<u>3</u>

No employees received emoluments in excess of £60,000.

**13. FINANCIAL COMMITMENTS, GUARANTEES AND CONTINGENT LIABILITIES**

The company is limited by guarantee - all members having a liability not exceeding £1 per member.

**14. TANGIBLE FIXED ASSETS**

	Fixtures and fittings £	Computer equipment £	Totals £
<b>COST</b>			
At 1 January 2020 and 31 December 2020	<u>12,374</u>	<u>65,774</u>	<u>78,148</u>
<b>DEPRECIATION</b>			
At 1 January 2020	11,881	11,997	23,878
Charge for year	<u>74</u>	<u>12,075</u>	<u>12,149</u>
At 31 December 2020	<u>11,955</u>	<u>24,072</u>	<u>36,027</u>
<b>NET BOOK VALUE</b>			
At 31 December 2020	<u>419</u>	<u>41,702</u>	<u>42,121</u>
At 31 December 2019	<u>493</u>	<u>53,777</u>	<u>54,270</u>

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**NOTES TO THE FINANCIAL STATEMENTS - continued  
for the year ended 31 December 2020**

**15. FIXED ASSET INVESTMENTS**

	2020	2019
	£	£
Shares	7,568,699	7,769,596
Other	<u>66,610</u>	<u>28,443</u>
	<u>7,635,309</u>	<u>7,798,039</u>

Additional information as follows:

	Shares in group undertakings £	Listed investments £	Totals £
<b>MARKET VALUE</b>			
At 1 January 2020	1	7,769,595	7,769,596
Additions	-	863,894	863,894
Disposals	-	(992,594)	(992,594)
Revaluations	<u>-</u>	<u>(72,197)</u>	<u>(72,197)</u>
At 31 December 2020	<u>1</u>	<u>7,568,698</u>	<u>7,568,699</u>
<b>NET BOOK VALUE</b>			
At 31 December 2020	<u>1</u>	<u>7,568,698</u>	<u>7,568,699</u>
At 31 December 2019	<u>1</u>	<u>7,769,595</u>	<u>7,769,596</u>

There were no investment assets outside the UK.

Investments (neither listed nor unlisted) were as follows:

	2020	2019
	£	£
Cash in portfolio	<u>66,610</u>	<u>28,443</u>

**16. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	2020	2019
	£	£
Other debtors	903,994	878,870
VAT	-	247
Prepayments	<u>8,679</u>	<u>15,443</u>
	<u>912,673</u>	<u>894,560</u>

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**NOTES TO THE FINANCIAL STATEMENTS - continued  
for the year ended 31 December 2020**

**17. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	2020	2019
	£	£
Trade creditors	4,050	929
VAT	15	-
Other creditors	940	52
Accrued expenses	<u>399,552</u>	<u>626,719</u>
	<u>404,557</u>	<u>627,700</u>

**18. ANALYSIS OF NET ASSETS BETWEEN FUNDS**

	Unrestricted fund	Designated funds	2020 Total funds	2019 Total funds
	£	£	£	£
Fixed assets	42,121	-	42,121	54,270
Investments	7,635,309	-	7,635,309	7,798,039
Current assets	68,048	997,106	1,065,154	1,093,975
Current liabilities	<u>(404,557)</u>	<u>-</u>	<u>(404,557)</u>	<u>(627,700)</u>
	<u>7,340,921</u>	<u>997,106</u>	<u>8,338,027</u>	<u>8,318,584</u>

**19. MOVEMENT IN FUNDS**

	At 1.1.20	Net movement in funds	Transfers between funds	At 31.12.20
	£	£	£	£
<b>Unrestricted funds</b>				
General fund	7,405,141	(224,690)	160,470	7,340,921
<b>Designated funds</b>				
Education Grants	34,610	105,840	-	140,450
Finance & General Purposes Grants	2,887	19,524	(3,487)	18,924
JSPS Grants	604,233	274,934	(78,555)	800,612
Research Grants	<u>271,713</u>	<u>(156,165)</u>	<u>(78,428)</u>	<u>37,120</u>
	<u>913,443</u>	<u>244,133</u>	<u>(160,470)</u>	<u>997,106</u>
<b>TOTAL FUNDS</b>	<u>8,318,584</u>	<u>19,443</u>	<u>-</u>	<u>8,338,027</u>

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**NOTES TO THE FINANCIAL STATEMENTS - continued**  
**for the year ended 31 December 2020**

**19. MOVEMENT IN FUNDS - continued**

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Gains and losses £	Movement in funds £
<b>Unrestricted funds</b>				
General fund	308,415	(460,908)	(72,197)	(224,690)
<b>Designated funds</b>				
Education Grants	181,242	(75,402)	-	105,840
Finance & General Purposes Grants	25,000	(5,476)	-	19,524
JSPS Grants	433,784	(158,850)	-	274,934
Research Grants	<u>220,314</u>	<u>(376,479)</u>	-	<u>(156,165)</u>
	<u>860,340</u>	<u>(616,207)</u>	-	<u>244,133</u>
<b>TOTAL FUNDS</b>	<u><u>1,168,755</u></u>	<u><u>(1,077,115)</u></u>	<u><u>(72,197)</u></u>	<u><u>19,443</u></u>

**Comparatives for movement in funds**

	At 1.1.19 £	Net movement in funds £	At 31.12.19 £
<b>Unrestricted funds</b>			
General fund	6,797,175	607,966	7,405,141
<b>Designated funds</b>			
Education Grants	49,000	35,158	84,158
Finance & General Purposes Grants	8,915	(35,113)	(26,198)
JSPS Grants	596,960	(55,457)	541,503
Research Grants	<u>279,599</u>	<u>34,381</u>	<u>313,980</u>
	<u>934,474</u>	<u>(21,031)</u>	<u>913,443</u>
<b>TOTAL FUNDS</b>	<u><u>7,731,649</u></u>	<u><u>586,935</u></u>	<u><u>8,318,584</u></u>

**THE PATHOLOGICAL SOCIETY OF GREAT  
BRITAIN AND IRELAND**

**NOTES TO THE FINANCIAL STATEMENTS - continued**  
**for the year ended 31 December 2020**

**19. MOVEMENT IN FUNDS - continued**

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Gains and losses £	Movement in funds £
<b>Unrestricted funds</b>				
General fund	528,879	(673,687)	752,774	607,966
<b>Designated funds</b>				
Education Grants	221,186	(186,028)	-	35,158
Finance & General Purposes Grants	-	(35,113)	-	(35,113)
JSPS Grants	144,482	(199,939)	-	(55,457)
Research Grants	<u>474,961</u>	<u>(440,580)</u>	-	<u>34,381</u>
	<u>840,629</u>	<u>(861,660)</u>	-	<u>(21,031)</u>
<b>TOTAL FUNDS</b>	<u><u>1,369,508</u></u>	<u><u>(1,535,347)</u></u>	<u><u>752,774</u></u>	<u><u>586,935</u></u>

**20. RELATED PARTY TRANSACTIONS**

**Remuneration of key management personnel**

The remuneration of key management personnel is as follows.

	2020 £	2019 £
Aggregate compensation	152,650	148,283

The above amounts were paid to the Royal College of Pathologists for the use of 3 (2019: 3) of their employees for administrative management of the society. As part of the agreement between the two entities, in the event of the Royal College of Pathologists being required to contribute to the pension scheme that it belongs to, the society could be liable to meet the obligations of the pension costs in respect of these individuals.

**21. SUBSIDIARIES**

There were no subsidiaries controlled by the charity as at 31 December 2020.